[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 173
1. Polton GA, Brearley MJ: Clinical stage, therapy, and prognosis in canine anal sac gland carcinoma. J Vet Intern Med; 2007 Mar-Apr;21(2):274-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical stage, therapy, and prognosis in canine anal sac gland carcinoma.
  • BACKGROUND: Reports of canine anal sac gland carcinoma (ASGC) describe varied clinical presentations and management and differing responses to therapy.
  • A unifying approach to clinical stage determination and management of this disease has yet to be presented.
  • RESULTS: Retrospective evaluation revealed 4 statistically significant negative prognostic indicators for survival: lack of therapy, presence of distant metastases, presence of lymph node metastases, and primary tumor size.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427388.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Spugnini EP, Dotsinsky I, Mudrov N, Bufalini M, Giannini G, Citro G, Feroce F, Baldi A: Adjuvant electrochemotherapy for incompletely excised anal sac carcinoma in a dog. In Vivo; 2008 Jan-Feb;22(1):47-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant electrochemotherapy for incompletely excised anal sac carcinoma in a dog.
  • Canine anal sac gland carcinoma (ASGC) is a frequently described neoplasm that is highly aggressive and can frequently lead to metastatic spread.
  • In this paper, we describe the successful treatment of an incompletely excised ASGC by using cisplatin selectively driven within the tumor cells by trains of biphasic pulses.
  • [MeSH-major] Anal Gland Neoplasms / drug therapy. Anal Sacs / drug effects. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Dog Diseases / drug therapy. Electrochemotherapy
  • [MeSH-minor] Animals. Combined Modality Therapy. Disease-Free Survival. Dogs. Male. Remission Induction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396781.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Anand BS, Verstovsek G, Cole G: Tubulovillous adenoma of anal canal: a case report. World J Gastroenterol; 2006 Mar 21;12(11):1780-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulovillous adenoma of anal canal: a case report.
  • Tumors arising from the anal canal are usually of epithelial origin and are mostly squamous cell carcinoma or basal cell carcinoma.
  • We present a case of benign anal adenomas arising from the anus, an extremely rare diagnosis.
  • The squamocolumnar junction was visible at the edges of the lesion confirming the anal origin of the tumor.
  • We believe the tubulovillus adenoma arose from either an anal gland or its duct that opens into the anus.
  • [MeSH-major] Adenoma, Villous / diagnosis. Anus Neoplasms / diagnosis
  • [MeSH-minor] Aged. Anal Canal / pathology. Cell Transformation, Neoplastic. Humans. Male

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):217-9 [15677547.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1634 [8548224.001]
  • (PMID = 16586552.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4124358
  •  go-up   go-down


Advertisement
4. Dahse R, Kromeyer-Hauschild K, Berndt A, Kosmehl H: No incidence of BRAF mutations in salivary gland carcinomas--implications for anti-EGFR therapies. J Biomed Biotechnol; 2009;2009:501736
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No incidence of BRAF mutations in salivary gland carcinomas--implications for anti-EGFR therapies.
  • We designed an allele-specific PCR and screened 65 salivary gland carcinoma (SGC) of the main histopathological types for the BRAF V600E mutation.
  • [MeSH-major] Proto-Oncogene Proteins B-raf / genetics. Salivary Gland Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Nucleic Acids Res. 1989 Apr 11;17(7):2503-16 [2785681.001]
  • [Cites] Anal Biochem. 1990 Apr;186(1):64-8 [2192583.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):729-34 [17350323.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3978-84 [17761983.001]
  • [Cites] Oral Oncol. 2009 Sep;45(9):826-9 [19362042.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5705-12 [19001320.001]
  • [Cites] Br J Cancer. 2009 Feb 24;100(4):623-5 [19174819.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):1851-7 [19223544.001]
  • [Cites] Oral Oncol. 2009 Jul;45(7):574-8 [18804410.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1953-61 [18339877.001]
  • (PMID = 19547661.001).
  • [ISSN] 1110-7251
  • [Journal-full-title] Journal of biomedicine & biotechnology
  • [ISO-abbreviation] J. Biomed. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Other-IDs] NLM/ PMC2699443
  •  go-up   go-down


5. Howard B, Ashworth A: Signalling pathways implicated in early mammary gland morphogenesis and breast cancer. PLoS Genet; 2006 Aug 25;2(8):e112
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signalling pathways implicated in early mammary gland morphogenesis and breast cancer.
  • Reflecting this intimate connection, a considerable number of signalling pathways have been implicated in both mammary gland morphogenesis and carcinogenesis.
  • [MeSH-major] Breast / metabolism. Breast Neoplasms / metabolism. Mammary Glands, Animal / cytology. Mammary Glands, Animal / metabolism. Mammary Neoplasms, Animal / metabolism. Morphogenesis. Signal Transduction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2004 Sep;25(3):641-9 [15289865.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):109-18 [15300007.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):119-31 [15300008.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):133-44 [15300009.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):165-81 [15300011.001]
  • [Cites] Oncogene. 2004 Aug 12;23(36):6047-55 [15208658.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] Acta Anat (Basel). 1995;152(3):195-204 [7572029.001]
  • [Cites] Mol Cell Biol. 1995 Oct;15(10):5770-6 [7565730.001]
  • [Cites] Mech Dev. 1995 Jun;51(2-3):341-50 [7547479.001]
  • [Cites] Breast Cancer Res Treat. 1996;39(1):33-44 [8738604.001]
  • [Cites] Nat Genet. 1997 Jul;16(3):311-5 [9207801.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9562-7 [9275162.001]
  • [Cites] Oncogene. 1997 Oct;15(18):2133-44 [9393971.001]
  • [Cites] Development. 1998 Apr;125(7):1285-94 [9477327.001]
  • [Cites] Nature. 1998 Oct 15;395(6703):702-7 [9790191.001]
  • [Cites] Cell. 1999 Jan 22;96(2):225-33 [9988217.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1999 Jan;4(1):9-19 [10219903.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] Cancer Res. 1959 Jun;19(5):515-20 [13663040.001]
  • [Cites] J Anat. 1950 Jul;84(3):227-35 [15436328.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R605-15 [15535842.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):48808-16 [15355992.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17138-43 [15569931.001]
  • [Cites] Development. 2005 Jan;132(2):267-77 [15590737.001]
  • [Cites] Nat Neurosci. 2004 Dec;7(12):1319-28 [15543145.001]
  • [Cites] Melanoma Res. 2005 Feb;15(1):21-8 [15714117.001]
  • [Cites] Development. 2005 Apr;132(8):1961-70 [15790970.001]
  • [Cites] J Cell Sci. 2005 Aug 15;118(Pt 16):3585-94 [16105882.001]
  • [Cites] Oncogene. 2005 Aug 29;24(37):5668-75 [16123800.001]
  • [Cites] Oncogene. 2005 Aug 29;24(37):5731-41 [16123806.001]
  • [Cites] Genes Dev. 2005 Sep 1;19(17):2078-90 [16140987.001]
  • [Cites] Breast Cancer Res. 2005;7(5):220-4 [16168142.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Sep;6(9):715-25 [16231422.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):412-21 [16049973.001]
  • [Cites] Dev Dyn. 2005 Dec;234(4):922-33 [16222716.001]
  • [Cites] J Cell Biol. 2005 Nov 21;171(4):663-73 [16301332.001]
  • [Cites] Nature. 2006 Jan 5;439(7072):84-8 [16397499.001]
  • [Cites] Oncol Rep. 2006 Mar;15(3):701-7 [16465433.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1930-5 [16446434.001]
  • [Cites] J Biol Chem. 2002 Feb 22;277(8):6567-72 [11748239.001]
  • [Cites] Nat Rev Genet. 2002 Mar;3(3):199-209 [11972157.001]
  • [Cites] Sci STKE. 2002 May 7;2002(131):pe22 [11997580.001]
  • [Cites] J Cell Biol. 2002 May 13;157(4):703-14 [12011115.001]
  • [Cites] Dev Cell. 2002 May;2(5):643-53 [12015971.001]
  • [Cites] Gene. 2002 Feb 20;285(1-2):203-11 [12039047.001]
  • [Cites] Dev Biol. 2002 Sep 1;249(1):131-9 [12217324.001]
  • [Cites] Cancer Cell. 2002 Oct;2(4):301-14 [12398894.001]
  • [Cites] Differentiation. 2003 Jan;71(1):1-17 [12558599.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3299-304 [12626757.001]
  • [Cites] Exp Cell Res. 2003 Mar 10;284(1):99-110 [12648469.001]
  • [Cites] Development. 2003 May;130(10):2263-73 [12668638.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):211-24 [12787560.001]
  • [Cites] Dev Biol. 2003 Jul 1;259(1):123-36 [12812793.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8281-6 [12824469.001]
  • [Cites] Nature. 2006 Feb 23;439(7079):993-7 [16395311.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3799-804 [16501043.001]
  • [Cites] Development. 2006 Apr;133(8):1553-63 [16524929.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(2):163-8 [16261396.001]
  • [Cites] Cancer Biol Ther. 2006 Mar;5(3):281-6 [16410723.001]
  • [Cites] Oncogene. 2006 Jun 8;25(24):3479-88 [16449975.001]
  • [Cites] Carcinogenesis. 2006 Jul;27(7):1341-8 [16501252.001]
  • [Cites] Dev Biol. 2006 Jul 1;295(1):219-31 [16678815.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Mech Dev. 2000 Mar 1;91(1-2):305-9 [10704854.001]
  • [Cites] Mamm Genome. 2000 Mar;11(3):234-7 [10723730.001]
  • [Cites] Nat Genet. 2000 Apr;24(4):391-5 [10742104.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4262-6 [10759547.001]
  • [Cites] Crit Rev Oncol Hematol. 2000 Jun;34(3):185-94 [10838264.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1997-2005 [10854222.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1996 Jan;1(1):21-35 [10887478.001]
  • [Cites] Breast Cancer Res Treat. 2000 Sep;63(1):61-9 [11079160.001]
  • [Cites] Hum Mol Genet. 2000 Dec 12;9(20):2981-91 [11115842.001]
  • [Cites] Development. 2001 Feb;128(4):513-25 [11171335.001]
  • [Cites] Endocr Relat Cancer. 2000 Dec;7(4):199-226 [11174844.001]
  • [Cites] J Cell Biol. 2001 Apr 30;153(3):555-68 [11331306.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(13):4265-75 [11390655.001]
  • [Cites] Development. 2001 Jun;128(12):2373-84 [11493556.001]
  • [Cites] Development. 2004 Oct;131(19):4819-29 [15342465.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):437-58 [15369447.001]
  • [Cites] Development. 2004 Oct;131(20):4907-19 [15371307.001]
  • [Cites] Int J Oncol. 2004 Nov;25(5):1337-42 [15492823.001]
  • [Cites] C R Acad Sci Hebd Seances Acad Sci D. 1967 May 29;264(22):2573-5 [4964613.001]
  • [Cites] Dev Biol. 1969 Jul;20(1):46-71 [5795848.001]
  • [Cites] Exp Gerontol. 1971 Feb 1;6(1):49-56 [5572739.001]
  • [Cites] Exp Gerontol. 1971 Feb 1;6(1):95-101 [5572743.001]
  • [Cites] Science. 1976 Dec 24;194(4272):1439-41 [827022.001]
  • [Cites] Dev Biol. 1978 Nov;67(1):225-31 [720754.001]
  • [Cites] Dev Biol. 1979 Oct;72(2):201-10 [510783.001]
  • [Cites] Cell. 1988 Nov 18;55(4):619-25 [3180222.001]
  • [Cites] Dev Biol (N Y 1985). 1986;4:315-33 [3078135.001]
  • [Cites] Oncogene. 1991 Apr;6(4):659-63 [1851551.001]
  • [Cites] J Cell Physiol. 1992 Nov;153(2):381-91 [1429857.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):740-4 [8380647.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):378-82 [8099571.001]
  • [Cites] Genes Chromosomes Cancer. 1993 Aug;7(4):219-26 [7692948.001]
  • [Cites] Genes Dev. 1994 Nov 15;8(22):2691-703 [7958926.001]
  • [Cites] J Virol. 1995 Apr;69(4):2501-7 [7884899.001]
  • [Cites] Int J Cancer. 1995 Apr 10;61(2):170-6 [7705943.001]
  • [Cites] Oncogene. 2001 Aug 23;20(37):5093-9 [11526497.001]
  • [Cites] Anal Cell Pathol. 2001;22(4):229-34 [11564899.001]
  • [Cites] Oncogene. 2001 Sep 13;20(41):5810-7 [11593386.001]
  • [Cites] Development. 2002 Jan;129(1):53-60 [11782400.001]
  • [Cites] Development. 2003 Nov;130(21):5257-68 [12954715.001]
  • [Cites] J Pathol. 2003 Oct;201(2):204-12 [14517837.001]
  • [Cites] Dev Biol. 2003 Oct 15;262(2):195-205 [14550785.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:589-621 [14570583.001]
  • [Cites] Dev Biol. 2003 Dec 1;264(1):153-65 [14623238.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2003 Apr;8(2):215-23 [14635796.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):832-44 [14668814.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15853-8 [14668450.001]
  • [Cites] Dev Dyn. 2004 Feb;229(2):349-56 [14745960.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4158-63 [15020770.001]
  • [Cites] Breast Cancer Res. 2004;6(3):105-8 [15084230.001]
  • [Cites] Cancer Biol Ther. 2004 Jan;3(1):36-41 [14739782.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3501-8 [15116089.001]
  • [Cites] J Pathol. 2004 Jun;203(2):672-80 [15141382.001]
  • [Cites] J Anat. 2004 Jul;205(1):1-13 [15255957.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5132-9 [15289316.001]
  • (PMID = 16933995.001).
  • [ISSN] 1553-7404
  • [Journal-full-title] PLoS genetics
  • [ISO-abbreviation] PLoS Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ectodysplasins; 0 / Fgf10 protein, mouse; 0 / Fibroblast Growth Factor 10; 0 / Intracellular Signaling Peptides and Proteins; 0 / Nrg3 protein, mouse; 0 / T-Box Domain Proteins; 0 / Tbx3 protein, mouse; 0 / Wnt Proteins
  • [Other-IDs] NLM/ PMC1557774
  •  go-up   go-down


6. Hoshino A, Yee CJ, Campbell M, Woltjer RL, Townsend RL, van der Meer R, Shyr Y, Holt JT, Moses HL, Jensen RA: Effects of BRCA1 transgene expression on murine mammary gland development and mutagen-induced mammary neoplasia. Int J Biol Sci; 2007;3(5):281-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of BRCA1 transgene expression on murine mammary gland development and mutagen-induced mammary neoplasia.
  • To characterize the role of BRCA1 in mammary gland development and tumor suppression, a transgenic mouse model of BRCA1 overexpression was developed.
  • Using the mouse mammary tumor virus (MMTV) promoter/enhancer, transgenic mice expressing human BRCA1 or select mutant controls were generated.
  • Morphometric analyses of mammary gland whole mount preparations were used to measure epithelial staining indices of ~35% for homozygous MMTV-BRCA1 mice and ~60% for both hemizygous and homozygous MMTV-BRCA1sv mice versus ~25% for non-transgenic mice.
  • In contrast, homozygous MMTV-BRCA1sv transgenic animals were sensitized to DMBA treatment and exhibited a very rapid onset of mammary tumor development and accelerated mortality.
  • MMTV-BRCA1 effects on mortality were restricted to DMBA-induced tumors of the mammary gland.
  • These results demonstrate in vivo roles for BRCA1 in both mammary gland development and in tumor suppression against mutagen-induced mammary gland neoplasia.
  • [MeSH-major] BRCA1 Protein / physiology. Genes, BRCA1. Mammary Glands, Animal / growth & development. Mammary Neoplasms, Experimental / genetics
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Animals. Carcinogens / toxicity. Female. Gene Expression. Gene Transfer Techniques. Mammary Tumor Virus, Mouse. Mice. Mice, Inbred Strains. Mice, Transgenic. Pregnancy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1998 Dec 17;17(24):3115-24 [9872327.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):1959-68 [9815585.001]
  • [Cites] Nat Genet. 1999 May;22(1):37-43 [10319859.001]
  • [Cites] Nature. 2000 Nov 23;408(6811):429-32 [11100717.001]
  • [Cites] Nat Struct Biol. 2001 Oct;8(10):838-42 [11573086.001]
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):25-37 [11801721.001]
  • [Cites] Cell. 2002 Jan 25;108(2):171-82 [11832208.001]
  • [Cites] Genes Dev. 2002 Mar 1;16(5):583-93 [11877378.001]
  • [Cites] EMBO J. 2002 Jul 15;21(14):3863-72 [12110597.001]
  • [Cites] Transgenic Res. 2002 Oct;11(5):467-78 [12437078.001]
  • [Cites] Hum Mol Genet. 2003 Apr 1;12 Spec No 1:R113-23 [12668603.001]
  • [Cites] Science. 2003 Oct 24;302(5645):636-9 [14576432.001]
  • [Cites] Science. 2003 Oct 24;302(5645):639-42 [14576433.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5792-8 [15122325.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38409-14 [15229228.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] DNA. 1988 May;7(4):261-7 [3293952.001]
  • [Cites] Cell. 1990 Jun 15;61(6):1147-55 [2161707.001]
  • [Cites] Am J Hum Genet. 1993 Apr;52(4):678-701 [8460634.001]
  • [Cites] Biotechniques. 1993 Sep;15(3):532-4, 536-7 [7692896.001]
  • [Cites] Genes Dev. 1993 Dec;7(12A):2308-17 [8253379.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1678-83 [8137281.001]
  • [Cites] Science. 1994 Oct 7;266(5182):66-71 [7545954.001]
  • [Cites] Nat Genet. 1994 Dec;8(4):387-91 [7894491.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4254-8 [7753792.001]
  • [Cites] Nat Genet. 1995 Sep;11(1):17-26 [7550308.001]
  • [Cites] Am J Hum Genet. 1995 Dec;57(6):1457-62 [8533776.001]
  • [Cites] Genes Dev. 1995 Nov 1;9(21):2712-22 [7590247.001]
  • [Cites] Mol Biol Cell. 1995 Oct;6(10):1287-303 [8573787.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):191-4 [8563759.001]
  • [Cites] Nat Genet. 1996 Mar;12(3):298-302 [8589721.001]
  • [Cites] Hum Mol Genet. 1995 Dec;4(12):2259-64 [8634696.001]
  • [Cites] Hum Mol Genet. 1995 Dec;4(12):2265-73 [8634697.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2318-24 [8635102.001]
  • [Cites] Cell. 1996 Jun 28;85(7):1009-23 [8674108.001]
  • [Cites] Oncogene. 1996 Jun 20;12(12):2507-13 [8700509.001]
  • [Cites] Genes Dev. 1996 Jul 15;10(14):1835-43 [8698242.001]
  • [Cites] Oncogene. 1996 Aug 1;13(3):649-53 [8760307.001]
  • [Cites] Mol Cell Biol. 1997 Jan;17(1):444-52 [8972225.001]
  • [Cites] Lab Invest. 1997 Mar;76(3):419-25 [9121124.001]
  • [Cites] Nucleic Acids Res. 1997 Jun 1;25(11):2138-46 [9153313.001]
  • [Cites] Genes Dev. 1997 Dec 15;11(24):3387-400 [9407031.001]
  • [Cites] J Histochem Cytochem. 1997 Nov;45(11):1559-65 [9358857.001]
  • [Cites] Genes Dev. 1997 May 15;11(10):1226-41 [9171368.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):56-9 [9425901.001]
  • [Cites] Mol Biol Cell. 1998 Feb;9(2):421-35 [9450965.001]
  • [Cites] Oncogene. 1998 Jan 8;16(1):61-8 [9467943.001]
  • [Cites] J Histochem Cytochem. 1999 Jan;47(1):119-26 [9857219.001]
  • (PMID = 17505536.001).
  • [ISSN] 1449-2288
  • [Journal-full-title] International journal of biological sciences
  • [ISO-abbreviation] Int. J. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / Carcinogens; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  • [Other-IDs] NLM/ PMC1865089
  •  go-up   go-down


7. Chatelain D, Mokrani N, Fléjou JF: [Anal and anal margin tumors]. Ann Pathol; 2007 Dec;27(6):459-75
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal and anal margin tumors].
  • [Transliterated title] Pathologie tumorale anale et péri-anale.
  • Tumors of the anal canal and anal margin are rare.
  • [MeSH-major] Anus Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Endocrine Gland Neoplasms / epidemiology. Endocrine Gland Neoplasms / pathology. France / epidemiology. Humans. Incidence. Leiomyosarcoma / pathology. Lymphoma / pathology. Melanoma / epidemiology. Melanoma / pathology. Papilloma / pathology. Sarcoma, Kaposi / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18554556.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 110
  •  go-up   go-down


8. Simeonov R, Simeonova G: Quantitative analysis in spontaneous canine anal sac gland adenomas and carcinomas. Res Vet Sci; 2008 Dec;85(3):559-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis in spontaneous canine anal sac gland adenomas and carcinomas.
  • Stained cytological specimens from 7 canine anal sac gland adenomas and 11 canine anal sac gland carcinomas were analyzed by computer-assisted nuclear morphometry.
  • The study aimed to evaluate (1) the possibility of using nuclear cytomorphometry as an auxiliary diagnostic method to differentiate between canine anal sac gland adenomas and adenocarcinomas, and (2) the prognostic value of nuclear morphometry in canine anal sac gland adenocarcinomas.
  • The results indicated that (1) MNA, MNP, MND and NR could be used as effective auxiliary tools for differential diagnosis between canine anal sac gland adenomas and adenocarcinomas, and (2) MNA, MNP and MND are reliable prognostic indicators for canine anal sac gland adenocarcinomas.
  • [MeSH-major] Anal Gland Neoplasms / pathology. Anal Sacs / pathology. Dog Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18457852.001).
  • [ISSN] 0034-5288
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Kuroda N, Tanida N, Ohara M, Hirouchi T, Mizuno K, Kubo A, Lee GH: Anal canal adenocarcinoma with MUC5AC expression suggestive of anal gland origin. Med Mol Morphol; 2007 Mar;40(1):50-3
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal canal adenocarcinoma with MUC5AC expression suggestive of anal gland origin.
  • Anal canal adenocarcinomas arising in the anal ducts or glands are very rare neoplasms, and few useful immunohistochemical markers of these carcinomas are known to date.
  • A 57-year-old man presented with anal bleeding, difficulty of defecation, and anal pain.
  • Macroscopic findings of the surgically resected material showed circular stenosis of the anal canal.
  • Immunohistochemically, normal rectal-type mucosa and normal anal ducts/glands showed the patterns of cytokeratin 7 (CK7)(-)/CK19(+, focal)/MUC5AC(-) and CK7(+, diffuse)/CK19(+, diffuse)/MUC5AC(+, focal), respectively, and neoplastic cells showed the pattern of CK7(+, diffuse)/CK19(+, diffuse)/MUC5AC(+, focal).
  • Finally, our preliminary report suggests that the immunohistochemical combination of CK7, CK19, and MUC5AC may be an available marker for adenocarcinoma of anal ducts/glands origin.
  • [MeSH-major] Adenocarcinoma / pathology. Anal Canal / pathology. Anus Neoplasms / pathology. Mucins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17384991.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucins
  •  go-up   go-down


10. Shoieb AM, Hanshaw DM: Anal sac gland carcinoma in 64 cats in the United kingdom (1995-2007). Vet Pathol; 2009 Jul;46(4):677-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal sac gland carcinoma in 64 cats in the United kingdom (1995-2007).
  • A retrospective study was performed to characterize 64 cases of anal sac gland carcinoma (ASGC) in cats.
  • Apocrine gland origin was confirmed in a subset of these tumors by immunohistochemistry and the use of the glandular cytokeratin antibody (CAM 5.2).
  • Anal sac gland carcinoma accounted for 0.5% of all feline skin neoplasms.
  • More than three quarters of the affected cats for which postsurgical outcome was known were euthanatized or died as a direct consequence of the neoplasm, with a median survival of 3 months.
  • [MeSH-major] Anal Gland Neoplasms / epidemiology. Anal Gland Neoplasms / pathology. Anal Sacs / pathology. Cat Diseases / epidemiology. Cat Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276061.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Lisovsky M, Patel K, Cymes K, Chase D, Bhuiya T, Morgenstern N: Immunophenotypic characterization of anal gland carcinoma: loss of p63 and cytokeratin 5/6. Arch Pathol Lab Med; 2007 Aug;131(8):1304-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic characterization of anal gland carcinoma: loss of p63 and cytokeratin 5/6.
  • Anal gland carcinoma (AGC) is a rare perianal invasive cancer composed of tubular glands lined by cuboidal epithelium.
  • The clinical features and histogenesis of AGC are not well understood and its origin from anal glands is often difficult to prove.
  • This study evaluated the immunohistochemical profile of 2 cases of AGC in comparison to anal glands from 11 hemorrhoidectomy specimens.
  • In biopsies from this case, the neoplastic anal glands had a tubular pattern, whereas most glands in the resection specimen exhibited mucinous features.
  • Normal anal glands showed immunoreactivity for myoepithelial and basal cell markers CK5/6 and p63 in basal and parabasal cell layers and for CK7 in superficial cell layers.
  • Anal gland carcinoma shares negativity for CDX2 and CK7+/CK20- profile with normal anal glands.
  • No evidence of myoepithelial cells was found in normal or malignant anal glands.
  • [MeSH-major] Adenocarcinoma / pathology. Anus Neoplasms / pathology. Biomarkers, Tumor / metabolism. Keratin-5 / metabolism. Keratin-6 / metabolism. Membrane Proteins / metabolism
  • [MeSH-minor] Anal Canal / metabolism. Anal Canal / pathology. Fluorescent Antibody Technique, Indirect. Hemorrhoids / pathology. Hemorrhoids / surgery. Humans. Immunoenzyme Techniques. Immunophenotyping. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Pathol Lab Med. 2008 Oct;132(10):1547-8 [18834205.001]
  • (PMID = 17683193.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Keratin-5; 0 / Keratin-6; 0 / Membrane Proteins
  •  go-up   go-down


12. Aguirre-Hernández J, Polton G, Kennedy LJ, Sargan DR: Association between anal sac gland carcinoma and dog leukocyte antigen-DQB1 in the English Cocker Spaniel. Tissue Antigens; 2010 Dec;76(6):476-81
SciCrunch. OMIA - Online Mendelian Inheritance in Animals: Data: Gene Expression .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between anal sac gland carcinoma and dog leukocyte antigen-DQB1 in the English Cocker Spaniel.
  • Anal sac gland carcinomas occur frequently in English Cocker Spaniels and, to a lesser extent, in other spaniel breeds.
  • The disease typically presents in dogs aged 8 years or older and frequently metastasises to the local lymph nodes.
  • The association between anal sac gland carcinoma in English Cocker Spaniels and the major histocompatibility complex class II loci (the dog leukocyte antigen loci DLA-DRB1, -DQA1, -DQB1) was investigated in 42 cases and 75 controls.
  • This is the second disease in English Cocker Spaniels for which the most common DLA-DQB1 allele in the breed has been shown to have a higher frequency in cases than controls, while the second most common allele in the breed (*02001) has a significantly higher frequency in the controls, compared with the cases.
  • [MeSH-major] Dog Diseases / immunology. Gene Frequency / immunology. Histocompatibility Antigens Class I / immunology. Histocompatibility Antigens Class II / immunology. Neoplasms / immunology. Neoplasms / veterinary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 John Wiley & Sons A/S.
  • (PMID = 20727114.001).
  • [ISSN] 1399-0039
  • [Journal-full-title] Tissue antigens
  • [ISO-abbreviation] Tissue Antigens
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / Histocompatibility Antigens Class II
  •  go-up   go-down


13. Parry NM: Anal sac gland carcinoma in a cat. Vet Pathol; 2006 Nov;43(6):1008-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal sac gland carcinoma in a cat.
  • A perianal mass in a 15-year-old domestic shorthair cat with a history of a firm, painful swelling in the left ventrolateral perianal region was surgically excised and submitted for light microscopic evaluation.
  • Histologically, this was a poorly demarcated, unencapsulated, multilobulated neoplasm that invaded surrounding perirectal skeletal muscle bundles.
  • These microscopic features are consistent with anal sac gland carcinoma.
  • This is the second report of this neoplasm in a cat.
  • [MeSH-major] Anal Gland Neoplasms / pathology. Anal Sacs / pathology. Carcinoma / veterinary. Cat Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17099161.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Wright ZM, Fryer JS, Calise DV, Oliveira FN: Carboplatin chemotherapy in a cat with a recurrent anal sac apocrine gland adenocarcinoma. J Am Anim Hosp Assoc; 2010 Jan-Feb;46(1):66-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin chemotherapy in a cat with a recurrent anal sac apocrine gland adenocarcinoma.
  • An 8-year-old, castrated male, domestic shorthaired cat was presented for evaluation of a perianal mass.
  • The mass was incompletely excised, and histological assessment resulted in a diagnosis of anal sac adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / veterinary. Anal Gland Neoplasms / drug therapy. Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Cat Diseases / drug therapy
  • [MeSH-minor] Anal Sacs / pathology. Animals. Cats. Fatal Outcome. Lung Neoplasms / secondary. Lung Neoplasms / veterinary. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local / veterinary

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20045840.001).
  • [ISSN] 1547-3317
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


15. Hobson HP, Brown MR, Rogers KS: Surgery of metastatic anal sac adenocarcinoma in five dogs. Vet Surg; 2006 Apr;35(3):267-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery of metastatic anal sac adenocarcinoma in five dogs.
  • OBJECTIVE: To identify survival and morbidity information after surgery for metastases from apocrine gland anal sac adenocarcinomas (AGACA).
  • CONCLUSION: Dogs with anal sac adenocarcinoma metastases to the iliac lymph nodes can experience long-term survival after surgical excision of the metastatic lesion.
  • CLINICAL RELEVANCE: Lymphadenectomy may afford long-term survival to patients with metastatic anal sac adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / veterinary. Anal Gland Neoplasms / surgery. Anal Sacs. Dog Diseases / surgery
  • [MeSH-minor] Animals. Dogs. Female. Lymph Node Excision / veterinary. Lymphatic Metastasis. Male. Neoplasm Metastasis. Postoperative Complications / veterinary. Records as Topic / veterinary. Retrospective Studies. Survival Analysis. Texas / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Compend Contin Educ Vet. 2008 Feb;30(2):69, 72 [23713167.001]
  • (PMID = 16635006.001).
  • [ISSN] 0161-3499
  • [Journal-full-title] Veterinary surgery : VS
  • [ISO-abbreviation] Vet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Emms SG: Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy. Aust Vet J; 2005 Jun;83(6):340-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy.
  • A retrospective study of anal sac tumours without pulmonary metastases, from the author's clinical records for the period July 1989 to July 2002, was conducted to establish the response to treatment with surgery and melphalan chemotherapy.
  • Of 21 dogs with tumours of the anal sacs 19 had apocrine gland adenocarcinomas of anal sac origin, one had a benign papillary cystadenoma and another had a malignant melanoma.
  • Two of the 19 dogs had bilateral anal sac adenocarcinomas.
  • Ten of the 19 dogs with apocrine gland adenocarcinomas of anal sac origin had sublumbar lymphadenopathy.
  • Fourteen dogs with apocrine gland adenocarcinomas of anal sac origin were treated by surgical cytoreduction and chemotherapy with melphalan.
  • Cytoreduction was by local excision of the anal sac in all 14 dogs and concurrent removal of the sublumbar retroperitoneal lymph nodes in the seven dogs with regional lymph node metastases.
  • The median survival time of dogs with sublumbar nodal metastasis was 20 months and for dogs with tumour localised to the anal sac the median survival time was 29.3 months.
  • This study suggests there is a role for melphalan in the treatment of dogs with anal sac adenocarcinoma when combined with cytoreductive surgery, with treatment survival times and the local recurrence rate of the primary tumour comparing favourably with previously published treatment regimes.
  • [MeSH-major] Anal Gland Neoplasms / epidemiology. Anal Sacs. Dog Diseases / epidemiology
  • [MeSH-minor] Adenocarcinoma / veterinary. Animals. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Cystadenoma, Papillary / veterinary. Dogs. Female. Male. Melanoma / veterinary. Neoplasm Metastasis. Records as Topic / veterinary. Retrospective Studies. Survival Analysis. Victoria / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986909.001).
  • [ISSN] 0005-0423
  • [Journal-full-title] Australian veterinary journal
  • [ISO-abbreviation] Aust. Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


17. Wakatsuki K, Oeda Y, Isono T, Yoshioka S, Nukui Y, Yamazaki K, Nabeshima S, Miyazaki M: Adenocarcinoma of the rectosigmoid colon seeding into pre-existing anal fistula. Hepatogastroenterology; 2008 May-Jun;55(84):952-5
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the rectosigmoid colon seeding into pre-existing anal fistula.
  • This paper reports a rare case of rectosigmoid colon carcinoma metastasizing to anal fistula.
  • Two years and 3 months later, a subcutaneous tumor was found at the external opening of fistula.
  • Trans perineal tumor excision plus fistulectomy was performed.
  • Pathology revealed that the colon cancer and the perianal tumor were both moderately differentiated adenocarcinoma.
  • Many reports support the concept of tumor cell implantation in mucosa that have been altered or denuded by various factors.
  • Sixteen reports could be found of implantation metastasis of colorectal cancer into anal fistula.
  • In diagnosis, it is important to differentiate implantation of colorectal cancer in anal fistula from primary anal fistular adenocarcinoma.
  • The histology of the perianal tumor in this patient closely resembles the tumor of the colon.
  • Furthermore, immunohistochemistry for cytokeratins 7 and 20 was performed on tissues to distinguish colorectal adenocarcinoma from anal gland carcinoma.
  • Both colorectal cancer and perianal tumor showed CK7-/CK20+.
  • [MeSH-major] Adenocarcinoma / secondary. Anus Neoplasms / secondary. Neoplasm Seeding. Rectal Fistula / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / surgery. Colon, Sigmoid / pathology. Colon, Sigmoid / surgery. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705305.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


18. Obaidat NA, Awamleh AA, Ghazarian DM: Adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma of the peri-anal region. Eur J Dermatol; 2006 Sep-Oct;16(5):576-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma of the peri-anal region.
  • We report the case of a 67-year-old woman who presented with a peri-anal skin tag.
  • Similar to vulvar lesions, peri-anal apocrine tumours are believed to arise in mammary like glands (MLGs).
  • To the best of our knowledge, this is the first description of a peri-anal adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Sweat Gland / pathology. Anus Neoplasms / pathology. Carcinoma in Situ / pathology. Sweat Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101482.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


19. Nakata M, Miwa Y, Nakayama H, Sakai T, Sasaki N: Localised radiotherapy for a ferret with possible anal sac apocrine adenocarcinoma. J Small Anim Pract; 2008 Sep;49(9):476-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localised radiotherapy for a ferret with possible anal sac apocrine adenocarcinoma.
  • A seven-year-old, neutered male ferret was referred to our hospital with two perianal masses (2.4x3.0 and 2.4x3.5 cm, respectively) that had recurred after initial surgical excision.
  • On histopathology, the masses were diagnosed as apocrine adenocarcinoma possibly of anal gland origin based on tumour location.
  • Cytology of a sample of the pleural effusion suggested mesothelioma, and no obvious pulmonary metastasis of anal sac adenocarcinoma were identified on thoracic radiography.
  • [MeSH-major] Adenocarcinoma / veterinary. Anal Gland Neoplasms / radiotherapy. Anal Sacs. Ferrets
  • [MeSH-minor] Animals. Fatal Outcome. Male. Mesothelioma / radiography. Mesothelioma / surgery. Mesothelioma / veterinary. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / surgery. Neoplasm Recurrence, Local / veterinary. Neoplasms, Second Primary / radiography. Neoplasms, Second Primary / surgery. Neoplasms, Second Primary / veterinary. Pleural Effusion / etiology. Pleural Effusion / radiography. Pleural Effusion / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18631226.001).
  • [ISSN] 0022-4510
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Chetty R, Serra S, Hsieh E: Basaloid squamous carcinoma of the anal canal with an adenoid cystic pattern: histologic and immunohistochemical reappraisal of an unusual variant. Am J Surg Pathol; 2005 Dec;29(12):1668-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous carcinoma of the anal canal with an adenoid cystic pattern: histologic and immunohistochemical reappraisal of an unusual variant.
  • Two cases of a distinctive variety of basaloid squamous carcinoma (BSC) of the anal canal are described.
  • However, the microscopic pattern was dominated by the presence of eosinophilic, hyaline, paucicellular basement membrane-like material around and within tumor nests.
  • The tumor cells exhibited diffuse nuclear positivity with p63.
  • BSC of the anal canal with an adenoid cystic pattern is an infrequently encountered and reported variant, although it is seen more often in the aerodigestive tract.
  • The histologic differential diagnosis is true salivary gland-type adenoid cystic carcinoma and basal cell adenocarcinoma.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Basosquamous / pathology
  • [MeSH-minor] Antibiotics, Antineoplastic / therapeutic use. Antigens, CD20 / metabolism. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cisplatin / therapeutic use. DNA-Binding Proteins. Female. Fluorouracil / therapeutic use. Follow-Up Studies. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Keratins / metabolism. Middle Aged. Mitomycin / therapeutic use. Phosphoproteins / metabolism. Radiotherapy. Time Factors. Trans-Activators / metabolism. Transcription Factors. Treatment Outcome. Tumor Burden. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327441.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antigens, CD20; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 50SG953SK6 / Mitomycin; 68238-35-7 / Keratins; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Miyamoto S, Maeda Y, Hishima T, Sasaki T: [Case of higher efficacy by chemoradiotherapy for anal canal cancer from left cervix metastases to lymph nodes]. Gan To Kagaku Ryoho; 2009 Feb;36(2):329-32
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of higher efficacy by chemoradiotherapy for anal canal cancer from left cervix metastases to lymph nodes].
  • She noticed a left neck tumor and had a checkup by a nearby doctor.
  • In examination, the anal region had phyma in a rectal examination, and biopsy revealed it to be a squamous cell carcinoma.
  • For anal canal cancer cStage IV, we performed chemotherapies of S-1+CDDP and local radiotherapy.
  • There was a contraction of a lymph gland, and CT four months later lower endoscopy did not show the apparent phyma.
  • We have continued chemotherapies in an outpatient department sequentially, but the image shows no increase of lymph gland nor increase of the primary tumor for 20 months with no decrease in QOL of the patient.
  • Chemoradiotherapy including S-1 was effective for this case of anal canal cancer distant metastasis for which no apparent cause has been established thus far.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / blood. Colonoscopy. Female. Humans. Lymphatic Metastasis / pathology. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223758.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


22. Jakab C, Rusvai M, Gálfi P, Mándoki M, Demeter Z, Szabó Z, Kulka J: Expression of claudin-5 in hepatoid gland biopsies. Vet Dermatol; 2010 Jun;21(3):276-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of claudin-5 in hepatoid gland biopsies.
  • There was intense lateral membrane expression of claudin-5 on epithelial cells from normal hepatoid glands, nodular hyperplasia and adenomas, but expression was weaker in hepatoid gland epitheliomas.
  • [MeSH-major] Anal Canal / metabolism. Anal Gland Neoplasms / metabolism. Claudins / biosynthesis. Dog Diseases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20136787.001).
  • [ISSN] 1365-3164
  • [Journal-full-title] Veterinary dermatology
  • [ISO-abbreviation] Vet. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Claudins
  •  go-up   go-down


23. Ganguly A, Wolfe LG: Canine perianal gland carcinoma-associated antigens defined by monoclonal antibodies. Hybridoma (Larchmt); 2006 Feb;25(1):10-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canine perianal gland carcinoma-associated antigens defined by monoclonal antibodies.
  • This study was conducted to distinguish canine perianal gland carcinomas from adenomas using monoclonal antibodies (MAbs).
  • To address this histopathological confusion, two perianal gland carcinoma-associated antigens were defined by mouse MAbs 4A9 and 1A10.
  • These MAbs, generated against a canine mammary carcinoma cell line, reacted strongly with perianal gland carcinoma in preliminary screening and therefore were selected for further investigation.
  • Cellular expression of antigens was examined by indirect immunoperoxidase (IP) assay using MAbs 4A9 and 1A10 against formalin-fixed, paraffin-embedded sections of normal and tumor tissue.
  • Of 25 perianal gland carcinomas, 4A9 antigen was expressed in 100% and 1A10 antigen in 84%.
  • In contrast, perianal gland adenomas were negative for both antigens, and little or no reactivity was detected with normal perianal glands.
  • With eight perianal gland tumors, diagnosis of carcinoma versus adenoma was histologically equivocal, while IP assays consistently revealed focal expression of the 4A9 and 1A10 antigens in these tumors, and the staining coincided with foci of anaplastic cells having a high mitotic index.
  • Results suggest that 4A9 and 1A10 antigens are markers of carcinoma and malignant transformation in canine perianal gland tumors, and can be very useful as diagnostic reagents where the identification of carcinoma versus adenoma requires additional clarification beyond routine histopathological examination.
  • [MeSH-major] Adenocarcinoma / veterinary. Adenoma / veterinary. Anal Gland Neoplasms / diagnosis. Antibodies, Monoclonal. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Carcinoma / veterinary
  • [MeSH-minor] Animals. Cell Line, Tumor. Diagnosis, Differential. Dogs. Female. Mice

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16475876.001).
  • [ISSN] 1554-0014
  • [Journal-full-title] Hybridoma (2005)
  • [ISO-abbreviation] Hybridoma (Larchmt)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  •  go-up   go-down


24. Nakano M, Taura Y, Inoue M: Protein expression of Mdm2 and p53 in hyperplastic and neoplastic lesions of the canine circumanal gland. J Comp Pathol; 2005 Jan;132(1):27-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein expression of Mdm2 and p53 in hyperplastic and neoplastic lesions of the canine circumanal gland.
  • Hyperplastic and neoplastic lesions of the circumanal gland in dogs were examined immunohistochemically for nuclear expression of Mdm2 and p53 proteins.
  • These results suggest that increased expression of Mdm2 is an early event in circumanal gland tumorigenesis, and may be present in the absence of nuclear p53 protein accumulation.
  • [MeSH-major] Adenocarcinoma / veterinary. Adenoma / veterinary. Anal Gland Neoplasms / pathology. Nuclear Proteins / analysis. Perianal Glands / pathology. Proto-Oncogene Proteins / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Animals. Biomarkers, Tumor. Dogs. Hyperplasia / veterinary. Immunoenzyme Techniques / veterinary. Male. Proto-Oncogene Proteins c-mdm2

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15629477.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


25. Jakab C, Rusvai M, Szabó Z, Szabára A, Kulka J: Expression of the claudin-4 molecule in benign and malignant canine hepatoid gland tumours. Acta Vet Hung; 2009 Dec;57(4):463-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the claudin-4 molecule in benign and malignant canine hepatoid gland tumours.
  • Claudin-4 was detected as a well-localised linear circumferential membranous staining pattern of epithelial cells (mature hepatoid cells) in normal hepatoid glands, perianal gland hyperplasias and adenomas.
  • There was a weaker expression in hepatoid gland epitheliomas.
  • The anaplastic, poorly differentiated hepatoid gland carcinomas showed an overexpression of claudin-4.
  • These results suggest that low claudin-4 expression in epitheliomas is a molecular characteristic indicative of increasing cellular disorientation, detachment motility and invasion by tumour cells, and claudin-4 seems to be helpful in distinguishing undifferentiated carcinomas from differentiated carcinomas and epitheliomas of the hepatoid gland.
  • In addition, claudin-4 can help distinguish epithelioma from differentiated carcinoma of the canine hepatoid gland.
  • [MeSH-major] Anal Gland Neoplasms / metabolism. Dog Diseases / metabolism. Gene Expression Regulation, Neoplastic / physiology. Membrane Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19897451.001).
  • [ISSN] 0236-6290
  • [Journal-full-title] Acta veterinaria Hungarica
  • [ISO-abbreviation] Acta Vet. Hung.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Claudin-4; 0 / Membrane Proteins
  •  go-up   go-down


26. Kirillov V, Akimova L: Regression analysis of the initial karyometric data on tumor cells in ductal carcinoma and fibroadenoma of the mammary gland. Anal Quant Cytol Histol; 2010 Apr;32(2):102-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression analysis of the initial karyometric data on tumor cells in ductal carcinoma and fibroadenoma of the mammary gland.
  • OBJECTIVE: To reveal the differences in the parameters of the second order regression curve with a cluster of experimental points on scattergrams showing the dependence of the perimeter on the area of tumor cell nuclei between ductal carcinoma and fibroadenoma of the mammary gland.
  • STUDY DESIGN: Punctate smears taken from patients with ductal carcinoma and fibroadenoma of the mammary gland with coincident histologic and cytologic conclusion were studied and selected.
  • Karyometry of tumor cells was performed with the help of a semiautomatic computer analyzer of digital images.
  • RESULTS: It has been shown that the cluster of experimental points on scattergrams showing the dependence of the perimeter on the area of tumor cell nuclei can be well described by a second order regression curve, which is a parabola.
  • The differences in parabola parameters (coefficients of the parabola equation) characterizing the population of tumor cells in ductal carcinoma and fibroadenoma of the mammary gland were revealed.
  • CONCLUSION: Parameters of the regression curve to a cluster of experimental points on scattergrams showing the dependence of the perimeter on the area of tumor cell nuclei can be used as an additional diagnostic criterion for breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701078.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Lunny DP, Weed E, Nolan PM, Marquardt A, Augustin M, Porter RM: Mutations in gasdermin 3 cause aberrant differentiation of the hair follicle and sebaceous gland. J Invest Dermatol; 2005 Mar;124(3):615-21
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in gasdermin 3 cause aberrant differentiation of the hair follicle and sebaceous gland.
  • Defolliculated (Dfl) is a spontaneous mouse mutant with a hair-loss phenotype that includes altered sebaceous gland differentiation, short hair shafts, aberrant catagen stage of the hair cycle, and eventual loss of the hair follicle.
  • Immunohistochemical analysis revealed that gasdermins are expressed specifically in cells at advanced stages of differentiation in the upper epidermis, the differentiating inner root sheath and hair shaft and in the most mature sebocytes of the sebaceous gland and preputial, meibomium, ceruminous gland, and anal glands.
  • [MeSH-minor] Animals. Antibodies. Antibody Specificity. Base Sequence. Carcinoma, Squamous Cell. Cell Differentiation. Cell Line, Tumor. Humans. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Mice, Mutant Strains. Molecular Sequence Data. Phenotype. Skin Neoplasms


28. Woel R, Beard C, Chen MH, Hurwitz M, Loffredo M, McMahon E, Ching J, Lopes L, D'Amico AV: Acute gastrointestinal, genitourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization. Int J Radiat Oncol Biol Phys; 2005 Jun 1;62(2):392-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute gastrointestinal, genitourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization.
  • A modified intrarectal balloon (Medrad) was used for prostate gland localization and immobilization.
  • However, there was a significant decrease in GU frequency (70% vs. 50%, p = 0.46) as a result of medical interventions and a significant increase in hemorrhoidal irritation (4% vs. 20%, p = 0.02) and anal cutaneous skin reaction (0% vs. 70%, p < 0.001).
  • By 3 months after EOT compared to baseline, there was no significant difference in the proportion of patients experiencing hemorrhoidal bleeding (4% vs. 8%, p = 0.52), requiring intervention for hemorrhoidal symptoms (7% vs. 5%, p = 0.8), or experiencing persistent anal cutaneous skin reaction (0% vs. 3%, p = 0.31).
  • [MeSH-major] Defecation / radiation effects. Hemorrhoids / etiology. Prostatic Neoplasms / radiotherapy. Radiation Injuries / etiology. Radiodermatitis / etiology. Radiotherapy, Conformal / adverse effects. Urination Disorders / etiology
  • [MeSH-minor] Aged. Aged, 80 and over. Anal Canal. Catheterization / methods. Gastrointestinal Tract / radiation effects. Humans. Immobilization / methods. Male. Middle Aged. Prostate. Quality of Life. Radiation Dosage. Radiotherapy Dosage. Urogenital System / radiation effects


29. Park C, Yoo JH, Kim HJ, Lim CY, Kim JW, Lee SY, Kim JH, Jang JI, Park HM: Cyclosporine treatment of perianal gland adenoma concurrent with benign prostatic hyperplasia in a dog. Can Vet J; 2010 Nov;51(11):1279-82
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclosporine treatment of perianal gland adenoma concurrent with benign prostatic hyperplasia in a dog.
  • The nodules were diagnosed as perianal gland adenoma based on histopathologic examination.
  • After therapy with cyclosporin A for 5 wk, the perianal masses were moderately shrunken.
  • [MeSH-major] Adenoma / veterinary. Anal Gland Neoplasms / drug therapy. Cyclosporine / therapeutic use. Dog Diseases / drug therapy. Immunosuppressive Agents / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2001 Mar 5;193(5):607-20 [11238591.001]
  • [Cites] J Neurochem. 1997 Mar;68(3):1142-9 [9048760.001]
  • [Cites] Vet Dermatol. 2002 Apr;13(2):77-87 [11972891.001]
  • [Cites] J Am Vet Med Assoc. 2002 Aug 1;221(3):370-7 [12164533.001]
  • [Cites] J Am Vet Med Assoc. 2002 Apr 1;220(7):1009-16 [12420778.001]
  • [Cites] Vet Dermatol. 2003 Feb;14(1):1-9 [12603680.001]
  • [Cites] Vet Dermatol. 2003 Feb;14(1):11-22 [12603681.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Jun;284(6):C1593-603 [12734112.001]
  • [Cites] J Small Anim Pract. 2004 May;45(5):238-43 [15163050.001]
  • [Cites] Vet Rec. 1975 Dec 13;97(24):464-7 [173072.001]
  • [Cites] Cancer Res. 1977 Jul;37(7 Pt 1):2068-71 [861936.001]
  • [Cites] Aust Vet J. 2004 Nov;82(11):681-5 [15977612.001]
  • [Cites] J Am Vet Med Assoc. 2005 Jun 1;226(11):1855-63 [15934253.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Mar;46(3):782-90 [15728531.001]
  • [Cites] J Neurol. 1999 May;246(5):339-46 [10399863.001]
  • [Cites] Transplant Proc. 1998 Aug;30(5):2167-70 [9723430.001]
  • [Cites] Vet Surg. 1998 Jan-Feb;27(1):64-8 [9449179.001]
  • [Cites] J Am Vet Med Assoc. 1997 Nov 15;211(10):1249-53 [9373359.001]
  • [Cites] J Urol. 1987 Oct;138(4 Pt 2):991-5 [3656581.001]
  • [Cites] Can Vet J. 1997 Jan;38(1):39-41 [8993784.001]
  • [Cites] J Am Vet Med Assoc. 1996 Feb 15;208(4):517-9 [8603899.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2689-98 [7545467.001]
  • [Cites] Mol Cell Endocrinol. 1994 Feb;99(1):21-4 [8187957.001]
  • [Cites] Transplantation. 1992 Jan;53(1):190-5 [1310171.001]
  • [Cites] Am J Vet Res. 1988 Oct;49(10):1742-6 [3189991.001]
  • [Cites] Endocrinology. 1988 Aug;123(2):1069-74 [3396498.001]
  • [Cites] Res Vet Sci. 2006 Oct;81(2):231-6 [16427103.001]
  • [Cites] Vet Rec. 2001 May 26;148(21):662-3 [11400987.001]
  • (PMID = 21286331.001).
  • [ISSN] 0008-5286
  • [Journal-full-title] The Canadian veterinary journal = La revue vétérinaire canadienne
  • [ISO-abbreviation] Can. Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  • [Other-IDs] NLM/ PMC2957039
  •  go-up   go-down


30. Ito FA, Ito K, Coletta RD, Graner E, de Almeida OP, Lopes MA: Salivary gland tumors: immunohistochemical study of EGF, EGFR, ErbB-2, FAS and Ki-67. Anal Quant Cytol Histol; 2009 Oct;31(5):280-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland tumors: immunohistochemical study of EGF, EGFR, ErbB-2, FAS and Ki-67.
  • OBJECTIVE: To analyze the expression of ErbB-1 (Her-1 or EGFR), ErbB-2 (Her-2 or neu), ErbB-3 (Her-3) and ErbB-4 (Her-4) and their correlation in 3 different types of salivary gland tumors.
  • CONCLUSION: EGF, EGFR, ErbB-2 and FAS were commonly found and seem to be important in the tumorigenesis of salivary gland tumors, particularly in percentage of strongly positive cases.
  • CONCLUSION: EGF, EGFR, ErbB-2 and FAS were commonly found and seem to be important in the tumorigenesis of salivary gland tumors, particularly in MEC. (Anal Quant Cytol Histol 2009;31:280-287)

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701095.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Biomarkers, Tumor; 0 / FAS protein, human; 0 / Ki-67 Antigen; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


31. Kestler DP, Foster JS, Macy SD, Murphy CL, Weiss DT, Solomon A: Expression of odontogenic ameloblast-associated protein (ODAM) in dental and other epithelial neoplasms. Mol Med; 2008 May-Jun;14(5-6):318-26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of odontogenic ameloblast-associated protein (ODAM) in dental and other epithelial neoplasms.
  • We now report that this molecule also is found in certain human tissues, principally the salivary gland and trachea, as evidenced by RNA array analysis and immunohistochemistry-utilizing antibodies prepared against synthetic ODAM-related peptides and recombinant protein.
  • Based on our findings, we posit that ODAM is a developmental antigen that has an essential role in tooth maturation and in the pathogenesis of certain odontogenic and other epithelial neoplasms; further, we suggest that ODAM may serve as a novel prognostic biomarker, as well as a potential diagnostic and therapeutic target for patients with breast and other epithelial forms of cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mech Dev. 2000 Mar 15;92(1):19-29 [10704885.001]
  • [Cites] J Biol Chem. 2007 Dec 14;282(50):36370-6 [17921454.001]
  • [Cites] Anal Biochem. 2000 May 1;280(2):216-20 [10790303.001]
  • [Cites] Oral Oncol. 2000 Jan;36(1):17-26 [10889914.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(3):794-810 [11154267.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4060-5 [12646701.001]
  • [Cites] Genomics. 2003 Oct;82(4):417-32 [13679022.001]
  • [Cites] J Lab Clin Med. 2003 Nov;142(5):348-55 [14647039.001]
  • [Cites] Jpn J Exp Med. 1978 Feb;48(1):61-8 [209229.001]
  • [Cites] Mech Ageing Dev. 2005 Feb;126(2):309-15 [15621212.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18147-52 [15608061.001]
  • [Cites] Histopathology. 2005 Mar;46(3):256-69 [15720411.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 May;46(5):1572-80 [15851553.001]
  • [Cites] Arch Oral Biol. 2005 Jul;50(7):599-609 [15892946.001]
  • [Cites] Mol Cancer. 2005;4(1):15 [15869706.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Jun;63(6):852-5 [15944987.001]
  • [Cites] Dev Dyn. 2005 Jul;233(3):754-9 [15861403.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1698-705 [15905200.001]
  • [Cites] Vet Immunol Immunopathol. 2005 Dec 15;108(3-4):253-64 [16040129.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 16;338(2):1197-203 [16259954.001]
  • [Cites] Cancer Lett. 2005 Dec 18;230(2):187-98 [16297705.001]
  • [Cites] J Dent Res. 2005 Dec;84(12):1127-32 [16304441.001]
  • [Cites] Oral Oncol. 2006 Apr;42(4):398-408 [16376138.001]
  • [Cites] Oncogene. 2006 Apr 20;25(17):2546-57 [16331256.001]
  • [Cites] Eur J Oral Sci. 2006 May;114 Suppl 1:139-46; discussion 164-5, 380-1 [16674676.001]
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):9-34 [16680569.001]
  • [Cites] J Exp Zool B Mol Dev Evol. 2006 May 15;306(3):295-316 [16358265.001]
  • [Cites] J Cell Biochem. 2008 Feb 15;103(3):941-56 [17647262.001]
  • [Cites] Amyloid. 2008 Jun;15(2):89-95 [18484335.001]
  • [Cites] Cancer Biol Ther. 2006 Jun;5(6):674-83 [16855373.001]
  • [Cites] Biochem J. 2006 Oct 1;399(1):37-46 [16787391.001]
  • [Cites] Arthritis Rheum. 2006 Nov;54(11):3545-50 [17075859.001]
  • [Cites] Oncol Rep. 2007 Jan;17(1):245-51 [17143505.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13(4):1033-67 [17158753.001]
  • [Cites] J Gastroenterol. 2006 Nov;41(11):1053-63 [17160516.001]
  • [Cites] DNA Res. 2006 Oct 31;13(5):229-43 [17107969.001]
  • [Cites] PLoS One. 2006;1:e93 [17183725.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):217-26 [17229949.001]
  • [Cites] Eur J Oral Sci. 2007 Apr;115(2):153-60 [17451507.001]
  • [Cites] BMC Cancer. 2007;7:73 [17474988.001]
  • [Cites] Cells Tissues Organs. 2007;186(1):25-48 [17627117.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2007 Sep;12(2-3):163-73 [17623270.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1777-88 [10766157.001]
  • (PMID = 18472969.001).
  • [ISSN] 1076-1551
  • [Journal-full-title] Molecular medicine (Cambridge, Mass.)
  • [ISO-abbreviation] Mol. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA010056; United States / NCI NIH HHS / CA / CA-10056
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / ODAM protein, human; 0 / ODAM protein, mouse; 0 / Proteins
  • [Other-IDs] NLM/ PMC2323332
  •  go-up   go-down


32. Kariagina A, Xie J, Leipprandt JR, Haslam SZ: Amphiregulin mediates estrogen, progesterone, and EGFR signaling in the normal rat mammary gland and in hormone-dependent rat mammary cancers. Horm Cancer; 2010 Oct;1(5):229-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amphiregulin mediates estrogen, progesterone, and EGFR signaling in the normal rat mammary gland and in hormone-dependent rat mammary cancers.
  • We investigated the molecular and cellular mechanisms of E and/or P-induced in vivo proliferation, in the normal rat mammary gland and in hormone-dependent rat mammary cancers which share many characteristics with the normal human breast and hormone-dependent breast cancers.
  • We show that E+P treatment induced significantly greater proliferation in both the normal gland and mammary cancers compared to E alone.
  • In both the normal gland and tumors, E+P-induced proliferation was mediated through the increased production of amphiregulin (Areg), an epidermal growth factor receptor (EGFR) ligand, and the activation of intracellular signaling pathways (Erk, Akt, JNK) downstream of EGFR that regulate proliferation.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Author(s) 2010. This article is published with open access at Springerlink.com.
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5209-18 [11717311.001]
  • [Cites] Mol Endocrinol. 2006 Nov;20(11):2656-70 [16762974.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):3-15 [12160084.001]
  • [Cites] Breast Cancer Res. 2002;4(5):187-90 [12223122.001]
  • [Cites] In Vivo. 2003 Jul-Aug;17(4):349-57 [12929590.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2003 Apr;8(2):215-23 [14635796.001]
  • [Cites] Steroids. 2003 Nov;68(10-13):789-94 [14667969.001]
  • [Cites] Endocrinology. 2004 Jan;145(1):104-12 [14512435.001]
  • [Cites] Cell Cycle. 2004 Feb;3(2):145-8 [14712077.001]
  • [Cites] Lab Invest. 1990 Mar;62(3):244-78 [2107367.001]
  • [Cites] Endocrinology. 1994 Jan;134(1):84-90 [8275973.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3868-77 [8033109.001]
  • [Cites] Breast Cancer Res Treat. 1996;39(1):7-20 [8738602.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):696-701 [9435255.001]
  • [Cites] J Biol Chem. 1998 Nov 20;273(47):31308-16 [9813039.001]
  • [Cites] Breast Cancer Res Treat. 1999 Feb;53(3):217-27 [10369068.001]
  • [Cites] Mol Endocrinol. 1999 Jun;13(6):829-36 [10379882.001]
  • [Cites] Mol Endocrinol. 1999 Oct;13(10):1657-71 [10517668.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(24):10542-57 [15572662.001]
  • [Cites] Mol Cell Biol. 2006 Feb;26(3):1002-13 [16428453.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(2):131-46 [16261397.001]
  • [Cites] Menopause. 2006 Jan-Feb;13(1):72-9 [16607101.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5304-13 [16707456.001]
  • [Cites] Mol Cell Biol. 2007 Jan;27(2):466-80 [17074804.001]
  • [Cites] Mol Endocrinol. 2007 Feb;21(2):359-75 [17138644.001]
  • [Cites] Pathobiology. 2006;73(5):213-23 [17314492.001]
  • [Cites] Steroids. 2007 Feb;72(2):188-201 [17173941.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5455-60 [17369357.001]
  • [Cites] Endocrinology. 2007 May;148(5):2290-300 [17317767.001]
  • [Cites] Endocrinology. 2007 Jun;148(6):2723-36 [17332059.001]
  • [Cites] J Biol Chem. 2008 Jan 11;283(2):739-50 [17942395.001]
  • [Cites] Mol Endocrinol. 2008 Apr;22(4):823-37 [18202149.001]
  • [Cites] Int J Biol Markers. 2008 Jan-Mar;23(1):1-9 [18409144.001]
  • [Cites] Mol Cancer Ther. 2008 Apr;7(4):972-9 [18375820.001]
  • [Cites] Endocrinology. 2008 May;149(5):2098-107 [18218689.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):181-94 [18470483.001]
  • [Cites] Endocrinology. 2009 Mar;150(3):1485-94 [18988671.001]
  • [Cites] J Steroid Biochem Mol Biol. 2009 Feb;113(3-5):163-70 [19103290.001]
  • [Cites] Int Arch Allergy Immunol. 2009;149 Suppl 1:39-44 [19494503.001]
  • [Cites] Breast Cancer Res Treat. 2009 Nov;118(1):161-8 [19205874.001]
  • [Cites] JAMA. 2010 Oct 20;304(15):1684-92 [20959578.001]
  • [Cites] Nature. 2010 Nov 4;468(7320):98-102 [20881962.001]
  • [Cites] Nature. 2010 Nov 4;468(7320):103-7 [20881963.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Dec;84(12):4559-65 [10599719.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1032-7 [10655479.001]
  • [Cites] Genes Dev. 2000 Mar 15;14(6):650-4 [10733525.001]
  • [Cites] Science. 2000 Sep 8;289(5485):1751-4 [10976068.001]
  • [Cites] Anal Biochem. 2005 Mar 1;338(1):136-42 [15707944.001]
  • [Cites] Endocrinology. 2005 Aug;146(8):3577-88 [15878961.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Jul;96(2):95-108 [15908197.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Nov;289(5):E857-63 [15985451.001]
  • [Cites] Horm Res. 2000;54(1):32-7 [11182633.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2390-400 [11402335.001]
  • [Cites] J Clin Pathol. 2001 Aug;54(8):624-30 [11477119.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(18):6122-31 [11509655.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):617-28 [16728587.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1604-9 [16685276.001]
  • [Cites] Dev Biol. 2006 Jul 15;295(2):589-603 [16678816.001]
  • [Cites] Breast Cancer Res Treat. 2002 Mar;72(2):163-72 [12038707.001]
  • (PMID = 21258428.001).
  • [ISSN] 1868-8500
  • [Journal-full-title] Hormones & cancer
  • [ISO-abbreviation] Horm Cancer
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / U01 ES012800
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AREG protein, human; 0 / Amphiregulin; 0 / Areg protein, rat; 0 / EGF Family of Proteins; 0 / Estrogens; 0 / Glycoproteins; 0 / Intercellular Signaling Peptides and Proteins; 4G7DS2Q64Y / Progesterone; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


33. Kirillov V, Stebenyaeva E, Demidchik E: Comparative morphometric analysis of thyrocytes in a primary tumor and regional metastases in papillary thyroid gland cancer. Anal Quant Cytol Histol; 2008 Aug;30(4):209-17
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative morphometric analysis of thyrocytes in a primary tumor and regional metastases in papillary thyroid gland cancer.
  • OBJECTIVE: To perform a comparative analysis of thyrocyte nuclei and the aggregability degree in tumor cells in the thyroid gland with papillary cancer and in cervical lymph nodes with metastases.
  • CONCLUSION: Malignant cells of the primary tumor have been shown to have evident quantitative features of nuclear atypia and a higher degree of aggregability compared with the norm.
  • The differences between the quantitative features of nuclei and aggregates in malignant cells of the primary tumor in the thyroid gland and its metastases in cervical lymph nodes were less pronounced.

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773739.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Mellanby RJ, Craig R, Evans H, Herrtage ME: Plasma concentrations of parathyroid hormone-related protein in dogs with potential disorders of calcium metabolism. Vet Rec; 2006 Dec 16;159(25):833-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The plasma concentrations of total calcium, ionised calcium, albumin, parathyroid hormone and parathyroid hormone-related protein (PTHrp) were measured in 25 dogs with lymphoma, nine dogs with primary hyperparathyroidism and seven dogs with adenocarcinoma of the apocrine gland of the anal sac.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / veterinary. Anal Sacs. Animals. Case-Control Studies. Dogs. Hyperparathyroidism / diagnosis. Hyperparathyroidism / veterinary. Lymphoma / diagnosis. Lymphoma / veterinary. Predictive Value of Tests. Sensitivity and Specificity. Sweat Gland Neoplasms / diagnosis. Sweat Gland Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17172477.001).
  • [ISSN] 0042-4900
  • [Journal-full-title] The Veterinary record
  • [ISO-abbreviation] Vet. Rec.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein
  •  go-up   go-down


35. Pisani G, Millanta F, Lorenzi D, Vannozzi I, Poli A: Androgen receptor expression in normal, hyperplastic and neoplastic hepatoid glands in the dog. Res Vet Sci; 2006 Oct;81(2):231-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neoplasms of the perianal glands are common in the dog, particularly in the male.
  • Thirty-one samples of canine hepatoid gland tissues were investigated.
  • The lesions, classified according to WHO criteria, were comprised of 19 hyperplastic tissues, 10 benign lesions (2 hepatoid gland epithelioma and 8 hepatoid adenomas), and 19 carcinomas.
  • These results demonstrate that increased AR expression is maintained throughout perianal gland cancer progression and that hepatoid gland carcinomas still express AR.
  • [MeSH-major] Anal Gland Neoplasms / metabolism. Dog Diseases / metabolism. Receptors, Androgen / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16427103.001).
  • [ISSN] 0034-5288
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Androgen
  •  go-up   go-down


36. Venclauskas L, Saladzinskas Z, Tamelis A, Pranys D, Pavalkis D: Mucinous adenocarcinoma arising in an anorectal fistula. Medicina (Kaunas); 2009;45(4):286-90
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous adenocarcinoma in association with chronic anal fistula is a rare case in clinical practice.
  • The aim of this article was to report a rare case of anal gland mucinous adenocarcinoma in a patient who was treated in the Hospital of Kaunas University of Medicine.
  • Endoanal ultrasound findings showed soft tissue induration at the site of anorectal fistula, no tumor in the rectum wall.
  • Histological examination after abdominoperineal resection revealed anal duct mucinous adenocarcinoma pT2 N0 L0 V0 R0, G2.
  • [MeSH-major] Adenocarcinoma, Mucinous. Anus Neoplasms. Rectal Fistula / complications
  • [MeSH-minor] Abscess / complications. Aged. Anal Canal / pathology. Humans. Male. Neoplasm Staging. Perineum

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19423959.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Lithuania
  •  go-up   go-down


37. Ranaldi R, Morichetti D, Goteri G, Martino A: Immature teratoma of the mediastinum arising in ectopic thyroid tissue: a case report. Anal Quant Cytol Histol; 2009 Aug;31(4):233-8
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histologic examination revealed the presence of a discontinuous rim of compressed thyroid follicles on the outer aspect of the tumor capsule.
  • This finding is consistent with the origin of the teratoma in ectopic thyroid tissue, and it has not been previously described in the literature.
  • The patient was free of disease after 22 months, in accordance with the benign behavior of immature teratoma in infancy.
  • CONCLUSION: Ectopic thyroid tissue can undergo the same pathologic changes as the thyroid gland, including the rare occurrence of teratoma.

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736871.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


38. Huang ZM, Li HZ, Xiao H, Ji ZG: [Melanoma adrenal metastasis: report of 3 cases and literature review]. Zhonghua Yi Xue Za Zhi; 2010 Apr 27;90(16):1123-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two cases had a history of cutaneous melanoma and another one suffered previously from anal melanoma.
  • The disease-free interval to adrenal metastasis were 25, 37, 33 months respectively.
  • One received adrenalectomy via retroperitoneal laparoscopic approach while another patient with tumor thrombus in inferior vena cava underwent right adrenalectomy and extraction of tumor thrombus out of inferior vena cava in traditional open surgery.
  • CONCLUSION: Melanoma metastasis to adrenal gland is rare and it generally has a poor prognosis.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646432.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 8
  •  go-up   go-down


39. Park JK, Hong IH, Ki MR, Hong KS, Ji AR, Do SH, Jeong KS: Multiple perianal infundibular follicular cysts in a dog. Vet Dermatol; 2010 Jun;21(3):303-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple perianal infundibular follicular cysts in a dog.
  • This case report describes a 7-year-old male cocker spaniel dog with multiple perianal infundibular follicular cysts.
  • Clinically the dog had moderate anal sacculitis, peri-anal pruritus causing it to 'scoot' and lick the area.
  • On examination of the perianal area, there were over 100 firm, well circumscribed papules, ranged from 0.2 to 0.5 cm in diameter with a central pore, and were found in the perianal region.
  • Alopecia was present in the perianal region.
  • The skin tissue in the perianal region resected surgically was submitted for histological examination.
  • The affected dog showed moderate anal sacculitis.
  • Anal sacculitis commonly causes repeated scooting or licking the area around the anus.
  • Therefore, the multiple follicular cysts in the present case appear to be primarily a sequela to chronic external trauma to the perianal area, probably in response to anal sacculitis.
  • To the best of the authors' knowledge, the present report is the first documented case of multiple perianal infundibular follicular cysts in a dog.
  • [MeSH-major] Anal Gland Neoplasms / pathology. Dog Diseases / pathology. Follicular Cyst / veterinary. Neoplasms, Multiple Primary / veterinary
  • [MeSH-minor] Anal Sacs / pathology. Animals. Dogs. Male. Perianal Glands / pathology. Perianal Glands / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20136788.001).
  • [ISSN] 1365-3164
  • [Journal-full-title] Veterinary dermatology
  • [ISO-abbreviation] Vet. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


40. Martins AM, Vasques-Peyser A, Torres LN, Matera JM, Dagli ML, Guerra JL: Retrospective--systematic study and quantitative analysis of cellular proliferation and apoptosis in normal, hyperplastic and neoplastic perianal glands in dogs. Vet Comp Oncol; 2008 Jun;6(2):71-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective--systematic study and quantitative analysis of cellular proliferation and apoptosis in normal, hyperplastic and neoplastic perianal glands in dogs.
  • Neoplasms in the perianal region are frequently diagnosed in dogs.
  • In this study, 240 neoplasms of the perianal glands of dogs were retrieved from the Department of Pathology archives of the Faculty of Veterinary Medicine and Zootechny of University of São Paulo (FMVZ/USP), from 1984 to 2004.
  • These results show up the importance of studying cell proliferation and apoptosis to understand the carcinogenesis of dog perianal gland.
  • [MeSH-major] Anal Gland Neoplasms / pathology. Apoptosis. Dog Diseases / pathology. Hyperplasia / veterinary. Perianal Glands / cytology. Proliferating Cell Nuclear Antigen / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178666.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


41. Di Ieva A, Grizzi F, Ceva-Grimaldi G, Russo C, Gaetani P, Aimar E, Levi D, Pisano P, Tancioni F, Nicola G, Tschabitscher M, Dioguardi N, Baena RR: Fractal dimension as a quantitator of the microvasculature of normal and adenomatous pituitary tissue. J Anat; 2007 Nov;211(5):673-80
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study provides the first demonstration that fractal dimension is an objective and valid quantitator of the two-dimensional geometrical complexity of the pituitary gland microvascular network in physiological and pathological states.
  • Further studies are needed to compare the vascular surface fractal dimension estimates in different subtypes of pituitary tumours and correlate them with clinical parameters in order to evaluate whether the distribution pattern of vascular growth is related to a particular state of the pituitary gland.
  • [MeSH-major] Adenoma / physiopathology. Fractals. Image Processing, Computer-Assisted. Pituitary Gland / blood supply. Pituitary Neoplasms / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Anat. 2005 Aug;207(2):107-15 [16050897.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1159-62 [10720055.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1441-5 [10780524.001]
  • [Cites] J Endocrinol. 2000 May;165(2):475-81 [10810311.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3683-8 [10919633.001]
  • [Cites] Virchows Arch. 2001 Jun;438(6):595-602 [11469692.001]
  • [Cites] J Theor Biol. 2001 Sep 21;212(2):183-90 [11531384.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3305-7 [11595729.001]
  • [Cites] Ital J Anat Embryol. 2001;106(2 Suppl 1):337-46 [11729975.001]
  • [Cites] Br J Cancer. 2002 Jan 21;86(2):244-9 [11870514.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 19;94(12):883-93 [12072542.001]
  • [Cites] Nat Rev Genet. 2002 Jul;3(7):513-23 [12094229.001]
  • [Cites] Cell. 2003 Jan 10;112(1):19-28 [12526790.001]
  • [Cites] J Endocrinol Invest. 2003 Jan;26(1):23-8 [12602530.001]
  • [Cites] Nat Med. 2003 Jun;9(6):653-60 [12778163.001]
  • [Cites] Nat Med. 2003 Jun;9(6):685-93 [12778167.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1835-41 [12932660.001]
  • [Cites] Pathol Res Pract. 2003;199(7):475-82 [14521264.001]
  • [Cites] Endocr Pathol. 2003 Fall;14(3):239-47 [14586069.001]
  • [Cites] Clin Neurosurg. 1969;16:185-217 [5811707.001]
  • [Cites] Am J Pathol. 1972 Apr;67(1):109-26 [5055626.001]
  • [Cites] Ann Surg. 1972 Mar;175(3):409-16 [5077799.001]
  • [Cites] J Microsc. 1981 Jan;121(Pt 1):51-63 [7230254.001]
  • [Cites] Arch Pathol Lab Med. 1983 Sep;107(9):488-91 [6309114.001]
  • [Cites] Neuroendocrinology. 1986;43(2):159-65 [3523276.001]
  • [Cites] Yale J Biol Med. 1987 Sep-Oct;60(5):421-35 [3424875.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Anal Quant Cytol Histol. 1993 Apr;15(2):144-9 [8318129.001]
  • [Cites] J Pathol. 1993 Aug;170(4):479-84 [8410497.001]
  • [Cites] J Pathol. 1994 Apr;172(4):317-23 [8207612.001]
  • [Cites] Micron. 1994;25(1):101-13 [8069610.001]
  • [Cites] J Neurosurg. 1994 Dec;81(6):902-9 [7525899.001]
  • [Cites] Pediatr Pathol Lab Med. 1995 Mar-Apr;15(2):259-68 [8597813.001]
  • [Cites] Mod Pathol. 1996 Mar;9(3):174-82 [8685210.001]
  • [Cites] J Pathol. 1996 Jun;179(2):210-7 [8758215.001]
  • [Cites] J Pathol. 1997 May;182(1):1-8 [9227334.001]
  • [Cites] Am J Pathol. 1997 Nov;151(5):1417-23 [9358768.001]
  • [Cites] Nat Med. 1998 Aug;4(8):882-5 [9701230.001]
  • [Cites] J Theor Biol. 1999 Apr 21;197(4):517-26 [10196094.001]
  • [Cites] Science. 1999 Jun 18;284(5422):1994-8 [10373119.001]
  • [Cites] BMC Cancer. 2005 Feb 8;5:14 [15701176.001]
  • [Cites] Histopathology. 2005 May;46(5):481-9 [15842629.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):71-6 [16078111.001]
  • [Cites] Hum Pathol. 2005 Oct;36(10):1090-5 [16226108.001]
  • [Cites] Cell Tissue Res. 2005 Nov;322(2):257-67 [16059703.001]
  • [Cites] J Anat. 2006 Jan;208(1):47-57 [16420378.001]
  • [Cites] Histopathology. 2006 Mar;48(4):407-16 [16487362.001]
  • [Cites] J Anat. 2006 Mar;208(3):353-9 [16533317.001]
  • (PMID = 17784937.001).
  • [ISSN] 0021-8782
  • [Journal-full-title] Journal of anatomy
  • [ISO-abbreviation] J. Anat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers
  • [Other-IDs] NLM/ PMC2375776
  •  go-up   go-down


42. Kirillov VA, Stebenyaeva EE, Paplevka AA, Demidchik EP: Quantitative changes in thyroid lymphoid cells as a marker of malignancy. Anal Quant Cytol Histol; 2005 Apr;27(2):101-10
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These features formed the criteria for differentiation between malignant and benign disease.
  • CONCLUSION: One can determine the presence of a malignant tumor in the thyroid gland from the diagnostic index value.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913203.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


43. Simeonov R, Simeonova G: Computer-assisted nuclear morphometry in the cytological evaluation of canine perianal adenocarcinomas. J Comp Pathol; 2008 Nov;139(4):226-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-assisted nuclear morphometry in the cytological evaluation of canine perianal adenocarcinomas.
  • Stained cytological specimens from 18 canine perianal adenocarcinomas were analyzed by computer-assisted nuclear morphometry in order to evaluate the prognostic value of this technique.
  • These results indicate that MNA, MNP, D max and D min may be used as prognostic indicators for canine perianal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / veterinary. Anal Gland Neoplasms / pathology. Cell Nucleus / ultrastructure. Diagnosis, Computer-Assisted / methods. Dog Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18822421.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Sierra Montenegro E, Sierra Luzuriaga G, Leone Stay G, Salazar Menéndez V, Quiñonez Auria C: Perianal nodular hidradenocarcinoma. Case report. Cir Cir; 2010 Mar-Apr;78(2):173-6
Genetic Alliance. consumer health - Hidradenocarcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perianal nodular hidradenocarcinoma. Case report.
  • Nodular hidradenocarcinoma (NH) is a rare malignant and aggressive tumor of the eccrine glands.
  • The objective of this study is to report a case of perianal hidradenocarcinoma.
  • Physical examination revealed a small perianal tumor that was palpated near the anal canal.
  • Pathology report revealed perianal hidradenoma.
  • Extensive resection of the tumor was done.
  • CONCLUSIONS: In patients with a first symptom of metastases in the inguinal region, suspicion must be directed to the anal canal.
  • [MeSH-major] Eccrine Glands. Sweat Gland Neoplasms
  • [MeSH-minor] Aged. Anal Canal. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20478121.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


45. Betancourt AM, Eltoum IA, Desmond RA, Russo J, Lamartiniere CA: In utero exposure to bisphenol A shifts the window of susceptibility for mammary carcinogenesis in the rat. Environ Health Perspect; 2010 Nov;118(11):1614-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Our goal in this study was to determine whether prenatal exposure to BPA predisposes the adult rat mammary gland to carcinogenesis.
  • RESULTS: Prenatal exposure of the dam to 250 microg BPA/kg BW combined with a single exposure of female offspring to DMBA on PND100, but not on PND50, significantly increased tumor incidence while decreasing tumor latency compared with the control group.
  • Differentially regulated proteins in the mammary gland included estrogen receptor-alpha, progesterone receptor-A, Bcl-2, steroid receptor coactivators, epidermal growth factor receptor, phospho-insulinlike growth factor 1 receptor, and phospho-Raf.
  • CONCLUSIONS: Our study demonstrates that oral prenatal exposure to BPA increases mammary cancer susceptibility in offspring and shifts the window of susceptibility for DMBA-induced tumorigenesis in the rat mammary gland from PND50 to PND100.

  • MedlinePlus Health Information. consumer health - Reproductive Hazards.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BISPHENOL A DISODIUM SALT .
  • Hazardous Substances Data Bank. BISPHENOL A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicol Appl Pharmacol. 2000 Nov 1;168(3):225-34 [11042095.001]
  • [Cites] Genome Res. 2010 Jun;20(6):733-44 [20442245.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):903-7 [11221879.001]
  • [Cites] Biol Reprod. 2001 Oct;65(4):1215-23 [11566746.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):67-76 [12160087.001]
  • [Cites] Environ Health Perspect. 2002 Nov;110(11):A703-7 [12417499.001]
  • [Cites] J Pharm Biomed Anal. 2003 Jan 15;30(6):1743-9 [12485715.001]
  • [Cites] Cancer Res. 1972 Jul;32(7):1404-15 [4337828.001]
  • [Cites] J Natl Cancer Inst. 1975 Apr;54(4):1007-9 [805252.001]
  • [Cites] Cancer Res. 1976 Feb;36(2 Pt 1):319-24 [816459.001]
  • [Cites] Proc Natl Acad Sci U S A. 1977 Sep;74(9):4020-4 [410031.001]
  • [Cites] J Natl Cancer Inst. 1978 Dec;61(6):1451-9 [102857.001]
  • [Cites] Am J Pathol. 1979 Sep;96(3):721-36 [112872.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Jul;79(13):3987-91 [6955785.001]
  • [Cites] Environ Health Perspect. 1983 Mar;49:185-99 [6403347.001]
  • [Cites] Cancer Res. 1985 Aug;45(8):3415-43 [3926298.001]
  • [Cites] Monogr Endocrinol. 1989;32:1-133 [2695836.001]
  • [Cites] Lab Invest. 1990 Mar;62(3):244-78 [2107367.001]
  • [Cites] J Cell Biol. 1994 Nov;127(4):1097-109 [7962070.001]
  • [Cites] Environ Health Perspect. 1995 Jun;103(6):608-12 [7556016.001]
  • [Cites] Environ Health Perspect. 1996 Mar;104(3):298-305 [8919768.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Carcinogenesis. 1998 Sep;19(9):1623-9 [9771934.001]
  • [Cites] Br J Cancer. 1965 Mar;19:160-6 [14289051.001]
  • [Cites] Environ Health Perspect. 2005 Apr;113(4):391-5 [15811827.001]
  • [Cites] Arch Toxicol. 2005 May;79(5):243-52 [15902421.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1067-78 [15920556.001]
  • [Cites] J Nutr. 2005 Dec;135(12 Suppl):2953S-2959S [16317154.001]
  • [Cites] Endocrinology. 2006 Jun;147(6 Suppl):S56-69 [16690810.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5624-32 [16740699.001]
  • [Cites] Toxicology. 2006 Sep 21;226(2-3):79-89 [16860916.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13(4):1135-45 [17158759.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1405-11 [17332282.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):80-6 [17366824.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):116-21 [17366830.001]
  • [Cites] Reprod Toxicol. 2007 Apr-May;23(3):383-90 [17123778.001]
  • [Cites] J Endocrinol. 2008 Jan;196(1):101-12 [18180321.001]
  • [Cites] Acta Oncol. 2009;48(4):522-31 [19173092.001]
  • [Cites] Environ Health Perspect. 2009 Jun;117(6):910-5 [19590682.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8217-22 [19843848.001]
  • [Cites] J Proteomics. 2010 Apr 18;73(6):1241-53 [20219716.001]
  • [CommentIn] Environ Health Perspect. 2010 Nov;118(11):A490 [21465746.001]
  • (PMID = 20675265.001).
  • [ISSN] 1552-9924
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / U01 ES012771; United States / NIEHS NIH HHS / ES / U01 ES/CA ES012771
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzhydryl Compounds; 0 / Carcinogens, Environmental; 0 / Endocrine Disruptors; 0 / Phenols; MLT3645I99 / bisphenol A
  •  go-up   go-down


46. Ginsburg E, Alexander S, Lieber S, Tarplin S, Jenkins L, Pang L, Heger CD, Goldsmith P, Vonderhaar BK: Characterization of ductal and lobular breast carcinomas using novel prolactin receptor isoform specific antibodies. BMC Cancer; 2010 Dec 13;10:678
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Prolactin is a polypeptide hormone responsible for proliferation and differentiation of the mammary gland.
  • Since these antibodies are specifically directed against each PRLR isoform, they are valuable tools for the evaluation of breast cancer PRLR content and have potential clinical importance in treatment of this disease by providing new reagents to study the protein expression of the human PRLR.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):41086-94 [11518703.001]
  • [Cites] Mol Endocrinol. 2001 May;15(5):819-31 [11328861.001]
  • [Cites] J Mol Endocrinol. 2003 Feb;30(1):31-47 [12580759.001]
  • [Cites] Endocr Rev. 2003 Feb;24(1):1-27 [12588805.001]
  • [Cites] JAMA. 2003 Mar 19;289(11):1421-4 [12636465.001]
  • [Cites] Mol Biol Cell. 2004 Jun;15(6):2523-36 [15034139.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5677-82 [15313907.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6814-9 [15375001.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Nov;18(11):1157-62 [6297917.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Apr;83(7):2258-62 [3083418.001]
  • [Cites] Cancer Res. 1987 Jul 1;47(13):3509-14 [3581086.001]
  • [Cites] FEBS Lett. 1989 Jun 5;249(2):189-94 [2500363.001]
  • [Cites] Int J Cancer. 1993 Nov 11;55(5):712-21 [7503956.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1673-7 [8156495.001]
  • [Cites] Br J Cancer. 1997;76(9):1234-40 [9365176.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):629-34 [10203283.001]
  • [Cites] Cancer Res. 1959 Jun;19(5):515-20 [13663040.001]
  • [Cites] Mol Cell Endocrinol. 2005 Mar 31;232(1-2):9-19 [15737464.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1291-303 [15695371.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):281-9 [16041220.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7509-15 [16103106.001]
  • [Cites] Endocr Relat Cancer. 2006 Mar;13(1):95-111 [16601282.001]
  • [Cites] Mol Endocrinol. 2006 Aug;20(8):1912-23 [16556730.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1482-8 [17372279.001]
  • [Cites] Biochemistry. 2008 Jan 8;47(1):479-89 [18081308.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):81-91 [18204982.001]
  • [Cites] BMC Cell Biol. 2008;9:46 [18710550.001]
  • [Cites] J Endocrinol. 2009 Apr;201(1):115-28 [19153125.001]
  • [Cites] Mod Pathol. 2009 Oct;22(10):1273-9 [19633648.001]
  • [Cites] Prostate. 2010 Jan 1;70(1):37-47 [19739126.001]
  • [Cites] J Mol Endocrinol. 2010 Mar;44(3):187-94 [19906835.001]
  • [Cites] Br J Cancer. 2010 Sep 28;103(7):1097-102 [20736944.001]
  • [Cites] J Clin Pathol. 2001 Dec;54(12):956-60 [11729217.001]
  • (PMID = 21144038.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Receptors, Prolactin
  • [Other-IDs] NLM/ PMC3009681
  •  go-up   go-down


47. MacNeill KN, Riddell RH, Ghazarian D: Perianal apocrine adenocarcinoma arising in a benign apocrine adenoma; first case report and review of the literature. J Clin Pathol; 2005 Feb;58(2):217-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for apocrine adenoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perianal apocrine adenocarcinoma arising in a benign apocrine adenoma; first case report and review of the literature.
  • Benign apocrine lesions have been described in the anogenital region, although according to the World Health Organisation convincing examples of anal apocrine adenocarcinomas have not been published.
  • This report describes the case of an invasive apocrine adenocarcinoma arising in a benign adenoma in the perianal region of a 45 year old woman.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Sweat Gland / pathology. Anus Neoplasms / pathology. Apocrine Glands / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Immunohistochemistry / methods. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for apocrine adenocarcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1999 Nov;52(11):829-32 [10690173.001]
  • [Cites] J Am Acad Dermatol. 2001 Nov;45(5):755-9 [11606929.001]
  • [Cites] J Am Acad Dermatol. 1980 Apr;2(4):322-6 [7364989.001]
  • [Cites] Arch Dermatol. 1980 Sep;116(9):1051-3 [7416759.001]
  • [Cites] Am J Clin Pathol. 1962 Feb;37:182-95 [14472046.001]
  • [Cites] Cancer. 1993 Jan 15;71(2):375-81 [7678545.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):832-6 [8037297.001]
  • [Cites] Am J Clin Pathol. 1998 Jan;109(1):75-84 [9426521.001]
  • [Cites] Mod Pathol. 1999 Aug;12(8):786-93 [10463481.001]
  • [Cites] Arch Pathol Lab Med. 1991 Dec;115(12):1249-54 [1662944.001]
  • (PMID = 15677547.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 12
  • [Other-IDs] NLM/ PMC1770559
  •  go-up   go-down


48. Gatta G, Ciccolallo L, Kunkler I, Capocaccia R, Berrino F, Coleman MP, De Angelis R, Faivre J, Lutz JM, Martinez C, Möller T, Sankila R, EUROCARE Working Group: Survival from rare cancer in adults: a population-based study. Lancet Oncol; 2006 Feb;7(2):132-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FINDINGS: Overall 5-year relative survival was good (ie, >65%) for placental choriocarcinoma (85.4% [95% CI 81.4-89.5]), thyroid medullary carcinoma (72.4% [69.2-75.5]), ovarian germ-cell cancer (73.0% [70.0-76.0]), lung carcinoid (70.1% [67.3-72.9]), and cervical adenocarcinoma (65.5% [64.3-66.6]); intermediate (ie, 35-65%) for testicular cancer at age 65 years or older (64.0% [59.3-68.7]), sarcoma of extremities (60.0% [58.9-61.2]), digestive-system endocrine cancers (55.6% [54.9-56.3]), anal squamous-cell carcinoma (53.1% [51.5-54.8]), and uterine sarcoma (43.5% [42.0-44.9]); low for carcinoma of adrenal-gland cortex (32.7% [28.3-37.2]) and bladder squamous-cell carcinoma (20.4% [18.8-22.0]); and poor for angiosarcoma of liver (6.4% [1.8-11.0]) and mesothelioma (4.7% [4.3-5.2]).
  • Survival significantly improved over time for ovarian germ-cell cancer, sarcomas of extremities, digestive-system endocrine tumours, anal squamous-cell carcinoma, and angiosarcoma of liver.
  • [MeSH-major] Neoplasms / mortality. Quality of Health Care. Rare Diseases / mortality

  • MedlinePlus Health Information. consumer health - Rare Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16455477.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


49. Basarab A, Liebgott H, Morestin F, Lyshchik A, Higashi T, Asato R, Delachartre P: A method for vector displacement estimation with ultrasound imaging and its application for thyroid nodular disease. Med Image Anal; 2008 Jun;12(3):259-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A method for vector displacement estimation with ultrasound imaging and its application for thyroid nodular disease.
  • The two other sets of data involve the thyroid gland and were acquired using freehand tissue compression by ultrasound probe of a clinical ultrasound scanner modified for research.
  • [MeSH-minor] Adult. Elasticity Imaging Techniques / methods. Female. Humans. Male. Middle Aged. Phantoms, Imaging. Thyroid Gland / ultrasonography. Thyroid Neoplasms / ultrasonography

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18065256.001).
  • [ISSN] 1361-8423
  • [Journal-full-title] Medical image analysis
  • [ISO-abbreviation] Med Image Anal
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


50. Hemminki K, Sundquist J, Bermejo JL: How common is familial cancer? Ann Oncol; 2008 Jan;19(1):163-7
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Family history of a disease may point to its heritable or environmental etiology.
  • It can be described by the proportion of the familial disease, i.e. same disease in two or more family members.
  • Salivary gland cancers showed the lowest familial proportion of 0.15%, but bone, laryngeal, anal, connective tissue and other genital cancers also remained <1%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17804474.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


51. Regauer S: Extramammary Paget's disease--a proliferation of adnexal origin? Histopathology; 2006 May;48(6):723-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramammary Paget's disease--a proliferation of adnexal origin?
  • AIM: To investigate a possible follicular origin of extramammary Paget's disease (EPD).
  • METHODS AND RESULTS: Formalin-fixed paraffin-embedded tissues of 12 cases of primary EPD (three anal, nine vulvar) were studied immunohistochemically with antibodies to CK15 and CK19.
  • All cases of EPD showed polygonal Paget cells in the interfollicular epidermis, hair follicles, sebaceous and apocrine glands distributed individually, in nests and in gland-like areas.
  • [MeSH-major] Anus Neoplasms / pathology. Paget Disease, Extramammary / pathology. Vulvar Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681689.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / KRT15 protein, human; 0 / Keratin-15; 68238-35-7 / Keratins
  •  go-up   go-down


52. Casco F, Illanes Moreno M, González Cámpora R, Moreno A, Galera Ruiz H: Spindle epithelial tumor with thymuslike differentiation in a 2-year-old boy: a case report. Anal Quant Cytol Histol; 2010 Feb;32(1):53-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spindle epithelial tumor with thymuslike differentiation in a 2-year-old boy: a case report.
  • BACKGROUND: The spindle epithelial tumor with thymuslike differentiation (SETTLE) is a rare thyroid tumor believed to be derived from ectopic thymus tissue or the embryonic remnants of branchial pouches, which displays primitive thymic differentiation.
  • Differential diagnosis using histochemical markers is essential since although there is a tendency to develop blood-borne metastases, tumor growth is slow and the survival rate in patients followed up is as high as 70%.
  • CASE: A 2-year-old boy presented with a tumor on the anteroinferior aspect of the neck, which had been growing since birth, suggesting a congenital origin.
  • Immunohistochemical markers revealed primitive differentiation; tumor cells stained positive for cytokeratin and vimentin but negative for markers indicative of greater differentiation, such as calcitonin, chromogranin, calretinin, synaptophysin and S-100 protein.

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701088.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


53. Yan H, Blackburn AC, McLary SC, Tao L, Roberts AL, Xavier EA, Dickinson ES, Seo JH, Arenas RB, Otis CN, Cao QJ, Lawlor RG, Osborne BA, Kittrell FS, Medina D, Jerry DJ: Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice. Am J Pathol; 2010 Mar;176(3):1421-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mammary gland proliferation rates were similar in both BALB/c-Trp53+/- mice and wild-type controls.
  • Expression of biomarkers was retained when tumor fragments were transplanted to syngeneic hosts.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Immunol. 2004 Mar;34(3):726-34 [14991602.001]
  • [Cites] Trends Genet. 2004 Jun;20(6):235-43 [15145576.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3525-32 [15150107.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5140-7 [15289317.001]
  • [Cites] Cell. 1987 May 22;49(4):465-75 [3032456.001]
  • [Cites] Cell Growth Differ. 1990 Apr;1(4):161-70 [1707299.001]
  • [Cites] Oncogene. 1991 Dec;6(12):2277-84 [1685017.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] Oncogene. 1995 Apr 6;10(7):1269-74 [7731676.001]
  • [Cites] Anal Biochem. 1995 Mar 20;226(1):91-9 [7785785.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):1-13 [9006316.001]
  • [Cites] Oncogene. 1997 Feb 20;14(7):865-71 [9047394.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9648-53 [9275177.001]
  • [Cites] Carcinogenesis. 1998 Sep;19(9):1573-81 [9771927.001]
  • [Cites] Oncogene. 1998 Nov 5;17(18):2305-12 [9811461.001]
  • [Cites] J Pathol. 1999 Jul;188(3):237-44 [10419589.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R605-15 [15535842.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):165-71 [15619621.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8166-73 [16166291.001]
  • [Cites] Cell Cycle. 2005 Dec;4(12):1808-16 [16294019.001]
  • [Cites] Development. 2006 Jan;133(2):363-9 [16368933.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):264-71 [16341146.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5104-10 [16707433.001]
  • [Cites] Cell Death Differ. 2006 Jun;13(6):1003-16 [16543940.001]
  • [Cites] Oncogene. 2006 Jun 8;25(24):3463-70 [16449974.001]
  • [Cites] Oncogene. 2006 Sep 25;25(43):5906-11 [16998505.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):437-49 [17097565.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):618-23 [17202265.001]
  • [Cites] Cell Res. 2007 Jan;17(1):42-9 [17211451.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1736-42 [17032926.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):661-5 [17251932.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):656-60 [17251933.001]
  • [Cites] Cancer Cell. 2007 Feb;11(2):103-5 [17292821.001]
  • [Cites] J Biol Chem. 2007 Feb 23;282(8):5842-52 [17179143.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):562-77 [17344417.001]
  • [Cites] Hum Mutat. 2007 Jun;28(6):622-9 [17311302.001]
  • [Cites] Am J Pathol. 2007 Jun;170(6):2030-41 [17525270.001]
  • [Cites] Trends Cell Biol. 2007 Jun;17(6):286-91 [17481900.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12111-6 [17626182.001]
  • [Cites] PLoS Biol. 2007 Aug;5(8):e201 [17676974.001]
  • [Cites] Stem Cell Rev. 2007 Jun;3(2):169-75 [17873349.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]
  • [Cites] Nat Genet. 2008 May;40(5):499-507 [18443585.001]
  • [Cites] Nat Cell Biol. 2008 Jun;10(6):676-87 [18454141.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4674-82 [18559513.001]
  • [Cites] Cell. 2008 Jul 11;134(1):62-73 [18614011.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R43 [18471300.001]
  • [Cites] Neurobiol Aging. 2009 Mar;30(3):483-97 [17850928.001]
  • [Cites] Nature. 2009 Jul 23;460(7254):529-33 [19626115.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):968-88 [10713680.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1052-8 [10713689.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3444-9 [10716706.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1996 Jan;1(1):5-19 [10887477.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):2151-9 [11106587.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):83-7 [11219776.001]
  • [Cites] Oncogene. 2001 Aug 2;20(34):4621-8 [11498785.001]
  • [Cites] Nat Genet. 2002 May;31(1):55-9 [11967536.001]
  • [Cites] FASEB J. 2002 Jun;16(8):881-3 [11967232.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):289-98 [12086865.001]
  • [Cites] Mutat Res. 2003 Jan 28;522(1-2):69-83 [12517413.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):292-300 [12619115.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6140-3 [14559792.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15853-8 [14668450.001]
  • (PMID = 20110418.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES015739; United States / NCI NIH HHS / CA / R01-CA105452; United States / NCI NIH HHS / CA / R01 CA095164; United States / NCI NIH HHS / CA / R01 CA105452; United States / NCI NIH HHS / CA / R01-CA095164; United States / NIEHS NIH HHS / ES / R01-ES015739
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Notch; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins; EC 2.7.10.1 / Erbb2 protein, mouse; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2832161
  •  go-up   go-down


54. Tampi C, Lotwala V, Lakdawala M, Coelho K: Retrorectal cyst hamartoma (tailgut cyst) with malignant transformation. Gynecol Oncol; 2007 Apr;105(1):266-8
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It develops from post anal foetal gut remnants, present anterior to the sacrum and posterior to the rectum.
  • This malformative lesion should be distinguished from teratomas, mullerian cysts, anal gland cysts and duplication cysts of the rectum.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Transformation, Neoplastic / pathology. Cysts / pathology. Hamartoma / pathology. Rectal Diseases / pathology. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17303225.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Yin X, Wolford CC, Chang YS, McConoughey SJ, Ramsey SA, Aderem A, Hai T: ATF3, an adaptive-response gene, enhances TGF{beta} signaling and cancer-initiating cell features in breast cancer cells. J Cell Sci; 2010 Oct 15;123(Pt 20):3558-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because ATF3 is an adaptive-response gene and is induced by various stromal signals, these findings have significant implications for how the tumor microenvironment might affect cancer development.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 1995 Jun;108 ( Pt 6):2241-51 [7673344.001]
  • [Cites] Anal Biochem. 1994 Feb 1;216(2):276-84 [8179182.001]
  • [Cites] Stem Cells. 1997;15(3):190-7 [9170210.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):862-73 [10360667.001]
  • [Cites] Gene Expr. 1999;7(4-6):321-35 [10440233.001]
  • [Cites] Mol Cancer Ther. 2005 May;4(5):693-703 [15897233.001]
  • [Cites] J Cell Sci. 2005 Aug 15;118(Pt 16):3573-84 [16105881.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10473-81 [16469745.001]
  • [Cites] Lab Invest. 2006 Dec;86(12):1203-7 [17075578.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11983-90 [17178897.001]
  • [Cites] Oncogene. 2007 Jan 11;26(2):284-9 [16847457.001]
  • [Cites] Front Biosci. 2007;12:4298-314 [17485376.001]
  • [Cites] Cancer Sci. 2007 Oct;98(10):1512-20 [17645776.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8131-8 [17804725.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(12):2153-60 [17825600.001]
  • [Cites] Curr Opin Biotechnol. 2007 Oct;18(5):460-6 [18023337.001]
  • [Cites] J Clin Invest. 2007 Dec;117(12):3988-4002 [18060036.001]
  • [Cites] Breast Cancer Res. 2007;9(6):216 [18190723.001]
  • [Cites] Diabetes. 2008 Mar;57(3):635-44 [18057093.001]
  • [Cites] Oncogene. 2008 Apr 3;27(15):2118-27 [17952119.001]
  • [Cites] Lab Invest. 2008 May;88(5):459-63 [18379567.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(6-7):1068-78 [18243766.001]
  • [Cites] Cell. 2008 May 16;133(4):704-15 [18485877.001]
  • [Cites] FEBS Lett. 2008 Jun 18;582(14):2051-65 [18375206.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R52 [18541018.001]
  • [Cites] PLoS One. 2008;3(8):e2888 [18682804.001]
  • [Cites] BMC Cancer. 2008;8:268 [18808719.001]
  • [Cites] Oncogene. 2008 Oct 16;27(47):6120-30 [18591932.001]
  • [Cites] Curr Opin Genet Dev. 2009 Feb;19(1):44-50 [19167210.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):265-73 [19262571.001]
  • [Cites] Development. 2009 Nov;136(22):3699-714 [19855013.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2000;64:343-69 [10697414.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1996 Oct;1(4):353-63 [10887509.001]
  • [Cites] Cell. 2000 Oct 13;103(2):295-309 [11057902.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):169-78 [11252892.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jan;65(2):101-10 [11261825.001]
  • [Cites] Gene. 2001 Jul 25;273(1):1-11 [11483355.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):117-29 [11586292.001]
  • [Cites] Oncol Res. 2001;12(8):343-6 [11589305.001]
  • [Cites] Brief Bioinform. 2002 Mar;3(1):92-4 [12002228.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Mol Cell. 2003 Apr;11(4):915-26 [12718878.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Genes Dev. 2003 May 15;17(10):1253-70 [12756227.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8621-3 [12861075.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8284-92 [14678987.001]
  • [Cites] Oncogene. 1990 Mar;5(3):427-31 [2107494.001]
  • [Cites] J Histochem Cytochem. 1993 Oct;41(10):1521-7 [8245410.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):1157-68 [8622660.001]
  • (PMID = 20930144.001).
  • [ISSN] 1477-9137
  • [Journal-full-title] Journal of cell science
  • [ISO-abbreviation] J. Cell. Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA118306; United States / NIDDK NIH HHS / DK / DK064938S1; United States / NINDS NIH HHS / NS / P30 NS045758; United States / NIDDK NIH HHS / DK / R01 DK064938; United States / NIAID NIH HHS / AI / R01 AI025032; United States / NINDS NIH HHS / NS / P30-NS045758
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Activating Transcription Factor 3; 0 / Antigens, CD24; 0 / Antigens, CD44; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ PMC2951469
  •  go-up   go-down


56. Jerevall PL, Jansson A, Fornander T, Skoog L, Nordenskjöld B, Stål O: Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer. Breast Cancer Res; 2010;12(4):R53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We used immunohistochemistry to analyze protein levels of HOXB13 in tumor samples from 912 postmenopausal node-negative breast cancer patients randomized to adjuvant tamoxifen therapy or no endocrine treatment.
  • However, for patients with a high or intermediate HOXB13 tumor expression, tamoxifen did not prolong the DRFS compared with the untreated patients (hazard ratio = 0.88, 95% confidence interval = 0.47 to 1.65, P = 0.69).
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Homeodomain Proteins / biosynthesis. Tamoxifen / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Agents, Hormonal / therapeutic use. Blotting, Western. Cell Line, Tumor. Chemotherapy, Adjuvant. Chi-Square Distribution. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Postmenopause. Predictive Value of Tests. Prognosis. Randomized Controlled Trials as Topic. Sweden. Tissue Array Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mammary Gland Biol Neoplasia. 1998 Jan;3(1):85-94 [10819507.001]
  • [Cites] Carcinogenesis. 2008 Jul;29(7):1459-65 [18499701.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(2):257-64 [12509959.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):607-16 [15193263.001]
  • [Cites] Anal Biochem. 1978 Apr;85(2):461-75 [565601.001]
  • [Cites] Cancer Res. 1979 May;39(5):1834-40 [427816.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2907-12 [3157451.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9185-92 [15604291.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):671-9 [15721472.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2080-7 [16609019.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4611-9 [17008703.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):662-8 [17308270.001]
  • [Cites] Acta Oncol. 2007;46(2):133-45 [17453361.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6327-34 [17975144.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jan;107(2):225-34 [17453342.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2601-8 [18451222.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • (PMID = 20649975.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / HOXB13 protein, human; 0 / Homeodomain Proteins; 094ZI81Y45 / Tamoxifen
  • [Other-IDs] NLM/ PMC2949642
  •  go-up   go-down


57. Zhan X, Desiderio DM: Signaling pathway networks mined from human pituitary adenoma proteomics data. BMC Med Genomics; 2010 Apr 28;3:13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The nitroproteomic data from a pituitary adenoma were related to cancer, cell death, lipid metabolism, and reproductive system disease, and the top canonical toxicity pathways mainly related to p38 MAPK signaling and cell-cycle G2/M transition regulation.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pineal Res. 2006 Apr;40(3):230-5 [16499559.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3177-87 [16540669.001]
  • [Cites] J Endocrinol Invest. 2005;28(11 Suppl International):87-92 [16625855.001]
  • [Cites] Br Med Bull. 2005;75-76:81-97 [16684928.001]
  • [Cites] Anal Biochem. 2006 Jul 15;354(2):279-89 [16777052.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4630-2 [16892077.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4812-30 [16892093.001]
  • [Cites] Arch Biochem Biophys. 2006 Oct 1;454(1):7-15 [16962985.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9483-91 [17018604.001]
  • [Cites] Biochem J. 2007 Jan 1;401(1):1-11 [17150040.001]
  • [Cites] Eur J Endocrinol. 2007 Feb;156(2):203-16 [17287410.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Mar;66(3):348-52 [17302867.001]
  • [Cites] Cancer. 1980 Aug 1;46(3):537-42 [6249483.001]
  • [Cites] Nature. 1987 Dec 10-16;330(6148):566-8 [2825031.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Apr;74(4):914-9 [1312542.001]
  • [Cites] Adv Cancer Res. 2004;92:95-118 [15530558.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 24;325(4):1180-6 [15555551.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):367-80 [15531919.001]
  • [Cites] Cell Cycle. 2004 Dec;3(12):1524-9 [15611622.001]
  • [Cites] Curr Mol Med. 2007 Feb;7(1):121-31 [17311537.001]
  • [Cites] Eur Respir J. 2007 Apr;29(4):643-50 [17182653.001]
  • [Cites] Drug News Perspect. 2007 Mar;20(2):109-17 [17440634.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3279-90 [17496922.001]
  • [Cites] Cardiovasc Res. 2007 Jul 15;75(2):261-74 [17498676.001]
  • [Cites] Med Hypotheses. 2007;69(4):826-8 [17368752.001]
  • [Cites] Toxicol Appl Pharmacol. 2008 Feb 1;226(3):236-43 [17980396.001]
  • [Cites] Antioxid Redox Signal. 2008 Mar;10(3):635-40 [17999628.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1211-6 [18230656.001]
  • [Cites] Pharmacol Res. 2008 May;57(5):325-31 [18455424.001]
  • [Cites] IUBMB Life. 2008 Jul;60(7):441-7 [18465793.001]
  • [Cites] Virology. 2008 Aug 1;377(2):319-29 [18570970.001]
  • [Cites] Pituitary. 2008;11(3):231-45 [18183490.001]
  • [Cites] Cell. 2008 Jul 11;134(1):112-23 [18614015.001]
  • [Cites] J Immunol. 2008 Sep 1;181(5):3540-8 [18714027.001]
  • [Cites] Neurochem Res. 2008 Dec;33(12):2502-9 [18998208.001]
  • [Cites] Mol Carcinog. 2009 Feb;48(2):91-104 [18618599.001]
  • [Cites] J Intern Med. 2009 Feb;265(2):193-209 [19192036.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11292-6 [7504302.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):170-4 [7529411.001]
  • [Cites] No To Shinkei. 1994 Oct;46(10):948-54 [7826710.001]
  • [Cites] Am J Pathol. 1995 Jan;146(1):86-94 [7531951.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Dec;41(6):815-20 [7889619.001]
  • [Cites] Nat Genet. 1995 Dec;11(4):376-81 [7493016.001]
  • [Cites] J Histochem Cytochem. 1997 Jun;45(6):847-57 [9199670.001]
  • [Cites] Neuroendocrinology. 1997 Dec;66(6):426-31 [9430448.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Jul;49(1):29-38 [9797844.001]
  • [Cites] Horm Res. 1999;51(5):242-7 [10559669.001]
  • [Cites] Front Neuroendocrinol. 2000 Jul;21(3):174-98 [10882539.001]
  • [Cites] Mol Endocrinol. 2000 Aug;14(8):1137-46 [10935539.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Sep;53(3):337-44 [10971451.001]
  • [Cites] Cell. 2000 Oct 13;103(2):239-52 [11057897.001]
  • [Cites] Z Rheumatol. 2000;59 Suppl 2:II/36-42 [11155802.001]
  • [Cites] Minerva Endocrinol. 2000 Sep-Dec;25(3-4):55-9 [11338396.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2631-7 [11397864.001]
  • [Cites] Med Hypotheses. 2001 Oct;57(4):429-31 [11601863.001]
  • [Cites] J Neurosci. 2001 Nov 1;21(21):8348-53 [11606622.001]
  • [Cites] Horm Res. 2001;55(5):229-35 [11740144.001]
  • [Cites] Arch Med Res. 2001 Nov-Dec;32(6):476-85 [11750723.001]
  • [Cites] Trends Pharmacol Sci. 2002 Jan;23(1):40-5 [11804650.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1048-55 [12170092.001]
  • [Cites] J Endocrinol. 2002 Sep;174(3):379-86 [12208657.001]
  • [Cites] Acta Neurol Scand. 2002 Dec;106(6):361-6 [12460142.001]
  • [Cites] Science. 2002 Dec 6;298(5600):1911-2 [12471242.001]
  • [Cites] Curr Pharm Des. 2003;9(5):381-90 [12570815.001]
  • [Cites] Folia Histochem Cytobiol. 2003;41(2):87-90 [12722794.001]
  • [Cites] Proteomics. 2003 May;3(5):699-713 [12748949.001]
  • [Cites] Nature. 2003 Jul 31;424(6948):561-5 [12891360.001]
  • [Cites] Mol Cell Endocrinol. 2003 Aug 29;206(1-2):49-62 [12943989.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):962-8 [14871826.001]
  • [Cites] Expert Rev Mol Med. 2002 Apr;4(9):1-19 [14987393.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2838-49 [15077147.001]
  • [Cites] Trends Mol Med. 2004 Mar;10(3):125-9 [15102355.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):20096-107 [14985350.001]
  • [Cites] Front Horm Res. 2004;32:34-62 [15281339.001]
  • [Cites] Front Horm Res. 2004;32:110-26 [15281342.001]
  • [Cites] Acta Neurochir (Wien). 1980;51(3-4):195-201 [7368994.001]
  • [Cites] Free Radic Biol Med. 2005 May 15;38(10):1278-95 [15855047.001]
  • [Cites] Mass Spectrom Rev. 2005 Nov-Dec;24(6):783-813 [15495141.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10214-22 [16288009.001]
  • [Cites] Trends Mol Med. 2005 Dec;11(12):571-8 [16290020.001]
  • [Cites] Chem Res Toxicol. 2005 Dec;18(12):1779-91 [16359168.001]
  • [Cites] J Natl Cancer Inst. 2005 Dec 21;97(24):1800-1 [16368937.001]
  • [Cites] Chem Biol Interact. 2006 Mar 10;160(1):1-40 [16430879.001]
  • (PMID = 20426862.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR016679
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cell Cycle Proteins; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC2884164
  •  go-up   go-down


58. Stuelten CH, Busch JI, Tang B, Flanders KC, Oshima A, Sutton E, Karpova TS, Roberts AB, Wakefield LM, Niederhuber JE: Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One; 2010;5(3):e9832
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer.
  • When a cancer cell metastasizes, it first will be exposed to cancer associated fibroblasts in the immediate tumor microenvironment and then to normal fibroblasts as it traverses the underlying connective tissue towards the bloodstream.
  • The interaction of tumor cells with stromal fibroblasts influences tumor biology by mechanisms that are not yet fully understood.
  • Transient treatment of MCF10CA1a cells with CoCM in vitro accelerated tumor growth at orthotopic sites in vivo, and resulted in an expanded pattern of metastatic engraftment.
  • The effects of CoCM on MCF10CA1a cells were dependent on small amounts of active TGF-beta1 secreted by fibroblasts under the influence of the tumor cells, and required intact ALK5-, p38-, and JNK signaling in the tumor cells.
  • In conclusion, these results demonstrate that transient interactions between tumor cells and normal fibroblasts can modify the acellular component of the local microenvironment such that it induces long-lasting increases in tumorigenicity and alters the metastatic pattern of the cancer cells in vivo.
  • [MeSH-major] Breast Neoplasms / pathology. Fibroblasts / cytology. Neoplasms / metabolism. Transforming Growth Factor beta / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Movement. Coculture Techniques. Culture Media, Conditioned / pharmacology. Female. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Models, Biological. Neoplasm Metastasis. Neoplasm Transplantation

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Cancer Biol. 2005 Oct;15(5):329-41 [15970443.001]
  • [Cites] Oncogene. 2005 Jul 28;24(32):5053-68 [15856015.001]
  • [Cites] Cell Cycle. 2005 Aug;4(8):1022-5 [16082203.001]
  • [Cites] Oncogene. 2005 Nov 17;24(51):7624-9 [16007121.001]
  • [Cites] Expert Opin Ther Targets. 2005 Dec;9(6):1217-33 [16300472.001]
  • [Cites] Cell Mol Life Sci. 2006 Feb;63(4):449-68 [16416030.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:383-8 [16869775.001]
  • [Cites] Immunol Invest. 2006;35(3-4):297-325 [16916756.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:287-309 [16824016.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4244-53 [17483336.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):851-61 [17486574.001]
  • [Cites] J Cell Biochem. 2007 Oct 15;102(3):593-608 [17729308.001]
  • [Cites] Biotechniques. 2007 Sep;43(3):289-90, 292, 294 [17907571.001]
  • [Cites] Clin Transl Oncol. 2008 Jan;10(1):14-9 [18208788.001]
  • [Cites] Front Biosci. 2008;13:3975-85 [18508491.001]
  • [Cites] Nature. 2008 Jul 24;454(7203):436-44 [18650914.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7278-82 [18794114.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):97-101 [15661539.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Oct;7(4):415-32 [12882526.001]
  • [Cites] J Clin Invest. 2003 Oct;112(7):1116-24 [14523048.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8284-92 [14678987.001]
  • [Cites] Science. 2004 Feb 6;303(5659):848-51 [14764882.001]
  • [Cites] Br J Cancer. 2004 Feb 23;90(4):822-32 [14970860.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71 [15051869.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4523-30 [15231662.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7678-82 [2217201.001]
  • [Cites] Semin Cancer Biol. 1990 Apr;1(2):99-106 [2103492.001]
  • [Cites] EXS. 1993;65:301-10 [7678533.001]
  • [Cites] Endocrinology. 1994 Mar;134(3):1039-45 [8119140.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11236-40 [7972041.001]
  • [Cites] Science. 1995 Dec 22;270(5244):2008-11 [8533096.001]
  • [Cites] Anal Biochem. 1997 Apr 5;247(1):45-51 [9126369.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Nat Rev Mol Cell Biol. 2000 Dec;1(3):169-78 [11252892.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Curr Opin Genet Dev. 2002 Feb;12(1):22-9 [11790550.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):331-9 [11832448.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):1057-68 [11891202.001]
  • [Cites] Br J Cancer. 2002 Oct 7;87(8):859-67 [12373600.001]
  • [Cites] Cell. 2005 Feb 25;120(4):513-22 [15734683.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] J Cell Sci. 2005 May 15;118(Pt 10):2143-53 [15855236.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5278-83 [15958574.001]
  • [Cites] Breast Cancer Res. 2005;7(4):R402-10 [15987445.001]
  • [Cites] J Immunol. 2005 Jul 15;175(2):1197-205 [16002723.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):241-54 [16169468.001]
  • (PMID = 20352126.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ PMC2843748
  •  go-up   go-down


59. van de Luijtgaarden AC, Veth RP, Slootweg PJ, Wijers-Koster PM, Schultze Kool LJ, Bovee JV, van der Graaf WT: Metastatic potential of an aneurysmal bone cyst. Virchows Arch; 2009 Nov;455(5):455-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sarcomatous transformation as an explanation for this behavior was ruled out by demonstrating diploid DNA content in both the pulmonary lesion and the primary tumor.
  • [MeSH-major] Bone Cysts, Aneurysmal / pathology. Bone Neoplasms / pathology. Neoplasms, Second Primary / pathology. Osteosarcoma / pathology. Proto-Oncogene Proteins / genetics. Ubiquitin Thiolesterase / genetics
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Bevacizumab. Carcinoma / complications. Cell Transformation, Neoplastic / pathology. Diabetes Mellitus, Type 2 / complications. Embolization, Therapeutic. Female. Humans. Hyperplasia. In Situ Hybridization, Fluorescence. Kidney Neoplasms / secondary. Lung Neoplasms / secondary. Middle Aged. Thyroid Gland / pathology. Uterine Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2000 Jun;28(2):233-4 [10825009.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):311-5 [16755186.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):e1; author reply e2 [16382110.001]
  • [Cites] Oncogene. 2005 May 12;24(21):3419-26 [15735689.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Nov;26(3):265-6 [10502326.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1206-10 [11106078.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jul;48(7):583-602 [19396867.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Oct 15;178(2):155-9 [17954273.001]
  • [Cites] Pediatr Dev Pathol. 2007 Jan-Feb;10(1):46-9 [17378626.001]
  • [Cites] Pediatr Dev Pathol. 2006 Jan-Feb;9(1):38-43 [16808643.001]
  • [Cites] Pediatr Dev Pathol. 2001 Jul-Aug;4(4):418-9 [11441369.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Sep;129(2):177-80 [11566352.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):636-9 [11764383.001]
  • [Cites] Anal Cell Pathol. 2001;23(2):89-95 [11904464.001]
  • [Cites] Life Sci. 2003 Aug 1;73(11):1427-36 [12850503.001]
  • [Cites] J Formos Med Assoc. 2003 Sep;102(9):631-6 [14625608.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1920-3 [15026324.001]
  • [Cites] Mod Pathol. 2004 May;17(5):518-25 [15044915.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1773-80 [15509545.001]
  • [Cites] Pediatr Radiol. 1986;16(2):140-3 [3456553.001]
  • [Cites] Skeletal Radiol. 1987;16(3):196-200 [3473690.001]
  • [Cites] Cancer. 1988 Jun 15;61(12):2532-40 [3163257.001]
  • [Cites] Ital J Orthop Traumatol. 1987 Dec;13(4):425-36 [3503870.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Jan;58(1):2-13 [1728946.001]
  • [Cites] Cancer. 1992 Jun 15;69(12):2921-31 [1591685.001]
  • [Cites] Surg Today. 1994;24(5):476-80 [8054822.001]
  • [Cites] Cytometry. 1995 Mar 1;19(3):256-62 [7736870.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Oct 1;84(1):27-31 [7497439.001]
  • [Cites] Pathologe. 1996 Jan;17(1):44-9 [8685095.001]
  • [Cites] Clin Orthop Relat Res. 1997 Feb;(335):253-61 [9020226.001]
  • (PMID = 19838726.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins; 2S9ZZM9Q9V / Bevacizumab; EC 3.1.2.15 / USP6 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase
  •  go-up   go-down


60. Powlesland AS, Hitchen PG, Parry S, Graham SA, Barrio MM, Elola MT, Mordoh J, Dell A, Drickamer K, Taylor ME: Targeted glycoproteomic identification of cancer cell glycosylation. Glycobiology; 2009 Aug;19(8):899-909
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glycan array screening demonstrated that the carbohydrate-recognition domain of GalMBP selectively binds common groups of tumor-associated glycans, including Lewis-type structures and T antigen, suggesting that engineered glycan-binding proteins such as GalMBP represent novel tools for the characterization of glycoproteins bearing tumor-associated glycans.
  • The pool of ligands was found to include the target ligands for anti-CD15 antibodies, which are commonly used to detect Lewis(x) antigen on tumors, and for the endothelial scavenger receptor C-type lectin, which may be involved in tumor metastasis through interactions with this antigen.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Electrophoresis. 1999 Dec;20(18):3551-67 [10612281.001]
  • [Cites] Glycobiology. 2009 Apr;19(4):437-50 [19129245.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2584-8 [10825125.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jul;6(3):355-64 [11547903.001]
  • [Cites] Glycoconj J. 2004;19(7-9):543-9 [14758078.001]
  • [Cites] J Immunol. 1981 May;126(5):1966-9 [7217675.001]
  • [Cites] Anal Biochem. 1981 Apr;112(2):195-203 [6266278.001]
  • [Cites] Cancer Res. 1986 Mar;46(3):1478-84 [2417704.001]
  • [Cites] Am J Pathol. 1986 Jun;123(3):508-19 [3717303.001]
  • [Cites] Methods Enzymol. 1994;230:108-32 [8139492.001]
  • [Cites] J Biol Chem. 1994 Jun 3;269(22):15512-9 [8195195.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1995 Apr;17(3):151-60 [7613641.001]
  • [Cites] J Biol Chem. 1996 Mar 22;271(12):6679-85 [8636086.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5309-18 [8968075.001]
  • [Cites] Biochem J. 1997 Jul 15;325 ( Pt 2):391-400 [9230118.001]
  • [Cites] Glycoconj J. 1997 Aug;14(5):569-76 [9298689.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9325-30 [9689079.001]
  • [Cites] Immunol Rev. 1998 Jun;163:19-34 [9700499.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):371-5 [9892640.001]
  • [Cites] J Biol Chem. 1999 Jan 29;274(5):3009-16 [9915839.001]
  • [Cites] J Biol Chem. 1999 Feb 5;274(6):3580-9 [9920905.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Sep 7;262(3):720-5 [10471392.001]
  • [Cites] Curr Opin Struct Biol. 1999 Oct;9(5):585-90 [10508765.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5):556-60 [10528904.001]
  • [Cites] Nat Rev Drug Discov. 2005 Jun;4(6):477-88 [15931257.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):22993-9 [15845541.001]
  • [Cites] Immunol Cell Biol. 2005 Aug;83(4):429-39 [16033539.001]
  • [Cites] Glycobiology. 2006 Aug;16(8):1C-7C [16670103.001]
  • [Cites] J Biol Chem. 2006 Jul 21;281(29):20440-9 [16682406.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jan;101(2):161-74 [16850248.001]
  • [Cites] J Biol Chem. 2007 Jun 8;282(23):17250-8 [17420244.001]
  • [Cites] J Mol Biol. 2007 Dec 14;374(5):1224-36 [17996897.001]
  • [Cites] J Membr Biol. 2000 Feb 1;173(3):165-77 [10667913.001]
  • (PMID = 19433864.001).
  • [ISSN] 1460-2423
  • [Journal-full-title] Glycobiology
  • [ISO-abbreviation] Glycobiology
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / / 075565; United States / NIGMS NIH HHS / GM / GM62116; United Kingdom / Biotechnology and Biological Sciences Research Council / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD98; 0 / Ligands; 0 / Mannose-Binding Lectin; 0 / Mucin-1; 0 / Polysaccharides; X2RN3Q8DNE / Galactose
  • [Other-IDs] NLM/ PMC2704901
  •  go-up   go-down


61. Spugnini EP, Dotsinsky I, Mudrov N, Citro G, D'Avino A, Baldi A: Biphasic pulses enhance bleomycin efficacy in a spontaneous canine genital tumor model of chemoresistance: Sticker sarcoma. J Exp Clin Cancer Res; 2008;27:58
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biphasic pulses enhance bleomycin efficacy in a spontaneous canine genital tumor model of chemoresistance: Sticker sarcoma.
  • Sticker's sarcoma (also known as transmissible venereal tumor) is a horizontally transmitted neoplasm of the dog, that is passed with coitus.
  • It is a locally aggressive tumor with a low tendency to metastatic spread.
  • The most common locations are the genitals, the nose, the perianal area.
  • In this article we describe the outcome of a small cohort of canine patients, with chemotherapy resistant transmissible venereal tumor (TVT), treated with bleomycin selectively driven by trains of biphasic pulses (electrochemotherapy).
  • [MeSH-major] Anal Gland Neoplasms / drug therapy. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Dog Diseases / drug therapy. Electrochemotherapy / veterinary. Sarcoma / veterinary. Venereal Tumors, Veterinary / drug therapy
  • [MeSH-minor] Animals. Combined Modality Therapy. Disease Models, Animal. Dogs. Male

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Biochem Cell Biol. 2008;40(2):159-63 [17977058.001]
  • [Cites] J Transl Med. 2007;5:48 [17910745.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Dec;26(4):483-7 [18365542.001]
  • [Cites] In Vivo. 2008 Jan-Feb;22(1):47-9 [18396781.001]
  • [Cites] In Vivo. 2008 Jan-Feb;22(1):51-3 [18396782.001]
  • [Cites] Cancer Immunol Immunother. 2008 Jul;57(7):1091-104 [18259750.001]
  • [Cites] Vet J. 2008 Nov;178(2):291-3 [17910926.001]
  • [Cites] Vet J. 2009 Jan;179(1):117-20 [17904882.001]
  • [Cites] Vet Immunol Immunopathol. 2003 May 12;92(3-4):149-62 [12730015.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1508-14 [14734728.001]
  • [Cites] Radiology. 2004 Mar;230(3):761-7 [14990840.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Dec;22(4):571-80 [15053299.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;29(3):214-8 [1733554.001]
  • [Cites] IEEE Eng Med Biol Mag. 1999 Jan-Feb;18(1):62-6 [9934602.001]
  • [Cites] J Vet Med A Physiol Pathol Clin Med. 2005 Sep;52(7):366-70 [16109105.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Jun;24(2):245-54 [16110758.001]
  • [Cites] Melanoma Res. 2006 Feb;16(1):23-7 [16432452.001]
  • [Cites] J Vasc Interv Radiol. 2006 Feb;17(2 Pt 1):351-8 [16517782.001]
  • [Cites] Cell. 2006 Aug 11;126(3):445-7 [16901777.001]
  • [Cites] Cell. 2006 Aug 11;126(3):477-87 [16901782.001]
  • [Cites] Vet Rec. 2006 Oct 28;159(18):598-600 [17071674.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Feb;59(3):375-81 [16807731.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6B):4585-9 [17201181.001]
  • [Cites] Bioelectrochemistry. 2007 May;70(2):283-6 [17150416.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Sep;26(3):343-6 [17987793.001]
  • [Cites] In Vivo. 2007 Sep-Oct;21(5):819-22 [18019417.001]
  • [Cites] In Vivo. 2007 Sep-Oct;21(5):897-9 [18019432.001]
  • [Cites] Vet Rec. 2008 Feb 9;162(6):186-8 [18263920.001]
  • (PMID = 18980687.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  • [Other-IDs] NLM/ PMC2596090
  •  go-up   go-down


62. Venkatesh SK, Yin M, Glockner JF, Takahashi N, Araoz PA, Talwalkar JA, Ehman RL: MR elastography of liver tumors: preliminary results. AJR Am J Roentgenol; 2008 Jun;190(6):1534-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumors were identified on T2- and T1-weighted and gadolinium-enhanced T1-weighted images, and the MRE images were obtained through the tumor.
  • The mean shear stiffness of the tumor was calculated with a manually specified region of interest over the tumor in the stiffness map.
  • The stiffness value of tumor-free hepatic parenchyma was calculated.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 2001 Jul;14(1):63-71 [11436216.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Oct;5(10):1207-1213.e2 [17916548.001]
  • [Cites] Med Image Anal. 2001 Dec;5(4):237-54 [11731304.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jun;178(6):1411-7 [12034608.001]
  • [Cites] Clin Radiol. 2002 Nov;57(11):1014-20 [12409113.001]
  • [Cites] Nat Cell Biol. 2003 Sep;5(9):803-11 [12942086.001]
  • [Cites] Med Image Anal. 2003 Dec;7(4):465-73 [14561551.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):695 [14973470.001]
  • [Cites] Ultrason Imaging. 1991 Apr;13(2):111-34 [1858217.001]
  • [Cites] Science. 1995 Sep 29;269(5232):1854-7 [7569924.001]
  • [Cites] Radiology. 1996 Mar;198(3):920-6 [8628896.001]
  • [Cites] Nat Med. 1996 May;2(5):601-3 [8616724.001]
  • [Cites] Radiology. 1997 Jan;202(1):79-86 [8988195.001]
  • [Cites] Magn Reson Imaging. 2005 Feb;23(2):159-65 [15833607.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Oct;9(4):325-42 [15838603.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):241-54 [16169468.001]
  • [Cites] Radiology. 2005 Oct;237(1):202-11 [16118150.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] NMR Biomed. 2006 Apr;19(2):173-9 [16521091.001]
  • [Cites] Radiology. 2006 Aug;240(2):440-8 [16864671.001]
  • [Cites] Radiology. 2007 Apr;243(1):258-67 [17293571.001]
  • [Cites] Acta Radiol. 2007 Apr;48(3):327-30 [17453505.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S49-60 [17486052.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • (PMID = 18492904.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB001981-07; United States / NIBIB NIH HHS / EB / R01 EB001981-08; United States / NIBIB NIH HHS / EB / R01 EB001981; United States / NIBIB NIH HHS / EB / EB001981; United States / NIBIB NIH HHS / EB / R01 EB001981-07; United States / NIBIB NIH HHS / EB / EB001981-08
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS196000; NLM/ PMC2894569
  •  go-up   go-down


63. Yan M, Shen J, Person MD, Kuang X, Lynn WS, Atlas D, Wong PK: Endoplasmic reticulum stress and unfolded protein response in Atm-deficient thymocytes and thymic lymphoma cells are attributable to oxidative stress. Neoplasia; 2008 Feb;10(2):160-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoplasmic reticulum stress and unfolded protein response in Atm-deficient thymocytes and thymic lymphoma cells are attributable to oxidative stress.
  • Both oxidative stress and endoplasmic reticulum (ER) stress have been implicated in carcinogenesis.
  • It is well documented that cells deficient in the ataxia-telangiectasia mutated (ATM) gene undergo oxidative stress, which is critically involved in thymic lymphomagenesis in Atm-/- mice.
  • Here we demonstrate that undifferentiated Atm-/- thymocytes show signs of ER stress and of the unfolded protein response (UPR).
  • Using two-dimensional (2-D) gel electrophoresis and mass spectrometry (MS) analysis, we identified 22 differentially expressed proteins, including the ER stress marker glucose-regulated protein 78 (GRP78), in Atm-/- thymocytes and in Atm-/- thymic lymphoma cells relative to Atm+/+ thymocytes.
  • The phosphorylated alpha subunit of eukaryotic translation initiation factor 2 (p-eIF2alpha), a UPR marker, was also increased in Atm-/- thymocytes.
  • Cells of the ATL-1 line, which were derived from an Atm-/- mouse thymic lymphoma, were more sensitive to the ER stress inducer tunicamycin than were Atm+/+ thymic leukemia ASL-1 cells.
  • Notably, treatment with hydrogen peroxide duplicated the effects of ATM deficiency in cultured thymocytes, and treatment with the novel cell-permeable thiol antioxidant N-acetylcysteine amide (AD4) reduced elevated p-eIF2alpha levels in thymocytes of Atm-/- mice.
  • Thus, we propose that ER stress and the UPR are secondary to oxidative stress in Atm-/- thymocytes.

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9946-51 [12902539.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33741-9 [9837962.001]
  • [Cites] Carcinogenesis. 1999 Nov;20(11):2063-73 [10545407.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1561-70 [10749124.001]
  • [Cites] Free Radic Biol Med. 2000 May 1;28(9):1349-61 [10924854.001]
  • [Cites] Mol Cell. 2000 Dec;6(6):1355-64 [11163209.001]
  • [Cites] Physiol Rev. 2001 Apr;81(2):807-69 [11274345.001]
  • [Cites] FASEB J. 2001 May;15(7):1132-8 [11344081.001]
  • [Cites] Trends Biochem Sci. 2001 Aug;26(8):504-10 [11504627.001]
  • [Cites] J Biol Chem. 2001 Sep 7;276(36):33869-74 [11448953.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8322-30 [11719466.001]
  • [Cites] Carcinogenesis. 2002 Jan;23(1):123-30 [11756233.001]
  • [Cites] Cell. 2001 Dec 28;107(7):881-91 [11779464.001]
  • [Cites] Mol Cell. 2000 Nov;6(5):1099-108 [11106749.001]
  • [Cites] Nature. 2002 Jan 3;415(6867):92-6 [11780124.001]
  • [Cites] EMBO Rep. 2002 May;3(5):420-5 [11991946.001]
  • [Cites] Dev Cell. 2002 Jul;3(1):99-111 [12110171.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):34287-94 [12097332.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5153-7 [12234978.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 10;300(2):327-32 [12504087.001]
  • [Cites] DNA Repair (Amst). 2002 Jan 22;1(1):3-25 [12509294.001]
  • [Cites] Nature. 2003 Jan 30;421(6922):499-506 [12556884.001]
  • [Cites] J Hepatol. 2003 May;38(5):605-14 [12713871.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):3095-102 [10082576.001]
  • [Cites] Cell Signal. 1999 Jan;11(1):1-14 [10206339.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):966-77 [15573118.001]
  • [Cites] Free Radic Biol Med. 2005 Jan 1;38(1):136-45 [15589382.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9018-26 [15604267.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Mar;55(3):203-12 [15570424.001]
  • [Cites] Eur J Neurosci. 2005 Feb;21(3):637-46 [15733082.001]
  • [Cites] J Biol Chem. 2005 Oct 7;280(40):33917-25 [16107336.001]
  • [Cites] Brain Res. 2006 Jan 19;1069(1):198-206 [16386719.001]
  • [Cites] Curr Mol Med. 2006 Feb;6(1):45-54 [16472112.001]
  • [Cites] Free Radic Biol Med. 2006 Aug 15;41(4):640-8 [16863997.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):721-2 [16880733.001]
  • [Cites] Antioxid Redox Signal. 2006 Sep-Oct;8(9-10):1391-418 [16986999.001]
  • [Cites] Biochem J. 2007 Jan 1;401(1):1-11 [17150040.001]
  • [Cites] J Proteome Res. 2007 Jan;6(1):273-86 [17203971.001]
  • [Cites] Science. 2007 May 25;316(5828):1160-6 [17525332.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8608-18 [14634622.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):20108-17 [14978030.001]
  • [Cites] Antioxid Redox Signal. 2004 Jun;6(3):561-70 [15130282.001]
  • [Cites] J Neurochem. 2004 Jun;89(5):1241-51 [15147517.001]
  • [Cites] Nature. 2004 Oct 21;431(7011):997-1002 [15496926.001]
  • [Cites] Anal Biochem. 1992 May 15;203(1):173-9 [1524213.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4405-11 [8044789.001]
  • [Cites] Free Radic Biol Med. 1995 Apr;18(4):775-94 [7750801.001]
  • [Cites] Cell. 1996 Jul 12;86(1):159-71 [8689683.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13084-9 [8917548.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):117-30 [9516960.001]
  • [Cites] Nature. 1999 Jan 21;397(6716):271-4 [9930704.001]
  • (PMID = 18283338.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA123601-01; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / R03 CA123601; United States / NIEHS NIH HHS / ES / P30 ES007784; United States / NIEHS NIH HHS / ES / ES07784
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Eukaryotic Initiation Factor-2; 0 / HSP70 Heat-Shock Proteins; 0 / Heat-Shock Proteins; 0 / Membrane Proteins; 0 / Molecular Chaperones; 0 / Tumor Suppressor Proteins; 0 / glucose-regulated proteins; 0 / molecular chaperone GRP78; 11089-65-9 / Tunicamycin; BBX060AN9V / Hydrogen Peroxide; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Atm protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ PMC2244691
  •  go-up   go-down


64. Jacobson EM, Hugo ER, Tuttle TR, Papoian R, Ben-Jonathan N: Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor. Trends Endocrinol Metab; 2010 Nov;21(11):691-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although prolactin (PRL) is known as a survival factor that supports tumor growth and confers chemoresistance in both cancers, its precise role in these tumors has not been studied extensively.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Endocrinology. 2007 Jul;148(7):3089-101 [17412813.001]
  • [Cites] J Biol Chem. 2007 Nov 9;282(45):33118-31 [17785459.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):236-48 [18172316.001]
  • [Cites] Endocr Rev. 2008 Feb;29(1):1-41 [18057139.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):41-53 [18246319.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):131-45 [18253708.001]
  • [Cites] BMC Biotechnol. 2008;8:11 [18254957.001]
  • [Cites] J Biol Chem. 2008 Jul 4;283(27):19085-94 [18467331.001]
  • [Cites] Breast Cancer Res Treat. 2008 Sep;111(2):241-50 [17955362.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14533-8 [18779591.001]
  • [Cites] Breast Cancer Res. 2008;10(4):R68 [18681966.001]
  • [Cites] Bioorg Med Chem. 2009 Feb 1;17(3):1026-33 [18234500.001]
  • [Cites] Structure. 2009 Apr 15;17(4):489-98 [19368882.001]
  • [Cites] Carcinogenesis. 2009 Aug;30(8):1298-304 [19443905.001]
  • [Cites] Mod Pathol. 2009 Oct;22(10):1273-9 [19633648.001]
  • [Cites] Growth Horm IGF Res. 2002 Apr;12(2):126-36 [12175650.001]
  • [Cites] J Clin Endocrinol Metab. 2010 Jan;95(1):271-9 [19897676.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3583-93 [10589775.001]
  • [Cites] Ann Surg Oncol. 2000 May;7(4):305-11 [10819372.001]
  • [Cites] Nat Struct Biol. 2000 Sep;7(9):808-15 [10966654.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33937-44 [10938266.001]
  • [Cites] Endocrinology. 2001 Feb;142(2):767-77 [11159849.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26 [11259830.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1217-22 [11290538.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):463-5 [11291087.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6098-104 [11507059.001]
  • [Cites] J Endocrinol. 2001 Oct;171(1):R1-4 [11572805.001]
  • [Cites] Mol Hum Reprod. 2002 Jul;8(7):606-11 [12087074.001]
  • [Cites] Oncogene. 2002 Aug 1;21(33):5047-55 [12140755.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1131-4 [12168912.001]
  • [Cites] Endocr Relat Cancer. 2010 Jun;17(2):R91-107 [20071456.001]
  • [Cites] Mol Cell Endocrinol. 2002 Nov 29;197(1-2):153-65 [12431808.001]
  • [Cites] Ann N Y Acad Sci. 2002 Nov;973:454-8 [12485910.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):689-96 [12574200.001]
  • [Cites] Nat Rev Drug Discov. 2003 May;2(5):369-78 [12750740.001]
  • [Cites] Breast Cancer Res Treat. 2003 May;79(2):241-52 [12825859.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4664-74 [12879011.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4955-66 [12960074.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4666-73 [14581335.001]
  • [Cites] Curr Med Res Opin. 2004 Apr;20(4):533-40 [15119991.001]
  • [Cites] Mol Cell Endocrinol. 2004 May 31;220(1-2):109-23 [15196705.001]
  • [Cites] Lancet. 1976 Aug 7;2(7980):279-82 [59853.001]
  • [Cites] Cancer. 1977 Apr;39(4):1693-9 [856451.001]
  • [Cites] Am J Clin Pathol. 1985 Dec;84(6):687-96 [3878077.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Dec;24(12):1851-3 [3065085.001]
  • [Cites] Lab Invest. 1993 Mar;68(3):354-60 [8450651.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2591-5 [7780973.001]
  • [Cites] Cell Growth Differ. 1995 Apr;6(4):477-83 [7794815.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Oct;80(10):3094-6 [7559904.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):639-69 [8969972.001]
  • [Cites] J Clin Invest. 1997 Feb 15;99(4):618-27 [9045863.001]
  • [Cites] Breast Cancer Res Treat. 1997 Jul;44(3):243-53 [9266104.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Nov;82(11):3692-9 [9360527.001]
  • [Cites] Endocrinology. 1997 Dec;138(12):5555-60 [9389544.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2744-51 [9389738.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):667-74 [9467590.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):202-11 [9583737.001]
  • [Cites] Endocr Rev. 1998 Aug;19(4):365-96 [9715372.001]
  • [Cites] Am J Pathol. 1999 Mar;154(3):863-70 [10079264.001]
  • [Cites] Prostate. 2005 Jul 1;64(2):109-15 [15666390.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5863-8 [16115927.001]
  • [Cites] Expert Opin Investig Drugs. 2006 Oct;15(10):1257-67 [16989600.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Oct;2(10):571-81 [17024156.001]
  • [Cites] J Biomol Screen. 2006 Oct;11(7):864-9 [16973922.001]
  • [Cites] Growth Horm IGF Res. 2006 Oct-Dec;16(5-6):297-307 [17010651.001]
  • [Cites] Oncogene. 2006 Dec 7;25(58):7565-76 [16785991.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D298-300 [17135201.001]
  • [Cites] J Biol Chem. 2007 Feb 2;282(5):3262-72 [17130123.001]
  • [Cites] J Biol Chem. 2010 Mar 12;285(11):8422-33 [20053995.001]
  • [Cites] J Biol Chem. 2010 Mar 12;285(11):8003-12 [20080972.001]
  • [Cites] Breast Cancer Res Treat. 2010 Apr;120(2):369-77 [19377875.001]
  • [Cites] Am J Pathol. 2010 Apr;176(4):1959-72 [20167868.001]
  • [Cites] Appl Microbiol Biotechnol. 2010 Jun;87(1):75-86 [20396881.001]
  • [Cites] Endocr Relat Cancer. 2010 Jun;17(2):481-93 [20233708.001]
  • [Cites] Anal Biochem. 2010 Aug;403(1-2):94-101 [20382104.001]
  • [Cites] J Biol Chem. 2010 Jun 25;285(26):20022-30 [20427283.001]
  • [Cites] Hum Reprod Update. 2007 Mar-Apr;13(2):121-41 [17068222.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1482-8 [17372279.001]
  • [Cites] Drugs. 2007;67(9):1329-41 [17547474.001]
  • (PMID = 20846877.001).
  • [ISSN] 1879-3061
  • [Journal-full-title] Trends in endocrinology and metabolism: TEM
  • [ISO-abbreviation] Trends Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES016803; United States / NCI NIH HHS / CA / R01 CA096613; United States / NCI NIH HHS / BC / Z01 BC005725; United States / NIEHS NIH HHS / ES / P30 ES006096; United States / NIEHS NIH HHS / ES / R21 ES016803; United States / NCI NIH HHS / CA / CA096613; United States / NIEHS NIH HHS / ES / P30 ES06096
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormone Antagonists; 0 / Receptors, Prolactin
  • [Other-IDs] NLM/ NIHMS237492; NLM/ PMC2967606
  •  go-up   go-down


65. Boyd ZS, Raja R, Johnson S, Eberhard DA, Lackner MR: A tumor sorting protocol that enables enrichment of pancreatic adenocarcinoma cells and facilitation of genetic analyses. J Mol Diagn; 2009 Jul;11(4):290-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tumor sorting protocol that enables enrichment of pancreatic adenocarcinoma cells and facilitation of genetic analyses.
  • Molecular profiling of human cancer is complicated by both stromal contamination and cellular heterogeneity within samples from tumor biopsies.
  • In this study, we developed a tissue-processing protocol using mechanical dissociation and flow cytometric sorting that resulted in the respective enrichment of stromal and tumor fractions from frozen pancreatic adenocarcinoma samples.
  • Molecular profiling of DNA from the sorted populations using high-density single nucleotide polymorphism arrays revealed widespread chromosomal loss of heterozygosity in tumor fractions but not in either the stromal fraction or unsorted tissue specimens from the same sample.
  • Similarly, a combination of KRAS mutations and chromosomal copy number changes at key pancreatic cancer loci, such as CDK2NA and TP53, was detected in a substantial proportion of the tumor fractions but not in matched stromal fractions from the same sample.
  • [MeSH-major] Adenocarcinoma. Cell Separation / methods. Flow Cytometry / methods. Pancreatic Neoplasms
  • [MeSH-minor] Aged. Base Sequence. Biomarkers, Tumor / genetics. DNA Mutational Analysis / methods. Female. Gene Expression Profiling. Humans. Loss of Heterozygosity. Male. Middle Aged. Molecular Sequence Data. Mutation. Oligonucleotide Array Sequence Analysis / methods. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2002 Jan;160(1):73-9 [11786401.001]
  • [Cites] J Gastrointest Surg. 2008 Oct;12(10):1664-72; discussion 1672-3 [18677542.001]
  • [Cites] Anal Biochem. 2002 May 15;304(2):200-5 [12009696.001]
  • [Cites] Expert Rev Anticancer Ther. 2001 Oct;1(3):321-2 [12113093.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):897-909 [12459728.001]
  • [Cites] Int J Gastrointest Cancer. 2002;31(1-3):99-106 [12622420.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1255-60 [14507635.001]
  • [Cites] Proteomics. 2003 Oct;3(10):1988-2001 [14625861.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Jan;9(1):95-104 [15082921.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3060-71 [15126342.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):3-27 [15221985.001]
  • [Cites] Mol Cancer. 2003 Jan 7;2:7 [12537585.001]
  • [Cites] J Pathol. 1991 Jul;164(3):215-24 [1716305.001]
  • [Cites] Am J Pathol. 1993 May;142(5):1534-43 [8494051.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2761-4 [8168108.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1547-50 [7992857.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2060-4 [8700885.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1731-4 [9135016.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):300-3 [9521327.001]
  • [Cites] Am J Clin Pathol. 1998 Jul;110(1):16-23 [9661918.001]
  • [Cites] Hum Genomics. 2004 May;1(4):287-99 [15588488.001]
  • [Cites] Cell Oncol. 2005;27(1):3-13 [15750203.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):117-22 [16001072.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Aug;161(1):36-50 [16080956.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):358-62 [16273091.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Aug;45(8):721-30 [16688744.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6019-25 [17947463.001]
  • [Cites] Oncogene. 2008 Mar 20;27(13):1951-60 [17952125.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6084-91 [18676830.001]
  • [Cites] Br J Cancer. 2002 Jan 21;86(2):257-62 [11870516.001]
  • (PMID = 19460940.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2710704
  •  go-up   go-down


66. Blackford A, Parmigiani G, Kensler TW, Wolfgang C, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Klein A, Cameron JL, Olino K, Schulick R, Winter J, Vogelstein B, Velculescu VE, Kinzler KW, Hruban RH: Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res; 2009 Apr 15;69(8):3681-8
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When adjusted for age and gender, analyses of the discovery screen revealed significantly more nonsynonymous mutations in the carcinomas obtained from ever smokers (mean, 53.1 mutations per tumor; SD, 27.9) than in the carcinomas obtained from never smokers (mean, 38.5; SD, 11.1; P = 0.04).
  • No differences were observed in mutations in carcinomas from the head versus tail of the gland.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3155-9 [10866304.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1641-51 [10793075.001]
  • [Cites] JAMA. 2001 Aug 22-29;286(8):921-9 [11509056.001]
  • [Cites] Cancer J. 2001 Jul-Aug;7(4):251-8 [11561601.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1525-30 [11745231.001]
  • [Cites] Chem Res Toxicol. 2002 May;15(5):677-85 [12018989.001]
  • [Cites] Cancer Causes Control. 2002 Apr;13(3):249-54 [12020106.001]
  • [Cites] Oncogene. 2002 Oct 21;21(48):7435-51 [12379884.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Oct;128(10):525-32 [12384795.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Dec;14(12):1343-53 [12468956.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Mar;130(3):303-6 [15023836.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 17;83(14):1024-7 [2072410.001]
  • [Cites] Am J Surg Pathol. 1993 Mar;17(3):213-20 [8434702.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):432-8 [8319174.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):545-54 [8342602.001]
  • [Cites] Am J Public Health. 1994 Jul;84(7):1086-93 [8017530.001]
  • [Cites] Nat Genet. 1994 Sep;8(1):27-32 [7726912.001]
  • [Cites] N Engl J Med. 1995 Mar 16;332(11):712-7 [7854378.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Semin Oncol. 1996 Apr;23(2):241-50 [8623060.001]
  • [Cites] Int J Cancer. 1996 Jul 3;67(1):63-71 [8690527.001]
  • [Cites] Science. 1996 Oct 18;274(5286):430-2 [8832894.001]
  • [Cites] Arch Intern Med. 1996 Oct 28;156(19):2255-60 [8885826.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1731-4 [9135016.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3126-30 [9242437.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):326-32 [10023699.001]
  • [Cites] Br J Cancer. 1999 Aug;80(11):1830-7 [10468306.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5076-83 [15958551.001]
  • [Cites] Int J Cancer. 2005 Nov 10;117(3):370-5 [15906354.001]
  • [Cites] Risk Anal. 2006 Aug;26(4):881-92 [16948683.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1825-8 [17035388.001]
  • [Cites] Pancreas. 2007 Jan;34(1):55-62 [17198183.001]
  • [Cites] Pancreas. 2007 Aug;35(2):135-41 [17632319.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1894-7 [17855711.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):155-64 [17893872.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Am J Gastroenterol. 2007 Dec;102(12):2696-707 [17764494.001]
  • [Cites] Int J Gastrointest Cancer. 2006;37(4):139-45 [18049799.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):287-95 [18271927.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4283-8 [18337506.001]
  • [Cites] Langenbecks Arch Surg. 2008 Jul;393(4):535-45 [18193270.001]
  • [Cites] Langenbecks Arch Surg. 2008 Jul;393(4):581-8 [18193450.001]
  • [Cites] Cancer Causes Control. 2000 Dec;11(10):915-23 [11142526.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3503-10 [18640931.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16224-9 [18852474.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1069-75 [18948947.001]
  • [Cites] Aust N Z J Public Health. 1999 Dec;23(6):654-6 [10641361.001]
  • (PMID = 19351817.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R37 CA043460; United States / NCI NIH HHS / CA / P50 CA062924-160011; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / P50 CA062924-08S30011; United States / NCI NIH HHS / CA / P50 CA062924-090011; United States / NCI NIH HHS / CA / CA062924-08S30011; United States / NCI NIH HHS / CA / R01 CA039416; United States / NCI NIH HHS / CA / CA062924-090011; United States / NCI NIH HHS / CA / CA062924-160011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS98299; NLM/ PMC2669837
  •  go-up   go-down


67. Neto LV, Machado Ede O, Luque RM, Taboada GF, Marcondes JB, Chimelli LM, Quintella LP, Niemeyer P Jr, de Carvalho DP, Kineman RD, Gadelha MR: Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J Clin Endocrinol Metab; 2009 Jun;94(6):1931-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This was supported by the finding that the in vivo response to octreotide-LAR was negatively associated with DR1 and positively associated with DR5.

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2000 Apr 7;288(5463):154-7 [10753124.001]
  • [Cites] Rev Endocr Metab Disord. 2009 Jun;10(2):83-90 [18651224.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Apr;54(4):469-77 [11318782.001]
  • [Cites] Endocrine. 2001 Apr;14(3):329-36 [11444429.001]
  • [Cites] J Neurophysiol. 2002 Apr;87(4):2167-75 [11929934.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1674-83 [15070930.001]
  • [Cites] J Biol Chem. 1978 Apr 10;253(7):2244-53 [416027.001]
  • [Cites] J Histochem Cytochem. 1979 Aug;27(8):1205-7 [383827.001]
  • [Cites] Endocrinology. 1983 May;112(5):1567-77 [6832061.001]
  • [Cites] Proc Soc Exp Biol Med. 1984 Feb;175(2):191-5 [6694976.001]
  • [Cites] Brain Res. 1988 Mar 8;443(1-2):77-84 [2896059.001]
  • [Cites] EMBO J. 1989 Dec 20;8(13):4025-34 [2531656.001]
  • [Cites] Nature. 1989 Dec 21-28;342(6252):923-6 [2531847.001]
  • [Cites] FEBS Lett. 1990 Apr 9;263(1):18-22 [2139615.001]
  • [Cites] Biochemistry. 1990 Feb 13;29(6):1367-71 [2139794.001]
  • [Cites] J Neurochem. 1991 Mar;56(3):1024-9 [1825222.001]
  • [Cites] J Neurochem. 1991 Sep;57(3):795-801 [1861151.001]
  • [Cites] Neurosci Lett. 1991 Sep 2;130(1):12-6 [1836253.001]
  • [Cites] Nature. 1992 Jul 9;358(6382):149-52 [1319557.001]
  • [Cites] Mol Endocrinol. 1992 Jun;6(6):920-6 [1323056.001]
  • [Cites] Mol Endocrinol. 1992 Nov;6(11):1815-24 [1282671.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1993;33:281-307 [8494342.001]
  • [Cites] Neuroendocrinology. 1994 Sep;60(3):314-22 [7969790.001]
  • [Cites] J Neurochem. 1995 Sep;65(3):1157-65 [7643093.001]
  • [Cites] Anal Biochem. 1995 Sep 20;230(2):353-5 [7503432.001]
  • [Cites] Endocrinology. 1997 May;138(5):1871-8 [9112381.001]
  • [Cites] Physiol Rev. 1998 Jan;78(1):189-225 [9457173.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):374-8 [9467544.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1368-75 [9543168.001]
  • [Cites] Brain Res Mol Brain Res. 1998 Apr;55(2):285-92 [9582438.001]
  • [Cites] Endocrinology. 1998 Oct;139(10):4213-21 [9751502.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Mar 5;256(1):33-40 [10066418.001]
  • [Cites] J Mol Endocrinol. 2005 Oct;35(2):333-41 [16216913.001]
  • [Cites] Trends Pharmacol Sci. 2005 Nov;26(11):595-602 [16183138.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):258-63 [17047391.001]
  • [Cites] Eur J Endocrinol. 2007 Jan;156(1):65-74 [17218727.001]
  • [Cites] Eur J Endocrinol. 2007 Apr;156 Suppl 1:S13-21 [17413183.001]
  • [Cites] Eur J Endocrinol. 2007 Apr;156 Suppl 1:S23-8 [17413184.001]
  • [Cites] Eur J Endocrinol. 2007 Apr;156 Suppl 1:S37-43 [17413187.001]
  • [Cites] Eur J Endocrinol. 2007 Apr;156 Suppl 1:S57-63 [17413190.001]
  • [Cites] Cell Signal. 2007 Nov;19(11):2304-16 [17706924.001]
  • [Cites] J Neuroendocrinol. 2007 Oct;19(10):773-8 [17850459.001]
  • [Cites] Eur J Endocrinol. 2008 Mar;158(3):295-303 [18299461.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1412-7 [18211974.001]
  • [Cites] Mol Pharmacol. 2000 Aug;58(2):455-62 [10908315.001]
  • (PMID = 19293270.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / 30677
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Receptors, Dopamine; 0 / Receptors, Somatostatin; RWM8CCW8GP / Octreotide
  • [Other-IDs] NLM/ PMC2730344
  •  go-up   go-down


68. Garcia-Closas M, Chanock S: Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res; 2008 Dec 15;14(24):8000-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast cancer is a heterogeneous disease, and risk factors could be differentially associated with the development of distinct tumor subtypes that manifest different biological behavior and progression.
  • In support of this view, there is growing evidence that known breast cancer risk factors vary by hormone receptor status and perhaps other pathologic characteristics of disease.
  • Recent work from large consortial studies has led to the discovery of novel breast cancer susceptibility loci in genic (CASP8, FGFR2, TNRC9, MAP3K1, LSP1) and nongenic regions (8q24, 2q35, 5p12) of the genome, and to the finding of substantial heterogeneity by tumor characteristics.
  • In particular, susceptibility loci in FGFR2, TNRC9, 8q24, 2q35, and 5p12 have stronger associations for estrogen receptor-positive (ER+) disease than estrogen receptor-negative (ER -) disease.
  • These findings suggest that common genetic variants can influence the pathologic subtype of breast cancer, and provide further support for the hypothesis that ER+ and ER(-) disease result from different etiologic pathways.
  • Current studies had limited power to detect susceptibility loci for less common tumor subtypes, such as ER(-) disease including triple-negative and basal-like tumors.
  • Ongoing work targeting uncommon subtypes is likely to identify additional tumor-specific susceptibility loci in the near future.
  • [MeSH-major] Breast Neoplasms / genetics. Genetic Predisposition to Disease. Receptors, Estrogen / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1991 Apr;6(4):659-63 [1851551.001]
  • [Cites] Br J Cancer. 1992 Aug;66(2):273-80 [1380281.001]
  • [Cites] Lancet. 1997 May 24;349(9064):1505-10 [9167459.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):435-41 [9241077.001]
  • [Cites] Oncol Rep. 1998 May-Jun;5(3):577-83 [9538155.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Breast Cancer Res Treat. 2005 Mar;90(2):127-37 [15803359.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):179-86 [15863033.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5175-80 [16033833.001]
  • [Cites] Nature. 2005 Oct 27;437(7063):1299-320 [16255080.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):977-85 [16341085.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2261-7 [16636340.001]
  • [Cites] Nat Genet. 2006 Jun;38(6):659-62 [16715099.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3288-96 [16740749.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:35-41 [16869736.001]
  • [Cites] Nat Genet. 2006 Aug;38(8):873-5 [16832357.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14068-73 [16945910.001]
  • [Cites] Am J Epidemiol. 2006 Oct 1;164(7):609-14 [16893921.001]
  • [Cites] Oncogene. 2006 Sep 25;25(43):5846-53 [16998499.001]
  • [Cites] Oncogene. 2006 Sep 25;25(43):5898-905 [16998504.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 4;98(19):1350-3 [17018776.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 4;98(19):1382-96 [17018785.001]
  • [Cites] Nat Genet. 2006 Nov;38(11):1239-41 [17033622.001]
  • [Cites] Lancet Oncol. 2006 Nov;7(11):910-8 [17081916.001]
  • [Cites] Breast Cancer Res. 2006;8(4):R43 [16859501.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):165-7 [17200668.001]
  • [Cites] Nat Genet. 2007 Mar;39(3):352-8 [17293864.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):439-43 [17372238.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):2951-6 [17409400.001]
  • [Cites] Nat Genet. 2007 May;39(5):645-9 [17401363.001]
  • [Cites] Nat Genet. 2007 May;39(5):638-44 [17401364.001]
  • [Cites] Nat Genet. 2007 May;39(5):631-7 [17401366.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):770-6 [11048727.001]
  • [Cites] Nat Genet. 2000 Dec;26(4):411-4 [11101836.001]
  • [Cites] FEBS Lett. 2001 Mar 9;492(1-2):166-70 [11248257.001]
  • [Cites] Breast Cancer Res. 1999;1(1):14-7 [11250676.001]
  • [Cites] Breast Cancer Res. 2000;2(3):191-6 [11250709.001]
  • [Cites] Nat Med. 2001 May;7(5):552-6 [11329055.001]
  • [Cites] Nat Genet. 2007 May;39(5):605-13 [17450141.001]
  • [Cites] Nature. 2007 Jun 7;447(7145):655-60 [17554299.001]
  • [Cites] Lab Invest. 2007 Jul;87(7):662-9 [17334408.001]
  • [Cites] Nat Genet. 2007 Jul;39(7):870-4 [17529973.001]
  • [Cites] Nat Genet. 2007 Jul;39(7):865-9 [17529974.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1087-93 [17529967.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):954-6 [17618282.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):989-94 [17618283.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):984-8 [17618284.001]
  • [Cites] Nature. 2007 Oct 18;449(7164):851-61 [17943122.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1328-32 [17496191.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4455-63 [17827388.001]
  • [Cites] BMC Genomics. 2008;9:12 [18190704.001]
  • [Cites] Nat Genet. 2008 Mar;40(3):259-60; author reply 260-1 [18305469.001]
  • [Cites] Am J Hum Genet. 2008 Apr;82(4):937-48 [18355772.001]
  • [Cites] Breast Cancer Res Treat. 2008 May;109(1):123-39 [17578664.001]
  • [Cites] Int J Cancer. 2008 Jun 15;122(12):2876-9 [18360876.001]
  • [Cites] PLoS Genet. 2008 Apr;4(4):e1000054 [18437204.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):703-6 [18438407.001]
  • [Cites] PLoS Biol. 2008 May 6;6(5):e108 [18462018.001]
  • [Cites] Cell Cycle. 2008 Jun 1;7(11):1630-9 [18469518.001]
  • [Cites] N Engl J Med. 2008 Jun 26;358(26):2796-803 [18579814.001]
  • [Cites] J Natl Cancer Inst. 2008 Jul 2;100(13):962-6 [18577746.001]
  • [Cites] Breast Cancer Res Treat. 2008 Sep;111(1):139-44 [17891485.001]
  • [Cites] J Natl Cancer Inst. 2008 Jul 16;100(14):1037-41 [18612136.001]
  • [Cites] Int J Oncol. 2008 Aug;33(2):233-7 [18636142.001]
  • [Cites] Breast Cancer Res Treat. 2008 Nov;112(2):367-8 [18097748.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8010-8 [19088017.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8019-26 [19088018.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8027-41 [19088019.001]
  • [Cites] Breast Cancer Res Treat. 2009 Feb;113(3):607-8 [18343995.001]
  • [Cites] Cancer Biol Ther. 2007 Jul;6(7):1143-7 [17630503.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):310-9 [9669814.001]
  • [Cites] J Natl Cancer Inst. 1998 Aug 5;90(15):1138-45 [9701363.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2541-6 [9703907.001]
  • [Cites] Breast Cancer Res. 2004;6(6):240-5 [15535853.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Jul;9(3):221-36 [15557796.001]
  • [Cites] Arch Histol Cytol. 2004 Dec;67(5):455-64 [15781986.001]
  • [Cites] Urol Oncol. 2009 Jul-Aug;27(4):373-6 [18625567.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Anal Cell Pathol. 2001;22(4):229-34 [11564899.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):233-7 [11586306.001]
  • [Cites] Clin Exp Metastasis. 2000;18(7):573-80 [11688962.001]
  • [Cites] Nat Genet. 2001 Nov;29(3):306-9 [11600885.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Genet Med. 2002 Mar-Apr;4(2):45-61 [11882781.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2310-8 [11981002.001]
  • [Cites] Nat Genet. 2002 May;31(1):55-9 [11967536.001]
  • [Cites] Science. 2002 Jun 21;296(5576):2225-9 [12029063.001]
  • [Cites] Am J Hum Genet. 2002 Aug;71(2):432-8 [12094328.001]
  • [Cites] Br J Cancer. 2002 Jul 29;87(3):294-300 [12177798.001]
  • [Cites] Nat Genet. 2003 Feb;33(2):177-82 [12524541.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):671-8 [12588355.001]
  • [Cites] Lancet. 2003 Mar 8;361(9360):865-72 [12642066.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5 [14519755.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2029-34 [15041722.001]
  • [Cites] Am J Hum Genet. 2004 Jun;74(6):1175-82 [15122511.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1128-35 [15247123.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1558-68 [15466970.001]
  • [Cites] Lab Invest. 2004 Nov;84(11):1460-71 [15311216.001]
  • [Cites] Nature. 2004 Oct 21;431(7011):931-45 [15496913.001]
  • (PMID = 19088016.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010126-12; United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / TNRC9 protein, human
  • [Number-of-references] 107
  • [Other-IDs] NLM/ NIHMS78615; NLM/ PMC2668137
  •  go-up   go-down


69. Kut C, Mac Gabhann F, Popel AS: Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer; 2007 Oct 8;97(7):978-85
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer.
  • Vascular endothelial growth factor (VEGF) is a major target for the inhibition of tumour vascularisation and the treatment of human cancer.
  • Many tumours produce large quantities of VEGF, and as a result, diagnosis and prognosis of cancer may be predicted by measuring changes in VEGF concentrations in blood.
  • In blood, the VEGF may be located in the plasma, or in the blood-borne cells and formed elements, in particular, platelets and leukocytes.
  • In this study, we collate the measurements of VEGF in platelets, leukocytes, plasma and serum for breast, prostate, colorectal and other cancers.
  • In addition, we analysed the concentration of VEGF in tumour tissue itself, as well as for other tissues in the human body.
  • Although the concentration of VEGF in tumours is high, the size of tumours is small compared to other tissues, in particular, skeletal muscle.
  • Thus, the total quantity of VEGF in tumours and in blood is small compared to the quantity in muscles.
  • This large reservoir of VEGF may have important implications for the treatment of cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Rep. 2002 Jan-Feb;9(1):159-65 [11748475.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):14-8 [11857378.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):73-80 [11863115.001]
  • [Cites] Ann Med. 2004;36(4):273-7 [15224653.001]
  • [Cites] Intern Med J. 2004 Jun;34(6):310-5 [15228391.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):733-40 [15252843.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2912-8 [8504432.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):843-8 [8922199.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):663-8 [9012841.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] J Surg Res. 1997 Feb 1;67(2):147-54 [9073561.001]
  • [Cites] Int J Cancer. 1997 Aug 22;74(4):455-8 [9291439.001]
  • [Cites] Cancer Lett. 1998 Mar 13;125(1-2):35-8 [9566693.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1279-85 [9607588.001]
  • [Cites] Obstet Gynecol. 1998 Sep;92(3):360-3 [9721770.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3129-36 [9738585.001]
  • [Cites] Clin Cancer Res. 1996 May;2(5):821-6 [9816236.001]
  • [Cites] Clin Cancer Res. 1997 May;3(5):647-51 [9815732.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2187-90 [9815613.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2451-8 [9815646.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2507-11 [9815654.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):178-87 [9921991.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2041-5 [10070308.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):487-91 [10100697.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jan;53(2):161-6 [10326793.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):892-7 [10360671.001]
  • [Cites] Thorax. 1999 Aug;54(8):707-10 [10413724.001]
  • [Cites] Urology. 1999 Sep;54(3):523-7 [10475365.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2324-9 [10499600.001]
  • [Cites] Cancer Immunol Immunother. 1999 Oct;48(7):396-400 [10501853.001]
  • [Cites] Anesth Analg. 2005 Jan;100(1):244-9 [15616085.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Br J Cancer. 2005 Feb 14;92(3):553-61 [15668703.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):584-93 [15701844.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1557-61 [15941972.001]
  • [Cites] Nat Rev Drug Discov. 2007 Apr;6(4):273-86 [17396134.001]
  • [Cites] Jpn J Cancer Res. 1999 Aug;90(8):874-9 [10543260.001]
  • [Cites] BJU Int. 2000 Feb;85(3):276-80 [10671881.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):812-7 [10732751.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1004-8 [10737380.001]
  • [Cites] Cancer Lett. 2000 May 29;153(1-2):7-12 [10779624.001]
  • [Cites] Oncologist. 2000;5 Suppl 1:37-44 [10804090.001]
  • [Cites] Cancer Treat Rev. 2000 Jun;26(3):191-204 [10814561.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2898-905 [10850435.001]
  • [Cites] Acta Neuropathol. 2000 Jul;100(1):101-5 [10912927.001]
  • [Cites] Clin Exp Metastasis. 1999;17(8):687-94 [10919714.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3147-52 [10955796.001]
  • [Cites] Prostate. 2000 Sep 15;45(1):42-50 [10960841.001]
  • [Cites] Chest. 2000 Oct;118(4):948-51 [11035661.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1425-31 [11076648.001]
  • [Cites] Anal Bioanal Chem. 2005 Jun;382(4):1010-6 [15928947.001]
  • [Cites] Respirology. 2002 Jun;7(2):93-8 [11985729.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):393-406 [12013529.001]
  • [Cites] Surgery. 2002 May;131(5):548-55 [12019409.001]
  • [Cites] Eur J Cancer Prev. 2002 Jun;11(3):245-52 [12131658.001]
  • [Cites] Cancer Lett. 2002 Nov 8;185(1):31-7 [12142076.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5325-35 [12235003.001]
  • [Cites] Scand J Clin Lab Invest. 2002;62(5):343-50 [12387579.001]
  • [Cites] APMIS. 2002 Sep;110(9):646-50 [12529018.001]
  • [Cites] Clin Exp Metastasis. 2002;19(8):651-63 [12553370.001]
  • [Cites] Urology. 2003 Apr;61(4):765-9 [12670562.001]
  • [Cites] J Physiol. 2003 Jul 1;550(Pt 1):217-25 [12754306.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2416-25 [12855613.001]
  • [Cites] Zhonghua Nei Ke Za Zhi. 2003 Jul;42(7):486-9 [12921610.001]
  • [Cites] Eur J Clin Invest. 2003 Oct;33(10):883-90 [14511360.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):535-40 [14520689.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4332-9 [14555503.001]
  • [Cites] Urol Res. 2003 Oct;31(5):335-40 [14574539.001]
  • [Cites] Eur Surg Res. 2003 Nov-Dec;35(6):492-6 [14593233.001]
  • [Cites] Cancer. 2003 Nov 15;98(10):2125-32 [14601081.001]
  • [Cites] J Appl Physiol (1985). 2004 Jan;96(1):19-24 [12949011.001]
  • [Cites] Breast Cancer Res. 2004;6(1):R38-45 [14680499.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):244-50 [14734476.001]
  • [Cites] Cancer Lett. 2004 Feb 10;204(1):87-95 [14744538.001]
  • [Cites] Curr Pharm Des. 2004;10(1):11-26 [14754402.001]
  • [Cites] Acta Oncol. 2003;42(8):837-45 [14968945.001]
  • [Cites] Urology. 2004 Feb;63(2):327-32 [14972483.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2694-704 [15102673.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):2941-55 [15126324.001]
  • [Cites] Angiogenesis. 2003;6(4):255-7 [15166493.001]
  • [Cites] Angiogenesis. 2003;6(4):283-7 [15166496.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):549-60 [16336962.001]
  • [Cites] Wound Repair Regen. 2006 May-Jun;14(3):259-64 [16808804.001]
  • [Cites] PLoS Comput Biol. 2006 Sep 22;2(9):e127 [17002494.001]
  • [Cites] PLoS Comput Biol. 2006 Dec 29;2(12):e180 [17196035.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H459-74 [16980341.001]
  • [Cites] Mol Pathol. 2000 Dec;53(6):307-12 [11193049.001]
  • [Cites] Ann Surg. 2001 Feb;233(2):227-35 [11176129.001]
  • [Cites] Eur J Surg Oncol. 2001 Feb;27(1):37-42 [11237490.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2533-6 [11289126.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2736-43 [11289156.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):538-43 [11297245.001]
  • [Cites] Neoplasia. 2001 Mar-Apr;3(2):143-53 [11420750.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1888-93 [11448901.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1932-6 [11448906.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5407-14 [11454684.001]
  • [Cites] Ann Surg Oncol. 2001 Oct;8(9):741-5 [11597016.001]
  • [Cites] Carcinogenesis. 2001 Nov;22(11):1765-73 [11698337.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3491-4 [11705867.001]
  • (PMID = 17912242.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL079653; United States / NHLBI NIH HHS / HL / R33 HL087351; United States / NHLBI NIH HHS / HL / HL079653; United States / NHLBI NIH HHS / HL / HL087351
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2360423
  •  go-up   go-down


70. Sameni M, Cavallo-Medved D, Dosescu J, Jedeszko C, Moin K, Mullins SR, Olive MB, Rudy D, Sloane BF: Imaging and quantifying the dynamics of tumor-associated proteolysis. Clin Exp Metastasis; 2009;26(4):299-309
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging and quantifying the dynamics of tumor-associated proteolysis.
  • Proteases from tumor-associated cells (e.g., fibroblasts, inflammatory cells, endothelial cells) as well as from tumor cells make important contributions to 'tumor proteolysis'.
  • Here we describe live cell assays for imaging proteolysis, protocols for quantifying proteolysis and the use of such assays to follow the dynamics of proteolysis by tumor cells alone and tumor cells interacting with other cells found in the tumor microenvironment.
  • In addition, we describe an in vitro model that recapitulates the architecture of the mammary gland, a model designed to determine the effects of dynamic interactions with the surrounding microenvironment on 'tumor proteolysis' and the respective contributions of various cell types to 'tumor proteolysis'.

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res. 2003;5(3):130-5 [12793893.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2006;46:301-15 [16402907.001]
  • [Cites] Nat Chem Biol. 2005 Sep;1(4):203-9 [16408036.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):227-39 [16498445.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):608-22 [16442099.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):716-28 [16469948.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5242-50 [16707449.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):231-47 [16807803.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11238-46 [17114237.001]
  • [Cites] Curr Opin Chem Biol. 2007 Feb;11(1):36-45 [17194619.001]
  • [Cites] Curr Pharm Des. 2007;13(3):253-61 [17313359.001]
  • [Cites] Int J Cancer. 2007 May 15;120(10):2086-95 [17290405.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2007 Mar;12(1):83-97 [17286208.001]
  • [Cites] J Proteome Res. 2007 Jul;6(7):2850-8 [17547438.001]
  • [Cites] Nat Cell Biol. 2007 Aug;9(8):893-904 [17618273.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):800-8 [17851543.001]
  • [Cites] Nat Methods. 2007 Oct;4(10):822-7 [17901872.001]
  • [Cites] Rev Endocr Metab Disord. 2007 Sep;8(3):279-87 [17447144.001]
  • [Cites] Birth Defects Res C Embryo Today. 2007 Dec;81(4):270-85 [18228260.001]
  • [Cites] Neoplasia. 2008 Apr;10(4):314-29 [18392133.001]
  • [Cites] J Clin Neurosci. 2008 Jul;15(7):725-37 [18468901.001]
  • [Cites] Biol Chem. 2008 Aug;389(8):1117-21 [18710343.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 19;92(14):1185-6 [10904098.001]
  • [Cites] Exp Cell Res. 2000 Nov 1;260(2):292-303 [11035924.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):496-504 [11228542.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):169-84 [11237532.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jan;65(2):101-10 [11261825.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6642-50 [11426650.001]
  • [Cites] Biol Chem. 2001 May;382(5):785-8 [11517931.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] Science. 2002 May 10;296(5570):1046-9 [12004111.001]
  • [Cites] Breast Cancer Res. 2003;5(3):140-6 [12793895.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] Hum Cell. 2003 Mar;16(1):1-14 [12971620.001]
  • [Cites] Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S127-33 [14508090.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6524-36 [14528277.001]
  • [Cites] Anal Bioanal Chem. 2003 Nov;377(6):956-63 [12955390.001]
  • [Cites] Mol Imaging. 2003 Jul;2(3):159-75 [14649059.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):379-91 [14973383.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 4;1654(1):13-22 [14984764.001]
  • [Cites] Histochem Cell Biol. 2004 Apr;121(4):299-310 [15042374.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] Front Biol. 1975;43(4):193-249 [780142.001]
  • [Cites] Lab Invest. 1978 Dec;39(6):531-40 [216851.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Mol Carcinog. 1991;4(1):25-35 [2009132.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):313-9 [8546221.001]
  • [Cites] Breast Cancer Res. 2004;6(2):93-101 [14979914.001]
  • [Cites] J Clin Invest. 2005 May;115(5):1163-76 [15841211.001]
  • [Cites] J Cell Biol. 2005 Jun 20;169(6):977-85 [15967816.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Jun;5(4):285-98 [15975049.001]
  • [Cites] Semin Cancer Biol. 2005 Oct;15(5):342-52 [15963732.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):675-88 [16148884.001]
  • [Cites] Oncogene. 2005 Oct 20;24(46):6870-6 [16007139.001]
  • [Cites] Circ Res. 2005 Nov 25;97(11):1093-107 [16306453.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):97-104 [12027581.001]
  • [Cites] Cell. 2002 Oct 4;111(1):29-40 [12372298.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] Expert Opin Ther Targets. 2003 Feb;7(1):71-88 [12556204.001]
  • [Cites] Breast Cancer Res. 2003;5(1):31-6 [12559043.001]
  • [Cites] Breast Cancer Res. 2003;5(2):101-6 [12631389.001]
  • [Cites] J Histochem Cytochem. 2003 Jun;51(6):821-9 [12754293.001]
  • [Cites] Cancer Cell. 2003 May;3(5):445-8 [12781362.001]
  • (PMID = 19082919.001).
  • [ISSN] 1573-7276
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA056586-17; United States / NCI NIH HHS / CA / R01 CA131990; United States / NCI NIH HHS / CA / R01 CA056586; United States / NCI NIH HHS / CA / CA 56586; United States / NIEHS NIH HHS / ES / P30 ES006639; United States / NCI NIH HHS / CA / P30 CA022453; United States / NCI NIH HHS / CA / P30 CA 22453; United States / NCRR NIH HHS / RR / U54 RR 020843; United States / NIEHS NIH HHS / ES / P30 ES 06639; United States / NCI NIH HHS / CA / CA056586-17; United States / NCRR NIH HHS / RR / U54 RR020843
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.- / Peptide Hydrolases
  • [Number-of-references] 70
  • [Other-IDs] NLM/ NIHMS223032; NLM/ PMC2991638
  •  go-up   go-down


71. Bastasch MD, Teh BS, Mai WY, McGary JE, Grant WH 3rd, Butler EB: Tolerance of endorectal balloon in 396 patients treated with intensity-modulated radiation therapy (IMRT) for prostate cancer. Am J Clin Oncol; 2006 Feb;29(1):8-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endorectal balloon catheter was inserted daily, inflated with 100 mL of air for immobilizing the prostate gland.
  • Topical anal medications were prescribed for 46 of 396 (11.6%) patients and antidiarrhea medication for 27 of 396 (6.8%) patients.
  • Of patients with pretreatment anorectal disease, 50% developed rectal toxicities over the 7 weeks.
  • Patients with pre-existing anorectal disease are at higher risk of developing acute anorectal toxicity with the use of an endorectal balloon.
  • [MeSH-major] Catheterization. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Anal Canal. Dose-Response Relationship, Radiation. Humans. Male. Middle Aged. Movement. Radiotherapy / instrumentation. Radiotherapy / methods

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462495.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Liu GY, Luo Q, Xiong B, Pan C, Yin P, Liao HF, Zhuang WC, Gao HZ: Tissue array for Tp53, C-myc, CCND1 gene over-expression in different tumors. World J Gastroenterol; 2008 Dec 21;14(47):7199-207
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tissue array included 120 points of esophagus, 120 points of stomach, 80 points of rectum, 60 points of thyroid gland, 100 points of mammary gland, 80 points of liver, and 80 points of colon.
  • The expression level of C-myc gene was different in esophagus carcinoma tissue samples (chi2 = 18.495, P = 0.000), stomach carcinoma tissue samples (chi2 = 23.750, P = 0.000), and thyroid gland tissue samples (chi2 = 10.999, P = 0.004).
  • [MeSH-major] Cyclin D1 / metabolism. Esophageal Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Proto-Oncogene Proteins c-myc / metabolism. Stomach Neoplasms / metabolism. Tissue Array Analysis. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Breast Neoplasms / ethnology. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. China. Colonic Neoplasms / ethnology. Colonic Neoplasms / genetics. Colonic Neoplasms / metabolism. Humans. Liver Neoplasms / ethnology. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. RNA, Messenger / metabolism. Rectal Neoplasms / ethnology. Rectal Neoplasms / genetics. Rectal Neoplasms / metabolism. Thyroid Neoplasms / ethnology. Thyroid Neoplasms / genetics. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1997 May 1;57(9):1769-75 [9135021.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):656-60 [17251933.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3622-34 [11504744.001]
  • [Cites] Lung Cancer. 2001 Nov;34(2):207-18 [11679179.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jul;74(1):25-31 [12150449.001]
  • [Cites] Mol Cell Biol. 1984 Feb;4(2):276-81 [6366518.001]
  • [Cites] Lab Invest. 1986 Aug;55(2):244-8 [3525985.001]
  • [Cites] Mol Cell Biol. 1985 Oct;5(10):2851-5 [3915536.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8403-7 [2236048.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):5006-10 [2052583.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8237-41 [1896475.001]
  • [Cites] Am J Pathol. 1992 Sep;141(3):545-50 [1519662.001]
  • [Cites] Anal Biochem. 1993 Nov 15;215(1):86-9 [7507651.001]
  • [Cites] Am J Clin Pathol. 1994 Nov;102(5):695-8 [7942638.001]
  • [Cites] J Cell Biochem Suppl. 1996;25:23-8 [9027594.001]
  • [Cites] Cell. 1997 Feb 7;88(3):405-15 [9039267.001]
  • [Cites] J Pathol. 1997 Mar;181(3):267-9 [9155710.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 May;123(5):497-502 [9158396.001]
  • [Cites] Br J Cancer. 1997;76(1):21-8 [9218727.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Br J Plast Surg. 1998 Apr;51(3):191-4 [9664877.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):259-62 [15668280.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):637-46 [15612024.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Nat Methods. 2006 Jan;3(1):27-9 [16369549.001]
  • [Cites] RNA. 2006 May;12(5):913-20 [16540696.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):661-5 [17251932.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1688-95 [11104567.001]
  • (PMID = 19084934.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  • [Other-IDs] NLM/ PMC2776877
  •  go-up   go-down


73. Sarathchandra SK, Lunn JA, Hunt GB: Ligation of the caudal mesenteric artery during resection and anastomosis of the colorectal junction for annular adenocarcinoma in two dogs. Aust Vet J; 2009 Sep;87(9):356-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The dogs were euthanased 8 and 10 months, respectively, after surgery because of clinical signs relating to metastatic disease.
  • [MeSH-major] Adenocarcinoma / veterinary. Anal Gland Neoplasms / surgery. Dog Diseases / surgery. Mesenteric Arteries / surgery
  • [MeSH-minor] Anastomosis, Surgical / veterinary. Animals. Dogs. Female. Ligation / veterinary. Neoplasm Metastasis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19703136.001).
  • [ISSN] 1751-0813
  • [Journal-full-title] Australian veterinary journal
  • [ISO-abbreviation] Aust. Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 16
  •  go-up   go-down


74. Spugnini EP, Dotsinsky I, Mudrov N, Cardosi G, Citro G, D'Avino A, Baldi A: Biphasic pulses enhance bleomycin efficacy in a spontaneous canine perianal tumors model. J Exp Clin Cancer Res; 2007 Dec;26(4):483-7
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biphasic pulses enhance bleomycin efficacy in a spontaneous canine perianal tumors model.
  • Perianal tumors (adenoma and carcinoma of the hepatoid glands) are frequently reported in veterinary literature.
  • An hormonal ethiology has been identified for the development of perianal adenomas in male dogs, while the carcinomas are free from hormonal influence.
  • In this article we describe the outcome of a small cohort of canine patients with perianal tumors treated with bleomycin selectively driven by trains of biphasic pulses (electrochemotherapy).
  • Twelve canine patients, eight with adenoma and four with carcinoma of the perianal glands, entered the study and received two sessions of ECT under sedation.
  • The overall response rate was 91% with a 83% of complete response (10/12); one dog had a PR that lasted 12 months and another had progressive disease.
  • Electrochemotherapy appears as a safe and efficacious modality for the treatment of perianal tumors and warrants further investigations.
  • [MeSH-major] Anal Gland Neoplasms / drug therapy. Antibiotics, Antineoplastic / analysis. Bleomycin / analysis. Dog Diseases / drug therapy. Electrochemotherapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365542.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


75. Li Y, Zhang Y, Hill J, Kim HT, Shen Q, Bissonnette RP, Lamph WW, Brown PH: The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br J Cancer; 2008 Apr 22;98(8):1380-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We also examined the regulation of a number of rexinoid-modulated genes including critical growth and cell cycle regulating genes using breast cell lines and mammary gland samples from mice treated with rexinoids.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Med (Berl). 1997 Jun;75(6):429-39 [9231883.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jul 18;236(2):294-8 [9240428.001]
  • [Cites] Genes Dev. 1997 Aug 15;11(16):2052-65 [9284045.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1658-64 [10430065.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4276-84 [10485472.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):52643-52 [15448136.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):441-8 [15591091.001]
  • [Cites] Cancer Cell. 2006 Jan;9(1):13-22 [16413468.001]
  • [Cites] Cancer Cell. 2006 Jan;9(1):23-32 [16413469.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(2):147-57 [16273314.001]
  • [Cites] Ann Oncol. 2006 Jul;17(7):1065-71 [16675486.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):12009-18 [17178900.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5488-96 [17875779.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6224-31 [17947490.001]
  • [Cites] J Natl Cancer Inst. 1999 Nov 3;91(21):1847-56 [10547391.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2118 [10601384.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1999 Oct;4(4):377-88 [10705921.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3696-704 [10999763.001]
  • [Cites] Oncogene. 2000 Dec 11;19(53):6130-7 [11156526.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jan 12;280(1):164-71 [11162494.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):240-1 [11158198.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):467-74 [12010861.001]
  • [Cites] Cancer. 2002 May 15;94(10):2766-92 [12173348.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3270-5 [12374698.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6376-80 [12438218.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):46544-51 [12297495.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):296-300 [12559863.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):16899-907 [12624110.001]
  • [Cites] J Biol Chem. 2003 May 30;278(22):20098-109 [12657651.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 17;95(24):1825-33 [14679152.001]
  • [Cites] J Natl Cancer Inst. 2004 May 5;96(9):715; author reply 715-6 [15126613.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3566-71 [15150113.001]
  • [Cites] Comp Med. 2004 Jun;54(3):280-7 [15253274.001]
  • [Cites] Proc Soc Exp Biol Med. 1983 Nov;174(2):270-5 [6227008.001]
  • [Cites] Anal Biochem. 1985 Oct;150(1):76-85 [3843705.001]
  • (PMID = 18362934.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA078480-02; United States / NCI NIH HHS / CA / R01 CA078480; United States / NCI NIH HHS / CA / R01 CA078480-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Bhlhe40 protein, mouse; 0 / Cyclin D; 0 / Cyclins; 0 / Homeodomain Proteins; 0 / Tetrahydronaphthalenes; A61RXM4375 / bexarotene
  • [Other-IDs] NLM/ NIHMS76206; NLM/ PMC2361704
  •  go-up   go-down


76. Iannicelli E, Galluzzo A, Salvi PF, Ziparo V, David V: A large porocarcinoma of perineal region: MR findings and review of the literature. Abdom Imaging; 2008 Nov-Dec;33(6):744-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Acrospiroma / pathology. Anus Neoplasms / pathology. Genital Neoplasms, Female / pathology. Magnetic Resonance Imaging / methods. Perineum / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / radiography. Anal Canal / surgery. Colostomy. Contrast Media. Eccrine Glands / pathology. Eccrine Glands / radiography. Eccrine Glands / surgery. Female. Follow-Up Studies. Heterocyclic Compounds. Humans. Image Enhancement / methods. Middle Aged. Organometallic Compounds. Rare Diseases. Tomography, X-Ray Computed. Vagina / pathology. Vagina / radiography. Vagina / surgery. Vulva / pathology. Vulva / radiography. Vulva / surgery

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18196314.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Heterocyclic Compounds; 0 / Organometallic Compounds; 92923-44-9 / gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate
  • [Number-of-references] 14
  •  go-up   go-down


77. Duray A, Demoulin S, Hubert P, Delvenne P, Saussez S: Immune suppression in head and neck cancers: a review. Clin Dev Immunol; 2010;2010:701657
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antitumor responses of HNSCC patients are compromised in the presence of functional defects or apoptosis of T-cells, both circulating and tumor-infiltrating.
  • [MeSH-major] Carcinoma, Squamous Cell / immunology. Head and Neck Neoplasms / immunology. Tumor Escape

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9281-9 [16982773.001]
  • [Cites] J Leukoc Biol. 2006 Oct;80(4):705-13 [16864600.001]
  • [Cites] J Dent Res. 2006 Dec;85(12):1061-73 [17122156.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):315-22 [16967326.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6B):4409-13 [17201162.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2553-62 [12171883.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):5069-75 [12208763.001]
  • [Cites] Mol Oncol. 2007 Dec;1(3):350-5 [19383307.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):177-89 [12463738.001]
  • [Cites] Curr Opin Immunol. 2003 Feb;15(1):75-81 [12495737.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):92-8 [12506176.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Aug;129(8):882-8 [12925349.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6478-87 [14559840.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):69-76 [14657228.001]
  • [Cites] Int J Mol Med. 2004 Feb;13(2):267-72 [14719133.001]
  • [Cites] Int J Exp Pathol. 2003 Dec;84(6):259-65 [14748745.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1444-53 [15240741.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5101-10 [15297413.001]
  • [Cites] Cancer Biother Radiopharm. 2008 Feb;23(1):25-33 [18298326.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):11-8 [18308558.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2B):1133-8 [18505048.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3706-15 [18559587.001]
  • [Cites] Otolaryngol Head Neck Surg. 1992 Jan;106(1):27-33 [1734363.001]
  • [Cites] J Oral Pathol Med. 1992 Mar;21(3):100-4 [1374796.001]
  • [Cites] J Surg Oncol. 1993 Jun;53(2):92-6 [8501912.001]
  • [Cites] J Oral Pathol Med. 1994 Feb;23(2):55-9 [8164153.001]
  • [Cites] In Vivo. 1994 Jul-Aug;8(4):543-7 [7893981.001]
  • [Cites] In Vivo. 1995 May-Jun;9(3):225-9 [8562888.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):436-40 [8630949.001]
  • [Cites] Int J Cancer. 1996 Jul 29;67(3):333-8 [8707405.001]
  • [Cites] Crit Rev Oral Biol Med. 1996;7(1):36-58 [8727106.001]
  • [Cites] Acta Otolaryngol. 1995 Nov;115(6):830-2 [8749207.001]
  • [Cites] Curr Opin Immunol. 1997 Feb;9(1):10-6 [9039784.001]
  • [Cites] Mod Pathol. 1997 Nov;10(11):1128-33 [9388064.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1310-7 [9552031.001]
  • [Cites] J Immunother. 1998 Jul;21(4):295-306 [9672851.001]
  • [Cites] J Cutan Pathol. 1998 Oct;25(9):463-8 [9821075.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5356-64 [10537320.001]
  • [Cites] Acta Otolaryngol. 1999;119(6):732-8 [10587010.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2065-6 [10601369.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2779-87 [15546137.001]
  • [Cites] Oncol Rep. 2002 Nov-Dec;9(6):1219-23 [12375023.001]
  • [Cites] Nat Immunol. 2004 Dec;5(12):1219-26 [15549123.001]
  • [Cites] Br J Cancer. 2007 Feb 26;96(4):617-22 [17262084.001]
  • [Cites] J Cell Physiol. 2007 May;211(2):273-8 [17311299.001]
  • [Cites] Anal Quant Cytol Histol. 2007 Feb;29(1):57-62 [17375875.001]
  • [Cites] Head Neck. 2010 Jul;32(7):946-58 [20191626.001]
  • [Cites] J Cancer Res Clin Oncol. 2011 Jan;137(1):173-81 [20376678.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2015-23 [10706869.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1458-64 [10735893.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2794-802 [10914726.001]
  • [Cites] J Exp Med. 2000 Nov 6;192(9):1213-22 [11067871.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6811-7 [11156370.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2136-47 [11391595.001]
  • [Cites] Int J Cancer. 2001 Sep15;93(6):781-5 [11519037.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):805-13 [11550151.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):769-79 [11560993.001]
  • [Cites] J Pathol. 2002 Mar;196(3):254-65 [11857487.001]
  • [Cites] Semin Cancer Biol. 2002 Feb;12(1):43-50 [11926411.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2A):545-57 [12014622.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1787-93 [12060618.001]
  • [Cites] Clin Exp Metastasis. 2002;19(3):247-58 [12067205.001]
  • [Cites] Histopathology. 2002 Aug;41(2):152-7 [12147093.001]
  • [Cites] Thromb Haemost. 1998 Nov;80(5):767-72 [9843169.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5344-7 [9850063.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):1111-6 [9849463.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):329-34 [10037182.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 1999;47(2):83-8 [10202560.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1263-73 [10389908.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3468-74 [10416612.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1999;256(6):299-302 [10456279.001]
  • [Cites] Cancer Immunol Immunother. 1999 Oct;48(7):346-52 [10501846.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1999;256(8):384-7 [10525939.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):8126-9 [15520225.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Nov;131(5):573-6 [15523428.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Nov;130(11):1269-75 [15545580.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):736-47 [16401683.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1984-91 [16284959.001]
  • [Cites] J Immunol. 2006 Mar 15;176(6):3402-9 [16517708.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):717-27 [16520032.001]
  • [Cites] Head Neck. 2006 May;28(5):462-70 [16284974.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3890-5 [16818683.001]
  • [Cites] Anticancer Res. 2006 May-Jun;26(3A):1833-48 [16827115.001]
  • [Cites] Immunol Rev. 2006 Aug;212:314-29 [16903923.001]
  • [Cites] Oral Dis. 2006 Sep;12(5):455-62 [16910915.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1137-46 [17476343.001]
  • [Cites] Cancer Immunol Immunother. 2007 Sep;56(9):1429-42 [17265021.001]
  • [Cites] J Immunol. 2007 Jul 15;179(2):977-83 [17617589.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4345-54 [17671115.001]
  • [Cites] Acta Otolaryngol. 2007 Sep;127(9):980-7 [17712679.001]
  • [Cites] Head Neck. 2007 Sep;29(9):874-84 [17315170.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6301-11 [17975141.001]
  • [Cites] Head Neck. 2008 Feb;30(2):251-61 [18172882.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] Int J Oncol. 2008 Mar;32(3):527-35 [18292929.001]
  • [Cites] Oral Oncol. 2008 Mar;44(3):277-85 [17475541.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 Feb;132(2):309-16 [15692546.001]
  • [Cites] Cancer Immunol Immunother. 2004 Dec;53(12):1055-67 [15095020.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1010-20 [15709166.001]
  • [Cites] Laryngoscope. 2005 Mar;115(3):522-7 [15744170.001]
  • [Cites] Br J Cancer. 2005 Mar 14;92(5):913-20 [15714205.001]
  • [Cites] Cancer Metastasis Rev. 2005 Jan;24(1):95-105 [15785875.001]
  • [Cites] Semin Immunol. 2005 Aug;17(4):273-83 [15953735.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):3045-52 [16116192.001]
  • [Cites] Med Sci Monit. 2005 Aug;11(8):BR280-92 [16049374.001]
  • [Cites] Immunol Res. 2005;33(2):113-33 [16234579.001]
  • [Cites] Acta Otolaryngol. 2005 Dec;125(12):1337-44 [16303684.001]
  • [Cites] Cell Oncol. 2005;27(4):203-13 [16308469.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11146-55 [16322265.001]
  • [Cites] Swed Dent J Suppl. 2005;(179):1-66 [16335030.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Nov;262(11):917-20 [15924277.001]
  • [Cites] Mol Ther. 2006 Jan;13(1):183-93 [16125469.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1123-31 [16424049.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):465-72 [16428488.001]
  • [Cites] Oral Oncol. 2008 Jul;44(7):672-82 [17996489.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3128-37 [18474878.001]
  • [Cites] Ann Diagn Pathol. 2008 Oct;12(5):322-7 [18774493.001]
  • [Cites] J Oral Pathol Med. 2008 Sep;37(8):485-9 [18355177.001]
  • [Cites] Crit Rev Immunol. 2008;28(3):201-13 [19024345.001]
  • [Cites] J Clin Oncol. 2009 Jan 10;27(2):186-92 [19064967.001]
  • [Cites] J Immunol. 2009 Feb 1;182(3):1469-80 [19155494.001]
  • [Cites] Head Neck. 2009 Mar;31(3):318-27 [19072995.001]
  • [Cites] Head Neck. 2009 Mar;31(3):371-80 [19073006.001]
  • [Cites] J Craniofac Surg. 2009 Mar;20(2):287-9 [19218858.001]
  • [Cites] J Otolaryngol Head Neck Surg. 2009 Feb;38(1):119-25 [19344621.001]
  • [Cites] Hum Immunol. 2009 May;70(5):289-93 [19217922.001]
  • [Cites] J Dent Res. 2009 Apr;88(4):300-6 [19407148.001]
  • [Cites] Immunol Lett. 2009 Apr 27;123(2):97-102 [19428556.001]
  • [Cites] Int J Surg Pathol. 2009 Jun;17(3):244-9 [19443887.001]
  • [Cites] J Laryngol Otol Suppl. 2009;(31):5-10 [19460197.001]
  • [Cites] Head Neck. 2009 Jul;31(7):911-8 [19283850.001]
  • [Cites] Cancer Epidemiol. 2009 Aug;33(2):118-22 [19679058.001]
  • [Cites] Biochim Biophys Acta. 2009 Aug;1796(1):11-8 [19269310.001]
  • [Cites] Oral Oncol. 2009 Oct;45(10):e167-74 [19576838.001]
  • [Cites] Clin Cancer Res. 2009 Oct 15;15(20):6348-57 [19825957.001]
  • [Cites] Indian J Med Res. 2009 Sep;130(3):266-76 [19901436.001]
  • [Cites] Immunology. 2009 Nov;128(3):439-50 [20067543.001]
  • [Cites] Eur J Dermatol. 2010 Jan-Feb;20(1):16-23 [19850548.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2010 Mar;267(3):335-44 [19967383.001]
  • [Cites] Mol Cancer. 2010;9:4 [20064222.001]
  • [Cites] Immunol Rev. 2010 Mar;234(1):45-54 [20193011.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Mar;3(3):266-78 [20179299.001]
  • [Cites] Cell. 2010 Apr 2;141(1):39-51 [20371344.001]
  • [Cites] J Med Virol. 2010 May;82(6):1017-23 [20419817.001]
  • [Cites] Cancer Immunol Immunother. 2004 Oct;53(10):865-78 [15118842.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] J Oral Pathol Med. 1991 Feb;20(2):49-52 [2016696.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1991 Sep;117(9):1007-10 [1910715.001]
  • (PMID = 21437225.001).
  • [ISSN] 1740-2530
  • [Journal-full-title] Clinical & developmental immunology
  • [ISO-abbreviation] Clin. Dev. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC3061296
  •  go-up   go-down


78. Cherrington BD, Morency E, Struble AM, Coonrod SA, Wakshlag JJ: Potential role for peptidylarginine deiminase 2 (PAD2) in citrullination of canine mammary epithelial cell histones. PLoS One; 2010;5(7):e11768
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous reports have documented that PAD2 expression and activity varies across the estrous cycle in the rodent uterus and pituitary gland, however, the expression and function of PAD2 in mammary tissue has not been previously reported.
  • Surprisingly, stimulation of canine mammary tumor cells (CMT25) shows that EGF, but not estrogen or progesterone, upregulates PAD2 transcription and translation suggesting EGF regulation of PAD2 and possibly citrullination in vivo.
  • [MeSH-minor] Animals. Blotting, Western. Cell Line, Tumor. Cell Nucleus / metabolism. Cytoplasm / metabolism. Dogs. Epidermal Growth Factor / pharmacology. Estrous Cycle / genetics. Estrous Cycle / physiology. Female. Fluorescent Antibody Technique. Gene Expression / drug effects. Immunohistochemistry. Mammary Neoplasms, Animal / metabolism. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microsc Res Tech. 2001 Jan 15;52(2):224-30 [11169869.001]
  • [Cites] BMC Genomics. 2009;10:135 [19327144.001]
  • [Cites] Arthritis Rheum. 2003 Sep;48(9):2489-500 [13130468.001]
  • [Cites] Bioessays. 2003 Nov;25(11):1106-18 [14579251.001]
  • [Cites] Ann Rheum Dis. 2004 Apr;63(4):373-81 [15020330.001]
  • [Cites] Gene. 2004 Apr 14;330:19-27 [15087120.001]
  • [Cites] J Cell Sci. 2004 Sep 1;117(Pt 19):4449-59 [15316069.001]
  • [Cites] J Natl Cancer Inst. 1986 Sep;77(3):783-92 [3462415.001]
  • [Cites] Endocrinology. 1989 Jun;124(6):2666-70 [2721440.001]
  • [Cites] J Biol Chem. 1989 Aug 5;264(22):13361-8 [2753915.001]
  • [Cites] J Biol Chem. 1992 Jan 5;267(1):520-5 [1730614.001]
  • [Cites] Anal Biochem. 1992 May 15;203(1):94-100 [1524220.001]
  • [Cites] Vet Res Commun. 1995;19(2):101-13 [7645193.001]
  • [Cites] Am J Vet Res. 1996 May;57(5):693-6 [8723884.001]
  • [Cites] J Neurosci Res. 2005 Apr 1;80(1):120-8 [15704193.001]
  • [Cites] Mol Carcinog. 2006 Mar;45(3):183-96 [16355400.001]
  • [Cites] Int J Biochem Cell Biol. 2006;38(10):1662-77 [16730216.001]
  • [Cites] Anal Biochem. 2006 Sep 1;356(1):36-43 [16844072.001]
  • [Cites] Birth Defects Res B Dev Reprod Toxicol. 2007 Jun;80(3):233-45 [17570128.001]
  • [Cites] Breast Dis. 2007;28:7-21 [18057539.001]
  • [Cites] Lab Invest. 2008 Apr;88(4):354-64 [18227806.001]
  • [Cites] Dis Model Mech. 2008 Nov-Dec;1(4-5):229-40 [19093029.001]
  • [Cites] Vet Pathol. 2003 Jul;40(4):412-20 [12824513.001]
  • (PMID = 20668670.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histones; 29VT07BGDA / Citrulline; 62229-50-9 / Epidermal Growth Factor; EC 3.- / Hydrolases; EC 3.5.3.15 / protein-arginine deiminase
  • [Other-IDs] NLM/ PMC2909897
  •  go-up   go-down


79. Monaco JP, Tomaszewski JE, Feldman MD, Hagemann I, Moradi M, Mousavi P, Boag A, Davidson C, Abolmaesumi P, Madabhushi A: High-throughput detection of prostate cancer in histological sections using probabilistic pairwise Markov models. Med Image Anal; 2010 Aug;14(4):617-29
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The classification of individual glands leverages two features: gland size and the tendency for proximate glands to share the same class.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • [Cites] IEEE Trans Med Imaging. 2001 Jan;20(1):45-57 [11293691.001]
  • [Cites] Med Phys. 2009 Sep;36(9):3927-39 [19810465.001]
  • [Cites] J Urol. 2004 Sep;172(3):910-4 [15310996.001]
  • [Cites] Hum Pathol. 2004 Sep;35(9):1121-31 [15343515.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2004 Mar;26(3):408-13 [15376887.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):125-8 [5948714.001]
  • [Cites] Comput Biomed Res. 1999 Feb;32(1):1-12 [10066352.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1499-507 [10334537.001]
  • [Cites] BJU Int. 2005 Jun;95(8):1146-52 [15877724.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7005-12 [16192588.001]
  • [Cites] IEEE Trans Med Imaging. 2005 Dec;24(12):1611-25 [16350920.001]
  • [Cites] Adv Anat Pathol. 2006 Jan;13(1):57-9 [16462155.001]
  • [Cites] J Urol. 2006 Apr;175(4):1337-40 [16515993.001]
  • [Cites] IEEE Trans Image Process. 2006 Apr;15(4):952-68 [16579381.001]
  • [Cites] Cytometry B Clin Cytom. 2007 Jul;72(4):227-40 [17285628.001]
  • [Cites] J Clin Invest. 2007 Jul;117(7):1876-83 [17557117.001]
  • [Cites] IEEE Trans Med Imaging. 2007 Oct;26(10):1366-78 [17948727.001]
  • [Cites] Eur Urol. 2008 Jan;53(1):68-80 [17920184.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2008 Jun;30(6):1068-80 [18421111.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3923-9 [18711180.001]
  • [Cites] IEEE Trans Med Imaging. 2009 Jun;28(6):906-15 [19164079.001]
  • [Cites] IEEE Trans Med Imaging. 2009 Jul;28(7):1037-50 [19164082.001]
  • [Cites] IEEE Trans Biomed Eng. 2003 Jun;50(6):697-704 [12814236.001]
  • (PMID = 20493759.001).
  • [ISSN] 1361-8423
  • [Journal-full-title] Medical image analysis
  • [ISO-abbreviation] Med Image Anal
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21CA1271-86-01; United States / NCI NIH HHS / CA / CA127186-02S1; United States / NCI NIH HHS / CA / R21 CA127186-02S1; United States / NCI NIH HHS / CA / R03CA128081-01; United States / NCI NIH HHS / CA / R01 CA136535; United States / NCI NIH HHS / CA / R03 CA128081-01; United States / NCI NIH HHS / CA / R21 CA127186; United States / NCI NIH HHS / CA / R01CA136535-01; United States / NCI NIH HHS / CA / CA128081-01; United States / NCI NIH HHS / CA / R21 CA127186-01; United States / NCI NIH HHS / CA / 3 R21 CA127186-02S1; United States / NCI NIH HHS / CA / R03 CA128081; United States / NCI NIH HHS / CA / CA127186-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS207594; NLM/ PMC2916937
  •  go-up   go-down


80. Visigalli D, Palmieri D, Strangio A, Astigiano S, Barbieri O, Casartelli G, Zicca A, Manduca P: The carboxyl terminal trimer of procollagen I induces pro-metastatic changes and vascularization in breast cancer cells xenografts. BMC Cancer; 2009;9:59
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We used a model of xenografts in BalbC/nude mice obtaining tumors by implanting i